TABLE OF CONTENTS DRUG CHEMISTRY

Last Review Date: December 6, 2023

Foreword

Ger	neral	Introductioni
	A.	Physical Identification
	В.	Color and Functional Group
	C.	Thin-Layer Chromatography (TLC)
	D.	Gas Chromatography with Flame Ionization Detection (GC-FID)D-1
	E.	Not Used/Removed 01/18/2016 E-1
	F.	Fourier Transform Infrared Spectroscopy (FTIR) Transmission and Internal
		ReflectanceF-1
	G.	Gas Chromatography - Mass Spectrometry (GC-MS)
	Н.	Sampling
		1. Sampling Plan H-1
		a. Hypergeometric SamplingH-1A
		b. Bayesian Sampling
		c. Determination of Weight or Number of UnitsH-1C
	I.	Gas Chromatography - Infrared Spectrometry (GC-IR) I-1
I.	Ans	alysis of Suspected Controlled Substances
1.	A.	Analysis of Tablets and Capsules
	11.	1. Analysis of Tablets and CapsulesIA-1
	В.	Analysis of Powdered Samples
	ъ.	1. Analysis of Powdered Samples
	C.	Analysis of Liquids, Paper, Non-Cannabis Plant Material, Residues, and Food
	С.	Products
		1. Analysis of Liquids, Paper, Non-Cannabis Plant Material, Residues, and
		Food Products
II.	Λne	alysis of a Controlled Substance
11.	A.	Quantitation
	Λ.	1. Centralized QuantitationIIA-1
		2. Not Used/Removed 01/18/2016
		3. Quantitation by Gas ChromatographyIIA-3
		4. Not Used/Removed 01/18/2016 IIA-4
		5. Not Used/Removed 01/18/2016
		6. Quantitation by GC/MS Selected ION Monitoring (SIM)IIA-6
	В.	Determination of Optical Isomers
	D .	1. PolarimetryIIB-1
		1. 1 Otal IIIIcu yIID-1

III. Analysis of Suspected Cannabis Samples	
A. The Identification of Cannabis	
1. The Botanical Observation of Leafy Plant Material	IIIA-1
2. The Use of the Duquenois-Levine Test for the Identificatio	on
of Cannabis	IIIA-2
APPENDICES	
Report Wording	Арр I
Data Suitability	App II
Extraction, Separation and Derivatization Methods	App III
Chemistry Minimum Standards and Controls	App IV
Administrative Policies Applicable to Any Analyses	Section A
Administrative Policies for Cannabis Analysis	
Administrative Policies for Controlled Substance Analysis	
Administrative Policies for Specific Controlled Substances	Section D
Administrative Policies for Food Product Sampling	
Measurement Uncertainty	

GENERAL INTRODUCTION

The Chemistry Procedures Manual contains common methods and techniques that can be used in the analysis of Controlled Substances and Cannabis. The procedures outlined in this manual represent only a small fraction of those which are available to the chemist and as such this manual should be considered as one of many resources available.

Minimum Standards and Controls are not to be used as a substitute for good scientific procedures. On an individual case, the minimum indicated may not suffice to complete identification as defined. It is the primary responsibility of the chemist to identify the controlled substance rather than simply fulfill these standards.

The analysis of controlled substances depends on the type of sample material submitted for analysis. This can be a powder, liquid, licit or illicit tablets or capsules, plant material or residue. The choice of methods used for the analysis of this wide variety of different materials will vary with each case.

Because of this, a specific procedure devoted to each drug is neither reasonable nor possible. Rather, the methods used in an analysis will be specified in a general manner for use by the examiner in the analysis of a particular sample.

Sample preparation consists of both mass determination and sampling techniques. Consideration should be given to each before conducting analytical tests. See Appendix II, Appendix IV (sections A-E), and Appendix V for policies regarding both of these areas.

After the mass is determined, the analyst must decide which method will be chosen to perform a preliminary or screening test. The most common choices are:

- 1. Physical identification by a reference source for legitimate preparations
- 2. Color Test
- 3. Thin-Layer Chromatography
- 4. Gas Chromatography

Less commonly, screening can be done by Infrared Spectroscopy or Gas Chromatography/ Mass Spectrometry or other acceptable analytical tests.

After the preliminary test is performed, a second test, which gives structural information sufficient for the positive identification of the compound, will be utilized. The most common choices for this requirement are Infrared Spectroscopy and/or Mass Spectrometry. The use of one preliminary and one structural test for the identification of a controlled substance is a minimum. If more tests are required to positively identify the material, an examiner is required to perform them to reach a conclusion as to whether a controlled substance is present or not.

For identification criteria and other guidelines for drug analysis see Appendix IV sections A through E.

ILLINOIS STATE POLICE

DRUG CHEMISTRY PROCEDURES MANUAL

METHOD: PHYSICAL IDENTIFICATION

Reviewed by:	
Forensic Scientist Adrienne A. Hirsch, Chairperson Drug Chemistry Command Advisory Board	
Approved by:	
Approved by:	
Bureau Chief Timothy A. Tripp Drug Chemistry Command Coordinator Forensic Sciences Command	

Accepted Date: February 1, 2023 Drug Chemistry Procedures Manual DC-A-1 Page 1 of 4 Version 2023.02.01 **Procedure:** Physical Identification

INTRODUCTION

The Physical Identification Procedure can only be used on pharmaceutical preparations. These preparations must be from a commercial manufacturer. Tablets and capsules of clandestine manufacture or counterfeit cannot be identified with this procedure. A positive identification obtained by comparing to a listed or similar reference can be used as a preliminary test on a standard commercial dosage unit.

SAFETY CONSIDERATIONS

Standard Laboratory Practices.

PREPARATIONS

None Required.

INSTRUMENTATION

Generally none required, however, a stereoscope may be useful in identifying numbers or symbols inscribed on the products.

MINIMUM STANDARDS AND CONTROLS

The reference used and the result will be documented in the analytical notes packet. The reference should include the year of the reference (e.g. PDR) or the number/volume and page number (e.g. Identidex). For webpages, a copy of the source (e.g. PDF) must be uploaded into LIMS. The date the webpage was accessed, URL, etc. must also be documented in the analytical notes packet.

When Physical Identification is used as a reference to determine the potential contents of a tablet, it is permissible to use the conclusion "Not Analyzed" provided no further analysis is performed. A conclusion of "Physically resembles a pharmaceutical preparation; no further analysis" is also allowed, but not required. For instances where the tablets can be seen through the evidence packaging, Physical Identification can be used as a reference in the analyst's notes without being included on the report.

PROCEDURE OR ANALYSIS

The chemist should make a thorough visual examination of the material submitted for analysis. This may include the use of the stereoscope. Notes should include a description of the following characteristics, if applicable

Color: A description of the color.

Shape: A description which may include a drawing.

Accepted Date: February 1, 2023 DC-A-1 Procedure: Physical Identification Drug Chemistry Procedures Manual Page 2 of 4

Themistry Procedures Manual Page 2 of 4
Version 2023.02.01

Markings: A description which may include a drawing of the markings found on the tablet or capsule.

Other: Additional observations may include: condition of the material, edge shape and size of the tablet or capsule, and any other relevant observations.

<u>Literature comparisons</u>: The use of identification guides is suggested in the case of pharmaceutical preparations. The unknown is compared to a known pharmaceutical or a representation description/picture of a known pharmaceutical. The information gained can be considered in much the same way as the information gained by any examination of external characteristics. The results provide preliminary or presumptive information.

When doing a physical identification on a dosage form, care must be taken to ascertain that the drug has not been tampered with and that it is of legitimate, as opposed to clandestine, origin. The markings, shape, size, color, etc. must be the same as shown in the reference.

Optical activity may be determined from a legitimate reference source or identification guide (e.g. PDR). If the reference/guide notates optical rotation, then no further testing for optical rotation need be performed. Propoxyphene is an example of this type of identification. However, the report must specify dextropropoxyphene as required from the Controlled Substance Act.

The Physicians' Desk Reference (PDR) is a yearly publication. It is an advertisement for manufacturers; therefore not every tablet, capsule or preparation made is contained in the book. The product identification section gives an actual size, full color reproduction of the product. All items listed in the PDR are also indexed according to manufacturer, trade name, and chemical name.

<u>Identidex</u>, a tablet and capsule identification system, is available through subscription from Micromedex and is updated quarterly. Information is provided on CD-ROM or on-line. The Identidex provides a verbal description of pharmaceuticals. Also included is information on slang descriptions of drugs.

The Drug Identification Bible is a publication that is intended for preliminary identification of illegal and legal drugs. It provides tablet and capsule markings for pharmaceutical preparations similar to the PDR or The Logo Index, as well as general information on Controlled Substances.

<u>Redbook</u> is a publication intended for use by pharmacies to reference physical identification of tablets and prescription dosages.

<u>The Logo Index</u> is a publication put out by the DEA to reference the contents of a pharmaceutical preparation (tablet or capsule). This publication is available in book form as well as a searchable DOS based computer software.

Accepted Date: February 1, 2023 Drug Chemistry Procedures Manual

DC-A-1 Page 3 of 4 Version 2023.02.01 Procedure: Physical Identification

<u>RX-ID</u> is a tablet and capsule identification system available through Ameri-Chem, the publishers of the Drug Identification Bible. It is similar to the Identidex and includes a color photograph of the tablet affiliated with the reference. It is available on a single CD or a yearly subscription that is updated quarterly.

<u>Drugs.com</u> is the most popular, comprehensive, and up to date source of drug information online, providing free, peer-reviewed, accurate, and independent data on more than 24,000 prescription drugs, over-the-counter medications, and natural products.

Other published materials similar to the above listed references may also be appropriate.

REPORT WORDING

See Appendix I - Report Wording.

REFERENCES

- 1. The Physicians' Desk Reference; Medical Economics: Data Productions, Montvale, NJ, Annual.
- 2. Identidex® System; Micromedex:, Thomson Reuters, 6200 S. Syracuse Way, Suite 300, Englewood, CO.
- 3. The Drug Identification Bible: Amera-Chem: P.O. Box 518, Grand Junction, Colorado.
- 4. Redbook; Thomson PDR: Montvale, NJ.
- 5. The Logo Index for Tablets and Capsules; Drug Enforcement Administration, Office of Forensic Sciences: Washington, D.C.
- 6. RX-ID; Amera-Chem: P.O. Box 518, Grand Junction, Colorado.
- 7. Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved. Copyright 2017

Accepted Date: February 1, 2023 Drug Chemistry Procedures Manual DC-A-1 Page 4 of 4 Version 2023.02.01 Procedure: Physical Identification

ILLINOIS STATE POLICE

DRUG CHEMISTRY PROCEDURES MANUAL

METHOD: COLOR AND FUNCTIONAL GROUP

Reviewed by:	
Forensic Scientist Adrienne A. Hirsch, Chairperson Drug Chemistry Command Advisory Board	
Approved by:	
Bureau Chief Timothy A. Tripp	
Drug Chemistry Command Coordinator	
Forensic Sciences Command	

Accepted Date: December 6, 2023 Drug Chemistry Procedures Manual DC-B-1 Page 1 of 9 Version 2023.12.06 Procedure: Color and Functional Group

INTRODUCTION

Color or spot tests are non-specific preliminary screening tests that respond to particular functional groups or a molecular moiety. They are not a positive identification test. They are, however, a good screening or presumptive test because they indicate the type of compound present and give clues as to its structure.

There is always a certain amount of subjectivity that must be taken into account when a color is reported. It is not uncommon for two chemists to describe the same color differently. Aside from the differences in reporting colors that can be attributed to the analyst, colors can also be influenced by the concentration of the solvent or solute or by the presence of diluents or contaminants. Also, the length of time during which the colors are observed may influence the color reported because color transitions and instabilities are not unusual. Allowances should be made for these differences, especially with street samples, where neither the concentration of the drug nor the presence or composition of any diluent or contaminant is known.

SAFETY CONSIDERATIONS

Precaution should be taken when preparing or handling color test reagents. Several reagents contain strong acids which can penetrate clothing or lab coats and cause injuries if they come in contact with skin. These reagents can also splatter, effervesce, or emit noxious or harmful vapors. For these reasons, the reagents should be prepared and the tests should be conducted in the hood while wearing proper Personal Protective Equipment (PPE).

PREPARATIONS

Some common reagent formulations are given on the following pages. The outline also includes information for the type of drug that reacts with each specific reagent. The intended uses are not an exhaustive list. Where possible, American Chemical Society (ACS) grade of chemicals should be employed when preparing in-house reagents. The amounts of reagent used in testing the samples are suggested guidelines and can vary.

CHEN'S TEST

Intended Use: Non-controlled stimulants and ephedrine

Formulation: A. 1% acetic acid

B. 1% copper sulfate in waterC. 2N sodium hydroxide

Add 1 drop of each, in order, to sample.

Positive: Purple Stability: Stable

Problems: Run blank since reagent mixture is light blue.

Accepted Date: December 6, 2023 DC-B-1 Procedure: Color and Functional Group Drug Chemistry Procedures Manual Page 2 of 9

Version 2023.12.06

COBALT THIOCYANATE

Intended Use: Cocaine

Formulation: 2 g cobalt thiocyanate

100 mL water

Positive: Blue

Stability: Very stable

Problems: The free base may cause false negatives. Adding a drop of concentrated

HCl to give the HCl salt will often prevent this problem. There is a large

group of false positives.

COBALT THIOCYANATE-ACIDIFIED

Intended Use: Cocaine

Formulation: 20 g cobalt thiocyanate

1 L distilled water

40 mL concentrated HCl

Positive: Blue Stability: Stable

Problems: There are few false positives. The salt form may produce a weak blue.

DILLE-KOPPANYI

Intended Use: Barbituric Acid derivatives Formulation: A. 0.1 g cobalt acetate

100 mL methanol

0.2 mL glacial acetic acid

B. 5 mL isopropylamine 95 mL methanol

Use 2 drops A and 1 drop B.

Positive: Purple

Stability: Very stable when stored as two solutions.

Problems: There are very few false positives. Note, the sodium salt of the Barbituric

Acid will give a violet color at step one.

Accepted Date: December 6, 2023 DC-B-1 Procedure: Color and Functional Group Drug Chemistry Procedures Manual Page 3 of 9

EHRLICH'S

Intended Use: LSD and hallucinogens

Formulation: 5 g paradimethylaminobenzaldehyde

100 mL concentrated HCl

If necessary, 95% ethanol can be used to dilute this formula to prevent

charring.

For spray, dilute Ehrlich's reagent 1:1 with ethanol.

Positive: Purple Stability: Stable

Problems: There are very few false positives.

FROEHDE'S

Intended Use: Phenols, especially narcotics

Formulation: 50 mg molybdic acid or sodium molybdate

10 mL hot concentrated sulfuric acid

The solution should be colorless.

Positive: Red-purple Stability: Stable Problems: None

LIEBERMANN'S

Intended Use: Amphetamines

Formulation: 10 g potassium nitrite or sodium nitrite

100 mL concentrated sulfuric acid

Note: Keep reagents cold when preparing.

Positive: Yellow, gold, bright colors

Stability: Stable Problems: None

MANDELIN'S

Intended Use: Narcotics, amphetamines, hallucinogens

Formulation: 1 g ammonium vanadate

100 mL concentrated sulfuric acid

Positive: Green, purple, red-purple

Stability: Stable Problems: None

Accepted Date: December 6, 2023 DC-B-1 Procedure: Color and Functional Group Drug Chemistry Procedures Manual Page 4 of 9

Version 2023.12.06

MARQUIS (LeRosen)

Intended Use: Amphetamines, narcotics, hallucinogens

Formulation: 8-10 drops 40% formaldehyde

10 mL concentrated sulfuric acid

Positive: Orange, purple, bright colors

Stability: Volatile due to the formaldehyde. Very sensitive to water, store in dry place.

Limited shelf life.

Problems: None

MECKE (Lafon)

Intended Use: Alkaloids

Formulation: 0.25 g selenious acid

25 mL concentrated sulfuric acid

Positive: Green, blue Stability: Stable Problems: None

SANCHEZ

Intended Use: Procaine, benzocaine

Formulation: Saturated aqueous solution of Furfural (2-Furaldehyde), slightly acidified

with acetic acid.

Positive: Red-violet

Stability: Volatile. Should be kept refrigerated.

Problems: None

SCOTT'S

Intended Use: Cocaine

Formulation: A. 50 mL 2% cobalt thiocyanate

50 mL U.S.P. glycerine

B. Concentrated hydrochloric acid

C. Chloroform

In test tube, add 5 drops A (if positive, will result in a blue precipitate), add 1 drop B (clear solution turns pink), add 3 to 4 drops C (blue color

will transfer to chloroform layer).

Positive: Pink-top layer/Blue-bottom layer

Stability: Stable

Problems: Some false positives.

Accepted Date: December 6, 2023 DC-B-1 Procedure: Color and Functional Group Drug Chemistry Procedures Manual Page 5 of 9

SODIUM NITROPRUSSIDE

Intended Use: Secondary Amines (e.g. Methamphetamine or MDMA)
Formulation: A. 0.5 g sodium nitroprusside dissolved in 50 mL water

1 mL acetaldehyde

B. 5 g sodium carbonate dissolved in 100 mL water

Add 1 drop of A, then 2 drops of B.

Positive: Blue, purple

Stability: Reagent A is volatile and should be refrigerated. Reagent A is blue when

bad.

Problems: Very few false positives.

WEBER

Intended Use: Psilocyn

Formulation: A. 0.01 g Fast Blue B

10 mL deionized water

B. Concentrated HCl

Add 2 drops of A, then 1 drop of B.

Positive: Red after addition of A and color change to blue after addition of B

Stability: Reagent A is unstable. Store in the freezer. If a freezer is not available, the

reagent should be stored in the refrigerator and may be used until it no longer produces the expected results with the required primary standards as specified in DC-App IV-D. Do not store at room temperature. Expiration will be one year after the date of preparation, if the previously mentioned storage conditions are followed. Per QM-14, the frozen reagents will not

be re-authenticated after one year.

Problems: A positive test result does not exclude psilocybin from being present.

A negative test result does not exclude psilocyn from being present.

WINTERGREEN

Intended Use: Cocaine

Formulation: Saturated potassium hydroxide or sodium hydroxide in methanol.

Note: Can also use 5% hydroxide solution.

Positive: Wintergreen odor

Stability: Stable

Problems: Water will interfere with the reaction.

Accepted Date: December 6, 2023 DC-B-1 Procedure: Color and Functional Group Drug Chemistry Procedures Manual Page 6 of 9

Version 2023.12.06

ANION TEST: SILVER NITRATE

Intended Use: Chloride ion, Iodide ion

Formulation: 1 g silver nitrate dissolved in 20 mL water

Positive: White precipitate for chloride

Yellow precipitate for iodide

Stability: Stable Problems: None

ANION TEST: BARIUM CHLORIDE

Intended Use: Sulfate ion

Formulation: 10% barium chloride in water

Positive: White precipitate

Stability: Stable Problems: None

ANION TEST: RING PRECIPITATION TEST

Intended Use: Phencyclidine (PCP)

Formulation: A. Sulfuric Acid: H₂O (4:1)

B. Concentrated NH₄OH

Add a sufficient amount of A to cover the sample. Then add drops of B along

the sides of the test tube.

Positive: Ring of Precipitate forms at the acid/base interface

Stability: Stable

Problems: Some false positives.

CHROMIC ACID

Intended Use: GHB, GBL, 1,4-Butanediol

Formulation: 5M H₂SO₄ saturated with Chromic Oxide

Positive: Blood Red-Brown

Stability: Volatile, should be refrigerated.

Problems: Can give false positive and false negatives.

FERRIC CHLORIDE

Intended Use: GHB, GBL

Formulation: Distilled H₂O saturated with FeCl₃

Positive: Rust Red-Brown Stability: Keep refrigerated.

Problems: May give false positives.

Accepted Date: December 6, 2023 DC-B-1 Procedure: Color and Functional Group Drug Chemistry Procedures Manual Page 7 of 9

Page 7 of 9 Version 2023.12.06

1% COBALT NITRATE IN EtOH SOLUTION

Intended Use: GHB

Formulation: 1% Cobalt nitrate in an absolute ethanol solution

Positive: Violet Stability: Stable

Problems: May give false positives.

TOLUENE/SOLID COBALT THIOCYANATE

Intended Use: GBL

Formulation: Add approximately 1 mL of sample into a test tube followed by 0.5 mL of

toluene. Vortex. Place a few crystals of solid cobalt thiocyanate in a spot

well and add 3-5 drops of the toluene layer.

Positive: Blue color developing upon drying

Stability: Stable

Problems: Running a blank is suggested, may give false positives.

INSTRUMENTATION

None

MINIMUM STANDARDS AND CONTROLS

The following conditions are to be met for the use of color tests or chemical tests (classical functional group tests):

- 1. A color test, if positive, may be used as a preliminary test for the identification of a controlled substance.
- 2. Color tests cannot be used as the preliminary test for a no scheduled substance found determination.

Notation of test done, and color or reaction produced will be recorded on the worksheet.

- 3. Stock bottles of color reagents are to be tested when prepared and as indicated in QM-14, using primary or secondary standards. A logbook (or online equivalent) will be kept of the
- 4. testing to include at least the identity of the preparer of the reagent, the date the reagent was authenticated (or re-authenticated), and the expiration date of the reagent. Any manufactured reagents will be tested when opened and as indicated in QM-14: if no manufacturer's expiration date is given, it will be assigned a one-year date and treated in the same manner as in-house reagents.

All stock solutions will be properly labeled (including a hazard label), initialed by the preparers, and dated. This includes an expiration date.

5.

Accepted Date: December 6, 2023 DC-B-1 Procedure: Color and Functional Group Drug Chemistry Procedures Manual Page 8 of 9

Version 2023.12.06

PROCEDURE OR ANALYSIS

The color tests are conducted by transferring a small amount of substance to a non-reactive surface. Suggested surfaces are porcelain spot plates, disposable polyethylene spot plates, culture tubes or shell vials. The suggested number of drops of reagent in the proper order is added to the sample. Any observed color, absence of color, odor or effervescence is noted.

REPORT WORDING

See Appendix I - Report Wording.

REFERENCES

- 1. The Drug Chemistry Training Manual, Section DC-IA-4.
- 2. Clarke, E. G. C. *Isolation and Identification of Drugs*, 2nd ed.; Pharmaceutical Press: London, England, 1986.
- 3. Feigl, F. Spot Tests in Organic Analysis, 7th ed. Elsevier Publishing: New York, NY, 1966; pp. 137-139, 251, 381-382.
- 4. Chemical Companies:

Sigma-Aldrich Chemical Company P O Box 14508 St. Louis, MO 63178-4508 1-800-325-3010

Fisher Scientific 300 Industry Drive Pittsburgh, PA 15275 1-800-766-7000

Alfa Aesar Chemical Company A. Johnson Matthey Company 2 Radcliff Road Tewksberry, MA 01876 1-800-343-0660 GFS Chemicals P O Box 245 Powell, OH 43065-0245 1-800-858-9682

Avantor Performance Materials 3477 Corporate Parkway Center Valley, PA 18034 1-855-282-6867

- 5. Garrett, A., Clemens, S., Gaskill, J., "The Weber Test: A Color Test for the Presence of Psilocin in Mushrooms," <u>SWAFS Journal</u>. 1993, Vol. 15, No. 1, pp 44-45.
- 6. Koppenhaver, D. J., "GHB Color Test," Microgram. 1997, Vol. XXX, No. 6, p. 130.
- 7. Morris, J., "Extraction of GHB for FTIR Analysis and a New Color Test for Gamma-Butyrolactone (GBL)," Microgram. 1999, Vol. 8, pp. 215-221.

Accepted Date: December 6, 2023 DC-B-1 Procedure: Color and Functional Group
Drug Chemistry Procedures Manual Page 9 of 9

Version 2023.12.06

ILLINOIS STATE POLICE

DRUG CHEMISTRY PROCEDURES MANUAL

METHOD: THIN-LAYER CHROMATOGRAPHY (TLC)

Reviewed by:
Forensic Scientist Adrienne A. Hirsch, Chairperson Drug Chemistry Command Advisory Board
Approved by:
Bureau Chief Timothy A. Tripp Drug Chemistry Command Coordinator
Forensic Sciences Command

Accepted Date: February 1, 2023 Drug Chemistry Procedures Manual DC-C-1 Page 1 of 5 Version 2023.02.01 **Procedure:** Thin-Layer Chromatography (TLC)

INTRODUCTION

Thin-Layer Chromatography (TLC) is a preliminary test. It can be used as a general screening test and the Rf and visualized colors can be compared to a known standard that is run with the sample to verify the results.

SAFETY CONSIDERATIONS

Standard Laboratory Practices. Both mobile phases and visualizers should be prepared in the hood. Also, any spraying of visualizers should be performed with the hood on and the spray directed into a spray box or similar container.

PREPARATIONS

Unless otherwise noted, all chemicals should be of the highest grade attainable (ACS or reagent grade preferable) to avoid contamination problems and to ensure reactivity.

VISUALIZERS

Vanillin 1 gram vanillin in 20 mL sulfuric acid

KIPT 0.25 g Platinic Chloride

5 g Potassium Iodide

Dilute to 100 mL with water

Acidified KIPT 5 mL concentrated Hydrochloric Acid is added to 100 mL KIPT

Ehrlich's Ehrlich's color reagent diluted 1:1 with Ethanol (95%)

Fiorese's Reagent A: 10 % Ferric Chloride in water

Reagent B: 15% Potassium Iodide in water

1 mL concentrated Hydrochloric Acid

Reagent C: Water (optional)

N,2,6 Reagent A: 1% Sodium Hydroxide in Methanol

Reagent B: 0.5% of N,2,6-Trichloro-p-benzoquinoneimine

(TCBI) in Chloroform

Fast Blue B salt 0.2 g in 10 mL of water

Fast Blue BB salt 0.2 g in 10 mL of water

MINIMUM STANDARDS AND CONTROLS

The following are requirements to meet the minimum standards and controls for Thin-Layer Chromatography:

Accepted Date: February 1, 2023 DC-C-1 Procedure: Thin-Layer Chromatography (TLC)
Drug Chemistry Procedures Manual Page 2 of 5

Version 2023.02.01

I. Documentation

- 1. Standards (primary or secondary) will be run on the plate. The results will be indicated on the worksheet. The lot number or laboratory inventory number of the standards used must be documented in the case file.
- 2. The solvent system and method of visualization will be indicated on the worksheet (abbreviations are acceptable).
- 3. Reviewable data such as a photo (color, if possible, otherwise accurately labeled) of the developed TLC plate shall be included in the case file whenever this technique is used.
- 4. TLC chambers will be labeled with the solvent system, preparer's initials, and date prepared.
- 5. All TLC visualizing reagents will be tested when prepared and as indicated in QM-14, using a primary or secondary standard. A logbook (or online equivalent) will be kept of all testing to include at least the initials of the preparer, the date the reagent was authenticated (or re-authenticated), and the expiration date of the reagent. Any manufactured reagents will be tested when opened and as indicated in QM-14; if no manufacturer's expiration date is given, it will be assigned a one year date and treated in the same manner as in-house reagents.
- 6. Spot color development (if any) and retention factor calculations must be documented in the case file.

II. Comparisons

- 1. Because the reference standard shall be run on the same plate as the sample, a direct comparison shall be made between the sample and the included standard(s) after the plate has been deemed suitable for comparison (see DC-App II).
- 2. The spots of the target analyte and the reference standard(s) should be approximately circular or a rectangular band (not a streak), adequately resolved from other sample components as well as other standards included on the plate, and visible when exposed to UV light or a chemical visualizing reagent.
- 3. The relative retention factor shall be calculated for spots of target analytes that will be subject to a comparison. Measurements shall be taken (in centimeters) from the origin to the center of the spot. For instances where multiple samples of the same case/item number are run on the same plate and are referenced to a single standard, it is acceptable to document the relative retention factor of each extreme sample spot (i.e. the low and the high) instead of every individual spot.

Accepted Date: February 1, 2023 Drug Chemistry Procedures Manual DC-C-1 Page 3 of 5 Version 2023.02.01

Procedure: Thin-Layer Chromatography (TLC)

4. A comparison may be considered to give a positive result or indication when the relative retention ratio is between 0.85 and 1.15 and the spot exhibits a similar color reaction to a chemical visualizer as the reference material (when a color is present).

PROCEDURE OR ANALYSIS

A standard must be run on the same plate as the unknown. Commercially prepared TLC plates, or HPTLC plates, are used (with or without a fluorescent indicator). The developing solvent is placed in a sealed TLC chamber which has been allowed to equilibrate. (Note: For HPTLC, a smaller glass chamber is used since only 5 to 10 mL of solvent is needed.)

The standards and unknowns are dissolved in a suitable, non-aqueous solvent and spotted near the bottom of the TLC plate, above the solvent line. The plate is placed in the chamber and developed to the desired height. The plate is then air dried, visualized by UV and/or sprayed with a selected visualizing agent. A positive test results if the distance traveled by the unknown and standard match and, if visualized with a visualizing agent, their colors are equivalent. These and other factors are noted.

EXAMPLES OF SOLVENT SYSTEMS

TYPE OF DRUG	DEVELOPING SYSTEM ((Vol: Vol Ratio)

Cannabis Hexane: Ether (4:1)
Cannabis, Salvinorin A Hexane: Acetone (4:1)
General Screen Methanol: Ammonia (95:5)

General Screen CDEN (Chloroform, Dioxane, Ethyl Acetate, Ammonia)

(25:60:10:5)

General Screen Acetonitrile: Ammonia (95:5)

LSD Acetone: Ammonia saturated chloroform (2:1)
LSD Cyclohexane: Acetone: Diethyl Ether: Diethylamine

(35:30:30:5)

Psilocyn/Psilocybin n-Butanol: Acetic Acid: Water (2:1:1)

Psilocyn/Psilocybin Methanol: Ammonia (95:5)
Salvinorin A Hexane: Ethyl Acetate (1:1)
Steroids Chloroform: Ethyl Acetate (4:1)

EXAMPLES OF VISUALIZERS

TYPE OF DRUG VISUALIZER

General Screening KIPT

Fiorese's

Cannabis Fast Blue B

Fast Blue BB

N,2,6-Trichloro-p-benzoquiononeimine (TCBI)

LSD diluted Ehrlich's Psilocyn/Psilocybin diluted Ehrlich's

Salvinorin A Vanillin

Accepted Date: February 1, 2023 DC-C-1 Procedure: Thin-Layer Chromatography (TLC)

Drug Chemistry Procedures Manual Page 4 of 5
Version 2023.02.01

Steroids Ethanol: Sulfuric Acid (4:1)

EXAMPLE OF A RELATIVE RETENTION FACTOR CALCULATION

Rf of sample versus Rf of Reference Standard Run on the Same Plate (=R_{st})

 $R_{st} = \frac{Analyte \ distance_{sample}}{Analyte \ distance_{standard}}$

A positive test result may be indicated when the $0.85 \le R_{st} \le 1.15$

REPORT WORDING

See Appendix I - Report Wording.

REFERENCES

- 1. The Drug Chemistry Training Manual, Section DC-IA-5.
- 2. Touchstone, J., Dobbins, M. Practice of Thin-Layer Chromatography, 2nd ed., John Wiley and Sons: New York, NY, 1983, pp. 1-15, 103-136.
- 3. Clarke, E. G. C. Isolation and Identification of Drugs, 2nd ed.; Pharmaceutical Press: London, England, 1986, PP 146-147.
- 4. Kirchner, J. G. (1967). *Technique of Organic Chemistry* (Vol. XII). (E. W. Perry, Ed.) New York: Interscience Publishers, pp. 8.
- 5. Munro, Thomas A., Goetchius, Glen W.; Roth, Bryan L., Vortherms, Timothy A., Rizzacasa, Mark A. (2005), Autoxidation of Salvinorin A Under Basic Conditions, Journal of Organic Chemistry, Vol. 70, pp. 10057-10061.
- 6. Valdéz III, Leande, J, Chang, Hui-Ming, Visger, Daniel C., Koreeda Masato. (2001). Salvinorin C, a new neoclerodane diterpene from a bioactive fraction of the hallucinogen Mexican mint Salvia divinorum. Organic Letters, Vol. 3, No. 24, pp. 3935-3957.

Accepted Date: February 1, 2023 DC-C-1 Procedure: Thin-Layer Chromatography (TLC)
Drug Chemistry Procedures Manual Page 5 of 5

Version 2023.02.01

ILLINOIS STATE POLICE

DRUG CHEMISTRY PROCEDURES MANUAL

METHOD: GAS CHROMATOGRAPHY WITH FLAME IONIZATION DETECTION (GC-FID)

Reviewed by:	
Forensic Scientist Adrienne A. Hirsch, Chairperson Drug Chemistry Command Advisory Board	-
Approved by:	
Bureau Chief Timothy A. Tripp	-
Drug Chemistry Command Coordinator	
Forensic Sciences Command	

Accepted Date: February 1, 2023 Drug Chemistry Procedures Manual DC-D-1 Page 1 of 4 Version 2023.02.01

INTRODUCTION

Gas Chromatography with Flame Ionization Detection (GC-FID) can be used for qualitative and quantitative purposes or as a general screen to detect the presence of controlled substances. The instrument can be used to perform individual analysis or in conjunction with an autosampler for automated analysis. Comparison of retention time data generated via GC-FID is a preliminary test.

SAFETY CONSIDERATIONS

Standard Laboratory Practices.

PREPARATIONS

The samples should be dissolved in a suitable solvent, e.g., chloroform, methanol, etc.

INSTRUMENTATION

Gas Chromatograph with Flame Ionization Detector with or without autosampler

Reference: Operator's Manual

MINIMUM STANDARDS AND CONTROLS

The following are requirements to meet the minimum standards and controls for GC-FID:

I. Documentation

- 1. A copy of the chromatogram(s) will be preserved in the case file.
- 2. The worksheet will indicate the result of the GC-FID and all chromatograms must be referenced to the worksheet (excluding standards). The chromatograms must be traceable to the GC-FID from which they were generated. Data that is NOT suitable for comparison, but is included in the case file, must be able to be distinguished from data that is suitable for comparison. This can be accomplished by associating samples with their corresponding chromatograms and results in the "Notes" panel in LIMS or through annotations on the included data.
- 3. The gas chromatography conditions, including the carrier gas, column, injection temperature, injection volume, split ratio, oven temperatures, oven ramps, and hold times, will be recorded in the case file. Any additional modifications to the method (e.g. turning the detector off/on, pressure ramps, etc.), not included on the footer, must be noted in the case file.
- 4. The case number, analyst's initials, date, and item number will be recorded on all copies. Item number is optional on standards. (Per the blank policy in Appendix IV-A, item number is also optional on blank chromatograms.)

Accepted Date: February 1, 2023 Drug Chemistry Procedures Manual DC-D-1 Page 2 of 4 Version 2023.02.01

II. Screening Parameters

- 1. For a general screening run, the injection volume will be between 1 and 3 microliters and the split ratio will be between 20:1 and 50:1 (for Shimadzu brand instruments and Agilent 8890 instruments, the injection volume may be as low as 0.5 microliter and the split may be as high as 200:1).
 - a. "Weak" methods that alter the split ratio, injection volume, or that employ manual injections to allow more sample onto the column are acceptable for use after a general screening run has been attempted.
 - b. When appropriate, it is acceptable to use a weak method for an initial screening (e.g. residue or small sample amount), however, this should not be routine and will be documented on the worksheet.
 - c. Methods tailored for the identification of a particular drug (or class of drugs) are exempt from these requirements.

III. Comparisons

- 1. Any qualitative comparison(s) will be made to in-house standards after the data has been assessed for suitability (see DC-App II).
 - a. The standards will be run on the same instrument and under the same conditions, including the column, carrier gas, oven temperatures, oven ramps, and oven hold times, as well as any other method modifications affecting retention time. (Injection parameters are excluded as they relate to sample introduction, not separation.)
 - b. For retention time comparisons, data shall not be more than six months old.
 - c. In order to be considered a positive result or indication, the retention time of the apex of the sample peak must be within +/- 1% of the retention time of the apex of the appropriate reference standard.
 - d. The standard for comparison (including the lot number or laboratory inventory number) must be included in the case file.

IV. Function Checks / Positive Controls

- 1. A logbook (or online equivalent) will be kept for the instrument to record maintenance, function checks, positive controls, standards for comparison, and the column installation date.
 - a. To insure the instrument is working properly, a positive control will be run monthly or more frequently if indicated by instrument performance or before operation if not used on a routine basis. For the purposes of GC-FID, the positive control is one or more reference materials run under the same conditions (isothermally or using a temperature program) on the same method on a routine basis. Before accepting a positive control, the chromatogram must be compared to a previously accepted control or to reference material and examined for peak shape, height, and retention time reproducibility.

Accepted Date: February 1, 2023 Drug Chemistry Procedures Manual DC-D-1 Page 3 of 4 Version 2023.02.01

- b. A program to be used as a general drug screen or unknown run will be checked by running low and high boiling standards. A general screening run shall demonstrate the ability to detect both GHB or GBL and Buprenorphine or Trazodone. This should occur monthly or before operation if the instrument is not used on a routine basis. If multiple screening methods vary only by their injection parameters and / or final hold time, only one needs to be verified. Injection parameters are not crucial, and the shortest final hold time should be chosen for verification.
- c. After the installation of a column, a test sample will be run to verify the column was properly installed and the instrument is functioning. This function test will be documented in the maintenance logbook (or online equivalent).

PROCEDURE OR ANALYSIS

SAMPLE DRUG PROGRAM

The following method is an example of a general drug screen. It includes low boilers (GHB, GBL) and high boilers (Buprenorphine, Trazodone).

Temperatures/Degrees Celsius

Injector 250 Detector 280

Oven 70 for 1 minute, ramp to 280 at 30/minute, hold at 280 for 10

minutes

Column

12 M, 5% Phenyl Methyl Siloxane ID 0.2 mm, film thickness 0.33 micrometer

Carrier Gas

Nitrogen, Hydrogen, or Helium

REPORT WORDING

See Appendix I - Report Wording.

REFERENCES

- 1. The Drug Chemistry Training Manual, Section DC-IA-7.
- 2. Grob, R., *Modern Practice of Gas Chromatography*, 2nd ed., John Wiley and Sons: New York, NY, 1985, pp. 159-176.

Accepted Date: February 1, 2023 Drug Chemistry Procedures Manual DC-D-1 Page 4 of 4 Version 2023.02.01

ILLINOIS STATE POLICE

DRUG CHEMISTRY PROCEDURES MANUAL

METHOD:	FOURIER TRANSFORM INFRARED SPECTROSCOPY (FTIR)
PROCEDURE:	TRANSMISSION AND INTERNAL

REFLECTANCE

Reviewed by:

Forensic Scientist Adrienne A. Hirsch, Chairperson
Drug Chemistry Command Advisory Board

Approved by:

Bureau Chief Timothy A. Tripp
Drug Chemistry Command Coordinator

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual

Forensic Sciences Command

DC-F-1 Page 1 of 7 Version 2023.08.01

INTRODUCTION

Fourier Transform Infrared Spectroscopy (FTIR) can be used as a screening procedure or, most commonly, as a tool for positive structural identification of a compound (confirmatory testing technique). FTIR data may be acquired by multiple methods. Two of the methods employed by ISP include transmission and internal reflection. Both methods often require purification of the sample prior to analysis.

Transmission spectra are produced by measuring the energy transmitted through a sample when a single-path infrared beam passes through it. Sample preparation may require chemical extraction in addition to pellet preparation.

For FTIR using internal reflection, a multiple-path infrared beam is passed through an internal reflecting element (IRE) with a high refractive index at a certain angle. The most common IRE is a diamond, and acquisition is usually via an attenuated total reflection (ATR) instrument accessory. The internal reflection creates an evanescent wave which extends above the crystal IRE. When a sample is held in contact with the IRE, the sample absorbs energy and the evanescent wave is altered or attenuated. This attenuated energy is passed back into the infrared beam. A detector measures the changes in the beam and produces an infrared spectrum.

Identifications made using FTIR rely on comparisons of peak positions and relative peak intensities between sample and standard spectra. This is true whether data is acquired via transmission or internal reflection methods. While transmission and internal reflection spectra of the same substance will show distinct similarities and may provide useful information as to the identification of a specific substance, care must be taken to ensure that identifications are made based on comparisons of spectra acquired in the same manner (i.e. transmission or internal reflection).

RELATED PROCEDURES

Extractions (Appendix III)

SAFETY CONSIDERATIONS

FTIRs use a laser beam to align the mirrors during the operation of the instrument. Do not look directly into the beam as damage to the eyes can result.

PREPARATIONS

In some instances, such as when an ATR accessory is used, there is no sample preparation required. The sample may be used directly (run neat) or extracted. However, when a pellet is required for transmission spectral acquisition, the sample must be pressed into an IR-transparent pellet, using

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-F-1 Page 2 of 7 Version 2023.08.01

IR grade Potassium Bromide and ground with a mortar and pestle.

Potassium Bromide Note: An IR of the KBr will be run when the new bottle is opened. The bottle will be marked with the date opened and initialed. The IR scan will be preserved until the KBr is consumed in analysis.

INSTRUMENTATION

Fourier Transform Infrared Spectrophotometer with A Pellet Press OR An Attenuated Total Reflection Accessory

Reference: Operator's Manuals

MINIMUM STANDARDS AND CONTROLS

The following are requirements to meet the minimum standards and controls for Infrared Spectroscopy:

I. Documentation

- 1. A copy of the IR spectrum will be included in the case file. At least two peaks will be peak-picked and labeled with the wavenumber of the apex. These peaks should be within the 2000-1300 cm⁻¹ region, whenever possible. The peaks selected for labeling shall correlate directly to the peaks used for comparison to a reference standard, which will be noted in the case file. In addition, if using an ATR accessory, a blank will be run and included in the case file. An ATR accessory requires a blank to be run before every sample.
- 2. The IR collection parameters (number of scans, resolution) as well as the case number, item number, analyst's initials, and date will be recorded on spectra. Item number is optional on standards. The optical isomer (where applicable) and the salt form of the standard used for comparison will be recorded.
- 3. The worksheet will indicate the result of the IR and any additional spectra will be referenced to the worksheet (excluding standards). Spectra shall be traceable to the IR from which they were generated. Data that is NOT suitable for comparison, but is included in the case file, must be distinguishable from data that is suitable for comparison. This can be accomplished by associating samples with their corresponding spectra and results in the "Notes" panel in LIMS or through annotations on the included spectra.

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-F-1 Page 3 of 7 Version 2023.08.01

4. If an acquisition method other than the ATR accessory is used, it shall be indicated in the work notes.

II. Screening Parameters

1. The following is an example of recommended method parameters:

Number of scans: 32 to 36*

*internal reflectance scans should be a square number

Resolution: 4 cm⁻¹ Gain: 1

Apodization: Triangular

Starting wavenumber: 4000 cm⁻¹ Ending wavenumber: 500 cm⁻¹

III. Comparisons

- 1. Any qualitative comparison(s) will be made to in-house standards after the data has been assessed for suitability (see DC-App II).
- 2. To make an identification, the spectrum must be compared to an in-house, peak-picked primary standard run on the same instrument and under the same conditions. For FTIR, this includes number of scans, scan range, resolution, and acquisition method (pellet or ATR).
- 3. A positive identification may be made when:
 - i. Sample and standard spectra exhibit general pattern correspondence of peaks and relative intensities, and
 - ii. At least two peaks are compared between the sample and the reference standard and are within +/- 1 cm⁻¹ of each other. These peaks should be within the 2000-1300 cm⁻¹ region whenever possible. When two peaks are not present in this region, then the most abundant peaks will be compared. Corresponding peak wavenumbers will be labeled on both the sample and the reference standard spectra. [NOTE: transmission and internal reflectance methods should produce *similar* spectra, but corresponding wavenumbers may differ by more than +/- 1 cm⁻¹. If a reference standard is available that was acquired by a different mode than the sample spectrum, the data may still be used to *support* a conclusion, given the presence of relevant data from a separate confirmatory testing technique.]
- 4. The reference standard used for comparison (including the lot number or laboratory inventory number) must be included in the case file, and the wavenumbers of the two peaks used for the comparison will be documented.
- 5. In the event that a primary, in-house spectrum is not available, an identification maybe made using two peer reviewed reference sources, ie. IDDA or Pfleger, provided the following is true:

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-F-1 Page 4 of 7 Version 2023.08.01

- i. Both sources are of independent and known origin, AND
- ii. Sample and both reference spectra exhibit overall pattern similarities, AND
- iii. On the sample and at least one of the standard reference spectra, exact wavenumbers of at least 2 peaks are identified, within the 2000-1300 cm⁻¹ whenever possible, and are within +/- 1 cm⁻¹ of each other, AND
- iv. Reference standards were obtained by the same acquisition method as the sample (e.g. samples analyzed via ATR must be compared to standards run via ATR), AND
- v. Images of the sources used for comparison shall be included in the case file.

IV. Function Checks/Positive Controls

- 1. A polystyrene standard or an internal function check mechanism (e.g. Valpro) will be run at least once a month on both the FTIR and ATR (when present), or more frequently if indicated by instrument performance. If the instrument is not used on a routine basis, the polystyrene standard or internal function check may be completed before use. The reports of the internal function check mechanism must pass all aspects of the reported tests as defined by the manufacturer and will be compared to previous run reports. A source voltage value, the IR peak to peak (P2P) value, and the P2P value for the ATR will be recorded and maintained in the instrument logbook (or online equivalent). For a single bounce diamond ATR accessory, the P2P with the ATR installed should be at least 10% of the FTIR P2P. If it is not, an alignment may need to be performed.
- 2. A positive control shall be run following any function checks. The **same** traceable reference material will be run monthly or as needed under the same instrumental conditions. A traceable polystyrene reference or drug standard will be used as the positive control. These control spectra will be peak-picked and compared to previous peak-picked spectra, and maintained in the instrument logbook (or online equivalent). Deviations of greater than +/- 1 cm⁻¹ of prominent peaks in the 2000-1300 cm-1 region from the prior function check will need to be considered.

PROCEDURE OR ANALYSIS

- I. FTIR using internal reflectance (ATR accessory)
 - 1. Background Spectrum
 - i. The ATR attachment should be cleaned, and a new background collected prior to use. The background is to be acquired with the arm in the up position.
 - ii. It is advisable to collect a background spectrum every 5-10 minutes to minimize the impact of environmental factors on analytical spectra.
 - 2. Blank Spectrum
 - i. Prior to each sample, a blank spectrum should be run with the arm down. It will be included in the working file and will be noted on the worksheet.

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-F-1 Page 5 of 7 Version 2023.08.01

ii. The analyst will ensure that the ATR attachment is clean. If the blank has any unusual peaks, the ATR attachment must be re-cleaned and the blank run again.

3. Sample Spectrum

- i. A sample is placed on the diamond mount area. The clamp containing the appropriate anvil is secured **only to the point that good contact is maintained** between the sample and the diamond.
- ii. When working with a liquid, it should be dropped onto the diamond mount and allowed to evaporate completely so that crystals may form directly on the diamond before clamping the anvil.
- iii. The resulting spectra are compared to standards obtained in the same manner.

II. FTIR using transmission (pellet)

1. A small amount of the sample is mixed with KBr using a mortar and pestle. After the two have been sufficiently mixed, the mixture is placed in the pellet die and a KBr pellet is made. (The size of the pellet is optional). If necessary, a background spectrum of KBr should be taken and stored in the computer. The sample pellet isplaced on the IR and a spectrum of the substance is obtained.

REPORT WORDING

See Appendix I – Report Wording

REFERENCES

- 1. The Drug Chemistry Training Manual, Section DC-IA-8.
- 2. Graf, R.T.; Koenig, J.L.; and Ishida, J.; In Fourier Transform Infrared Characterization of Polymers; H. Ishida, Ed.; Plenum: New York, 1987.
- 3. Harrick, N.J.; Internal Reflection Spectroscopy; Interscience Publishers: New York 1967.
- 4. Koulis, C.V.; Hymes, K.J.; and Rawlins, J.L.; A New Spectral Library of Controlled and Non-controlled Drug Standards Using Internal Reflection Spectroscopy; Journal of Forensic Sciences; 45 (4):876-881
- 5. Koulis, C.V. and Raffner, J.A.; Comparison of Transmission and Internal Reflection Infrared Spectra of Cocaine; Journal Forensic Sciences; 46 (5) 822-829.
- 6. Mariabella, F.M. and Harrick, N.J.; Internal Reflection Spectroscopy: Review and Supplement; Harrick Scientific Corporation, Ossining, New York; 1985.

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-F-1 Page 6 of 7 Version 2023.08.01

- 7. Neil, J.E. and Bibby, A.; Improvements in the use of Attenuated Total Reflection Fourier Transform Infrared Dichroism for Measuring Surface Orientation in Polymers; Applied Spectroscopy. Vol. 51 Number 8, 1997. Pages 1083-1091.
- 8. Silverstein, R. M., Bassler, G. Clayton, and Morrill, Terence C. Spectrometric Identification of Organic Compound, 5th ed., John Wiley and Sons: New York, NY, 1991, pp. 91-132.
- 9. Urban, M.W.; Attenuated Total Refection Spectroscopy of Polymers Theory and Practice; ACS Book, Copyright 1996. Chapter 1-2.

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-F-1 Page 7 of 7 Version 2023.08.01

ILLINOIS STATE POLICE

DRUG CHEMISTRY PROCEDURES MANUAL

METHOD: GAS CHROMATOGRAPHY - MASS SPECTROMETRY (GC-MS)

Reviewed by:	
Forensic Scientist Adrienne A. Hirsch, Chairperson Drug Chemistry Command Advisory Board	_
Approved by:	
Bureau Chief Timothy A. Tripp Drug Chemistry Command Coordinator Forensic Sciences Command	_

Accepted Date: February 1, 2023 Drug Chemistry Procedures Manual DC-G-1 Page 1 of 6 Version 2023.02.01 **Procedure:** Gas Chromatography - Mass Spectrometry (GC-MS)

INTRODUCTION

When a gas chromatograph is coupled with a mass selective detector, it gives rise to the hyphenated technique known as GC-MS, or gas chromatography-mass spectrometry. GC-MS can be used for screening purposes, however, its most common use is for structural information from the mass spectrometer for the positive identification of a compound. The instrument can be used with an automated sampler and for quantitation.

The qualitative analysis of unknown substances by GC-MS is accomplished by direct comparison with a standard spectrum for an identification. The mass spectrum must be interpreted. This does not mean that all the fragments must be assigned but rather the chemist must determine if the unknown and the standard are the same substance. This is done by comparing the mass of each fragment and its relative intensity in the unknown to the standard. Retention time comparisons from GC-MS can also be used as preliminary testing. When retention time data is used in conjunction with mass spectral data, a GC-MS run is still considered a single test for the purposes of meeting the minimum requirement of two tests.

The computer is used to acquire data in a form which can be used by the chemist. It should not alter the fundamental data.

SAFETY CONSIDERATIONS

Standard Laboratory Practices.

PREPARATIONS

The sample will usually be dissolved in a suitable solvent prior to introduction into the GC-MS. Examples include but are not limited to:

Methanol Chloroform

INSTRUMENTATION

Computer manipulations, including subtractions of background noise, should not change the fundamental data, and therefore need not be recorded on the worksheet. A subtraction of the spectrum of a separate compound from the sample spectrum will need to be documented in the case file.

MINIMUM STANDARDS AND CONTROLS

The following is a list of requirements to meet minimum standards and controls for gas chromatography - mass spectrometry:

Accepted Date: February 1, 2023 Drug Chemistry Procedures Manual DC-G-1 Page 2 of 6 Version 2023.02.01 **Procedure:** Gas Chromatography - Mass Spectrometry (GC-MS)

I. Documentation

- 1. A copy of the spectrum and the total ion chromatogram will be included in the case file.
- 2. The identification of a compound must be based on visual comparison of the fragmentation pattern.
- 3. The instrumental conditions, including carrier gas, column, injection temperature, injection volume, split ratio, oven temperature, oven ramps, oven hold times, solvent delay, auxiliary or MSD interface temperature, scan range, and tune file or tune type (e.g. atune, stune, etc.) will be recorded in the case file. Any additional modifications to the method (e.g. turning the detector off/on, pressure ramps, etc.), not included on the footer, must be noted in the case file.
- 4. The case number, analyst's initials, item number, and date will be recorded on all copies. Item number is optional on standards. (Per the blank policy in Appendix IV-A, item number is also optional on blank chromatograms/spectra.)
- 5. The worksheet will indicate mass spectrometer results and all spectra must be referenced to the worksheet (excluding standards). The spectra should be traceable to the GC-MS from which they were generated. Data that is NOT suitable for comparison, but is included in the case file, must be distinguishable from data that is suitable for comparison. This can be accomplished by associating samples with their corresponding spectra and results in the "Notes" panel in LIMS or through annotations on the included spectra.

II. Screening Parameters

- 1. For a general screening run, the injection volume will be between 1 and 3 microliters and the split ratio will be between 20:1 and 50:1 (for Shimadzu brand instruments and Agilent 8890/5977 instruments, the injection volume may be as low as 0.5 microliter and the split may be as high as 100:1).
 - a. "Weak" methods that alter the split ratio, injection volume, or that employ manual injections to allow more sample onto the column are acceptable for use after a general screening run as been attempted.
 - b. When appropriate, it is acceptable to use a weak method for an initial screening (e.g. residue or small sample amount), however, this should not be routine and will be documented on the worksheet.
 - c. Methods tailored for the identification of a particular drug (or class of drugs) are exempt from these requirements.

III. Comparisons

Accepted Date: February 1, 2023 Drug Chemistry Procedures Manual DC-G-1 Page 3 of 6 Version 2023.02.01 **Procedure:** Gas Chromatography - Mass Spectrometry (GC-MS)

- 1. The mass spectrum shall be compared to an in-house standard, either primary or secondary, after the data has been assessed for suitability (see DC-App II).
 - a. The standard must be run on the same instrument and under the same mass spectral conditions. This includes auxiliary or MSD interface temperature, scan range, and tune file or tune type. (Solvent delay is not required as it relates to turning the detector off/on.)
 - b. The standard for comparison (including the lot number or the laboratory inventory number) must be included in the case file.
 - c. For a qualitative mass spectral comparison, the age of the spectrum of the inhouse reference standard is not crucial if the analytical conditions meet the criteria in item (a) above, and the instrument has met the requirements of function checks and positive controls.
 - d. An identification shall only result when a preponderance of ions across the spectrum exhibit general correspondence of abundances between ions of corresponding nominal m/z values.
 - a. The sample and the reference standard shall exhibit the same base peak, unless variations have been documented by the laboratory.
 - b. The sample and reference standard shall exhibit the same molecular ion, when observed, unless variations have been documented by the laboratory.
 - c. Isotopic ion distributions observed in the reference spectrum shall be present in the analyte spectrum.
 - e. In the case that a standard is unavailable, an identification may be made using two appropriate literature sources or external standard references, provided the sources are evaluated according to parameters outlined in DC-App IV-A. Care must be taken to verify that mass spectral data coupled to other available testing is sufficient to conclusively identify the substance in question. Additionally, the following conditions must be met:
 - a. The sources used for comparison must be of independent origin, and these shall be documented in the case file,
 - b. Both spectra shall be of sufficient abundance to allow for meaningful comparisons,
 - c. Both shall exhibit the same base peak and molecular ion, when one is observed,
 - d. Both shall exhibit general correspondence in relative abundance of a majority of ions across the spectra, and
 - e. Both shall be included in the case file.
- 2. If GC-MS data is used to compare retention times, this comparison will be clearly documented. It is not required to utilize this information unless it is necessary to support a specific conclusion. (Examples of useful retention time comparisons include, but are not limited to, isomer differentiation such as between pseudoephedrine and ephedrine, or the positional isomers of methylethcathinone.)
 - a. If no retention time comparison is noted, it will be understood that the retention time data from the coupled technique was not considered.
 - b. For retention time comparisons, the standard for comparison must be run on the same instrument under the same conditions. This includes the column, carrier

Accepted Date: February 1, 2023 Drug Chemistry Procedures Manual DC-G-1 Page 4 of 6 Version 2023.02.01 **Procedure:** Gas Chromatography - Mass Spectrometry (GC-MS)

- gas, oven temperatures, oven ramps, oven hold times, auxiliary or MSD interface temperature, scan range, and tune file or tune type, as well as any other method modifications affecting retention time. (Injection parameters and solvent delay are excluded as they relate to sample introduction into the system, not separation.)
- c. Criteria for reference standard expirations, positive test results, and reference standard documentation specifically associated with retention time data can be found in Section DC-D-1.

IV. Function Checks / Positive Controls

- 1. The function check for mass spectrometry utilizes Perfluorotributylamine (PFTBA) as a reference sample to tune the mass spectrometer. The following ranges are used to qualify the function check:
 - \circ Mass assignments of 69, 219, 502 are \pm 0.2 amu.
 - \circ Isotopic ratio of 70 to 69 falls in the 0.5 1.6% range
 - \circ Isotopic ratio of 220 to 219 falls in the 3.2 5.4% range
 - o Isotopic ratio of 503 to 502 falls in the 6.5-13.5% range (for MSD)
 - 2. A logbook (or online equivalent) will be kept for the instrument to record maintenance, function checks, positive controls, and standards for comparison.
 - a. An autotune will be performed monthly or more frequently if indicated by instrument performance or usage, or before operation if not used on a routine basis. A record of the tune will be retained.
 - b. A positive control will be run after every autotune. For the purposes of mass spectrometry, the positive control is one or more reference materials run under the same conditions, on the same method on a routine basis. Before accepting a positive control, it must be compared to a previously accepted control or reference material.
 - c. A program to be used as a general drug screen or unknown run will be checked by running low and high boiling standards. A general screening run shall demonstrate the ability to detect both GHB (or GBL) and Buprenorphine (or Trazodone). This should occur monthly or before operation if the instrument is not used on a routine basis. If multiple screening methods vary only by their injection parameters and / or final hold time, only one needs to be verified. Injection parameters are not crucial, and the shortest final hold time should be chosen.
 - d. For GC-MS, after the installation of a GC column a test sample will be run to verify the column was properly installed and the instrument is functioning. This function test will be documented in the maintenance logbook (or online equivalent).

PROCEDURE OR ANALYSIS

Accepted Date: February 1, 2023 Drug Chemistry Procedures Manual DC-G-1 Page 5 of 6 Version 2023.02.01 **Procedure:** Gas Chromatography - Mass Spectrometry (GC-MS)

SAMPLE DRUG PROGRAM

The following method is an example of a general drug screen. It detects low boilers (GHB,GBL) and high boilers (Buprenorphine, Trazodone).

Temperatures (Degrees Celsius)

Inlet: 250

Auxiliary or

MSD interface: 280

Oven: 70 for 0 minutes, ramp to 300 at 30/minute, hold at 300 for

7.3333 minutes

<u>Injection Parameters</u>

Injection Volume: 1.0 μL Split Ratio: 30:1

Column

30 m, 100% dimethyl polysiloxane ID 0.25 mm, film thickness 0.25 micrometer

Carrier Gas

Hydrogen or Helium

Detector Parameters

Solvent Delay: 1.0 minScan Range: 40 - 550 amu

Tune file/Tune type: stune.u

REPORT WORDING

See Appendix I - Report Wording.

REFERENCES

1. The Drug Chemistry Training Manual, Section DC-IA-9.

2. Watson, J. T., *Introduction to Mass Spectrometry*, Raven Press, NY, 1985; pp. 1-16, 75-93, 121-143, 153-165 189-295.

Accepted Date: February 1, 2023 DC-G-1 Procedure: Gas Chromatography - Mass Drug Chemistry Procedures Manual Page 6 of 6 Spectrometry (GC-MS)

Version 2023.02.01

DRUG CHEMISTRY PROCEDURES MANUAL

METHOD: SAMPLING PLAN

Reviewed by:		
Forensic Scientist Adrienne A. Hirsch, Chairperson Drug Chemistry Command Advisory Board	_	
Approved by:		
Bureau Chief Timothy A. Tripp Drug Chemistry Command Coordinator Forensic Sciences Command	_	

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-H-1 Page 1 of 4 Version 2023.08.01 Procedure: Sampling Plan

When multiple unit cases are submitted for analysis, it may be appropriate to employ a statistically based sampling plan. In addition, an extrapolation of weight or number of tablets may need to be done. This section will outline Hypergeometric Sampling, Bayesian Theorem, and the Determination of Weight or Total Number of Objects. The calculated number of units must be individually tested as to meet the Minimum Standards and Controls for analysis.

SAFETY CONSIDERATIONS

No additional safety considerations. Follow the requirements of the selected testing procedure.

PREPARATIONS

No additional preparations are necessary.

INSTRUMENTATION

ENFSI Sampling Software (Second Edition, dated July 2017)

Follow the requirements of the selected testing procedure.

DEFINITIONS

Bias: Having a preference or tendency to favor.

Consistent: The same in physical appearance, markings, color, size.

Dosage: Distinct segregated items that are intended for individual

consumption.

Homogenous: Uniform in physical appearance (size, color, consistency, markings,

etc.)

Negative: Having composition that strays in comparison to other items tested. Positive: Having composition that yields consistent results with all other

items tested, whether the substance contained is controlled or not.

Random Sample: Selection of items to be tested without bias.

Representative A small sample portion that is characteristic of the whole population

Sample: and is sufficient for testing.

Sampling: Selecting a representative portion of a population to make a

determination about the whole.

Test Portion: The number of units determined from the sampling plan that is set

aside for analysis.

Unit: A single individual object/member of a population

MINIMUM STANDARDS AND CONTROLS

Accepted Date: August 1, 2023

DC-H-1

Procedure: Sampling Plan

Drug Chemistry Procedures Manual

Page 2 of 4

Version 2023.08.01

- 1. The worksheet/work notes and report will reflect the sampling plan used.
- 2. The sampling plan should maintain a minimum confidence level of at least 95%.
- 3. A copy of the results of the sampling plan will be included in the case file. When employed, the results of a random number generator and/or weight estimation program also will be included.

PROCEDURE OR ANALYSIS

- 1. The analyst will determine if the population is visually homogeneous in nature.
- 2. The analyst's worksheet/work notes will reflect the sampling plan used and a copy of the results of the calculations will be included in the case file.
- 3. Typically, with Hypergeometric Sampling, the analyst will call 90% of a population at a 95% confidence level. Utilizing Bayesian Theorem, the analyst will call the entire population at a 95% confidence level. The analyst may use discretion and adjust the percentage of the population used in order to reach the highest attainable sentencing class.
- 4. The units to be tested shall be randomly selected from the total population. A random number generator may be used.
- 5. Each unit in the test portion will be analyzed individually according to the testing requirements for that particular type of evidence (e.g., powders, tablets, plant material, etc.).
- 6. If a negative result is obtained, the sampling plan will be aborted and testing the appropriate number of units necessary for the charge will be done.

REPORT WORDING

Clarification will be made in the description for extrapolated weights (estimated) or for extrapolated number of units.

The analyst will use a remarks line on the report to indicate the sampling plan used.

REFERENCES

- 1. European Network of Forensic Science Institutes, Drugs Working Group. Guidelines on Representative Drug Sampling; 2003.
- 2. European Network of Forensic Science Institutes, Drugs Working Group. Guidelines on Sampling of Illicit Drugs for Qualitative Analysis; Second Edition; 2016.

Accepted Date: August 1, 2023 DC-H-1 Procedure: Sampling Plan Drug Chemistry Procedures Manual Page 3 of 4

Version 2023.08.01

- 3. Coulson, S.A.; Coxon, A.; and Buckleton, J. "How Many Samples from a Drug Seizure Need to be Analyzed?" Jour. For. Sci. 2001; 46(6):1456-1461.
- 4. Aitken, C. G. G. "Sampling How Big a Sample?" Jour. For. Sci. 1999; 44(4):750-760.
- 5. Frank, R.S.; Hinkley, S.W.; and Hoffman, C.G. "Representative Sampling of Drug Seizures in Multiple Containers" Jour. For. Sci. 1991;36(2):350-357.
- 6. SWGDRUG Methods and Reports Subcommittee. Minimum Recommended Standards for Sampling Seized Drugs for Qualitative Analysis 2004.
- 7. Hedayat, A.S. and Zhang, W.G. "Sampling Plans and Related Statistical Inferences of Forensic Drug Study" 1994 Technical Report No. 94-01.
- 8. Colon, M.; Rodriguez, G.; and Orlando, D. "Representative Sampling of 'Street' Drug Exhibits" Jour. For. Sci. 1993; 38(3):641-648.
- 9. Clark, A. B. and Clark, C.C. "Sampling of Multi-Unit Drug Exhibits" Jour. For. Sci. 1990;35(3):713-719.
- 10. Joyce, James, "Bayes' Theorem", *The Stanford Encyclopedia of Philosophy* (Fall 2008 Edition), Edward N. Zalta (ed.), URL = http://plato.stanford.edu/archives/fall2008/entries/bayes-theorem/>.
- 11. Drug Chemistry Training Manual Section DC-IA-17.

Accepted Date: August 1, 2023 DC-H-1
Drug Chemistry Procedures Manual Page 4 of 4

Version 2023.08.01

Procedure: Sampling Plan

DRUG CHEMISTRY PROCEDURES MANUAL

METHOD: SAMPLING PLAN			
PROCEDURE: HYPERGEOMETRIC SAMPLING			
Reviewed by:			
Forensic Scientist Adrienne A. Hirsch, Chairperson Drug Chemistry Command Advisory Board			
Approved by:	Approved by:		

Bureau Chief Timothy A. Tripp Drug Chemistry Command Coordinator Forensic Sciences Command

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-H-1A Page 1 of 3 Version 2023.08.01 **Procedure:** Hypergeometric Sampling

Hypergeometric Sampling is a mathematical probability calculation used to make a determination on a population, based on testing a representative sample of that population. The population to be called positive and the number to be tested can be determined from the ENFSI software program. Hypergeometric Sampling will always have a "Not Analyzed" portion of the population. It is recommended that the Hypergeometric plan is applied to populations of at least 35 units. This plan may not be appropriate for situations where the estimated weight or the total population is near or at a charging limit.

INSTRUMENTATION

ENFSI Sampling Software (Second Edition, dated July 2017)

PROCEDURE - ENFSI SOFTWARE

- 1. Determine the population is visually homogeneous in nature. Remove any units that are not homogeneous to the population and test each differing population appropriately.
- 2. Utilizing the ENFSI program, enter the total number of units in the population.
- 3. Enter (AS A PERCENT) the percentage of the population to be called positive as a decimal. (e.g. 90% entered as 0.90)
- 4. Enter "0" for the number of negatives. (If a negative result is obtained, the sampling plan will be aborted and testing the appropriate number of units necessary for the charge will be done.)
- 5. Enter a confidence level percentage as a decimal. (95% is entered as 0.95)
- 6. Attach the Calculation Parameter Table and graph (or "yes/no" table up to the number of units required in place of the graph) to the analytical notes packet. (SOFTWARE NOTE: Do not include all pages from the program.)
- 7. Test the appropriate number of units as determined by the calculations.
- 8. The report will reflect an Item (#) being the amount called positive and an Item (#) being a "Not Analyzed" portion.

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-H-1A Page 2 of 3 Version 2023.08.01 **Procedure:** Hypergeometric Sampling

REPORT WORDING

The following is an example of the report wording for use of hypergeometric sampling in a case. Remember, when using the Hypergeometric sampling plan, the call is the portion of the population (e.g. 90%) set as positive in the sampling calculation.

Item 1-1 21.2 grams of 270 tablets 3,4-Methylenedioxymethamphetamine

(MDMA)

Item 1-2 2.3 grams of 30 tablets Not Analyzed

REMARKS: The Hypergeometric sampling plan was used to analyze Item 1.

REFERENCES

- 1. European Network of Forensic Science Institutes, Drugs Working Group. Guidelines on Representative Drug Sampling; 2003.
- 2. European Network of Forensic Science Institutes, Drugs Working Group. Guidelines on Sampling of Illicit Drugs for Qualitative Analysis; Second Edition; 2016.
- 3. Aitken, C. G. G. "Sampling How Big a Sample?" Jour. For. Sci. 1999; 44(4):750-760.
- 4. Frank, R.S.; Hinkley, S.W.; and Hoffman, C.G. "Representative Sampling of Drug Seizures in Multiple Containers" Jour. For. Sci. 1991;36(2):350-357.
- 5. SWGDRUG Methods and Reports Subcommittee. Minimum Recommended Standards for Sampling Seized Drugs for Qualitative Analysis 2004.
- 6. Hedayat, A.S. and Zhang, W.G. "Sampling Plans and Related Statistical Inferences of Forensic Drug Study" 1994 Technical Report No. 94-01.
- 7. Drug Chemistry Training Manual Section DC-IA-17.

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-H-1A Page 3 of 3 Version 2023.08.01 Procedure: Hypergeometric Sampling

DRUG CHEMISTRY PROCEDURES MANUAL

METHOD: SAMPLING PLAN

PROCEDURE: BAYESIAN SAMPLING

Reviewed by:

Forensic Scientist Adrienne A. Hirsch, Chairperson
Drug Chemistry Command Advisory Board

Approved by:

Bureau Chief Timothy A. Tripp
Drug Chemistry Command Coordinator

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual

Forensic Sciences Command

DC-H-1B Page 1 of 3 Version 2023.08.01 Procedure: Bayesian Sampling

The Bayesian sampling plan is based on Bayes' Theorem. It is a statistically based sampling plan with a scientific subjective conclusion drawn by the tendency of homogenous populations to test consistently. This experience and mathematics allows an analyst to test a representative sample as determined from the ENFSI program (hypergeometric mathematics) and draw a conclusion for the entire population. Limits of 90% of the population at a 95% confidence level were chosen from the Coulson, et al. and the Frank, et al. articles. It is recommended that if this approach is selected, that it be applied to population of at least 50 units.

INSTRUMENTATION

ENFSI Sampling Software (Second Edition, dated July 2017)

PROCEDURE

- 1. Determine the population is visually homogeneous in nature. Remove any units that are not homogeneous to the population and test each differing population appropriately.
- 2. Utilizing the ENFSI program, enter the total number of units in the population.
- 3. Enter a value for a and b. Use "1" for each if there is no prior information known. (This is the most conservative approach and the most recommended. Those who are both comfortable in statistics and have an understanding of a and b can utilize a more aggressive approach and enter appropriate numbers.)
- 4. Enter 90% as the portion of the population to be called positive as a decimal. (90% entered as 0.90.)
- 5. Enter "0" for the number of negatives. (If a negative result is obtained, the sampling method will be aborted.)
- 6. Enter a confidence level percentage as a decimal. (95% is entered as 0.95)
- 7. Attach the Calculation Parameter Table and graph (or "yes/no" table up to the number of units required in place of the graph) to the analytical notes packet. (SOFTWARE NOTE: Do not include all pages from the program.)
- 8. Test the appropriate number of units as determined by the calculations.
- 9. The conclusions will represent the total population.

REPORT WORDING

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-H-1B Page 2 of 3 Version 2023.08.01 Procedure: Bayesian Sampling

The following is an example of the report wording for use of Bayesian sampling in a case. Remember, when using the Bayesian sampling plan, the entire population is called positive based on the homogeneity and the experience of the analyst.

Item 1 21.0 grams of 1602 tablets 3,4-Methylenedioxymethamphetamine (MDMA) **REMARKS:** The Bayesian sampling plan was used to analyze Item 1.

REFERENCES

- 1. European Network of Forensic Science Institutes, Drugs Working Group. Guidelines on Representative Drug Sampling; 2003.
- 2. European Network of Forensic Science Institutes, Drugs Working Group. Guidelines on Sampling of Illicit Drugs for Qualitative Analysis; Second Edition; 2016.
- 3. Coulson, S.A.; Coxon, A.; and Buckleton, J. "How Many Samples from a Drug Seizure Need to be Analyzed?" Jour. For. Sci. 2001; 46(6):1456-1461.
- 4. Aitken, C. G. G. "Sampling How Big a Sample?" Jour. For. Sci. 1999; 44(4):750-760.
- 5. Frank, R.S.; Hinkley, S.W.; and Hoffman, C.G. "Representative Sampling of Drug Seizures in Multiple Containers" Jour. For. Sci. 1991;36(2):350-357.
- 6. Joyce, James, "Bayes' Theorem", *The Stanford Encyclopedia of Philosophy* (Fall 2008 Edition), Edward N. Zalta (ed.), URL = http://plato.stanford.edu/archives/fall2008/entries/bayes-theorem/>.
- 7. Drug Chemistry Training Manual Section DC-IA-17.

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-H-1B Page 3 of 3 Version 2023.08.01 **Procedure:** Bayesian Sampling

DRUG CHEMISTRY PROCEDURES MANUAL

SAMPLING PLAN
DETERMINATION OF WEIGHT OR NUMBER OF UNITS
ne A. Hirsch, Chairperson ad Advisory Board
Tripp ad Coordinator

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual

Forensic Sciences Command

DC-H-1C Page 1 of 5 Version 2023.08.01

There are cases that may be submitted where sampling is the preferred method of analysis. In these cases, it may be necessary to estimate the total weight or the total number of units (especially tablets) in a population. The extrapolated weight will be determined using individual unit weights, the mean, and the standard deviation. The extrapolated number of units can be determined using the total population weight and the weight of a known number of units. The use of these estimates/extrapolations will be made clear in the report.

SAFETY CONSIDERATIONS

Standard Laboratory Practices

PREPARATIONS

No additional preparations are necessary.

INSTRUMENTATION

ENFSI Sampling Software (Second Edition, dated July 2017)

MINIMUM STANDARDS & CONTROLS

- 1. The calculated values for the mean and standard deviation will be noted on the worksheet/work notes.
- 2. A copy of the estimation of weight spreadsheet will be included in the case file.
- 3. The report will reflect that the weight is calculated, or the number of units estimated, as applicable to the case.

PROCEDURE - DETERMINATION OF THE NUMBER OF OBJECTS

The total number of units in the population (e.g. tablets) may be manually counted. If the population is large, the population number may be determined using the following:

- 1. The weight of the total population will be recorded.
- 2. The weight of a known quantity of units will be recorded.
- 3. The weight of the known quantity divided by the number of units in that quantity will be done.
- 4. The results of the division will be divided into the total weight of the population and the result will be the extrapolated number of units.

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-H-1C Page 2 of 5 Version 2023.08.01

Extrapolated Number of Units $= \frac{\text{Weight of population}}{\text{(Weight of known number of units/Known number of units)}}$ An example. . . $X = \frac{15.7 \text{ grams total weight of population}}{1.4 \text{ grams } / 10 \text{ units from population}}$ $X = \frac{112 \text{ estimated units}}{112 \text{ estimated units}}$

PROCEDURE – DETERMINATION OF WEIGHT (ENFSI software)

- 1. The number of units to be tested (sample size), as determined by the sampling plan (Hypergeometric or Bayesian), will be individually weighed. These weights will be recorded in an Excel spreadsheet.
- 2. The mean (or average, μ) of the sample size weights will be calculated using Excel (AVERAGE).
- 3. The standard deviation of the sample size weights will be calculated using Excel (STDEV.P).
- 4. Enter the values in the ENFSI software Estimation of Weight panel.
 - a. Enter the confidence level (0.95)
 - b. Enter the population (90% of the total population)
 - c. Enter the sample size
 - d. Enter the mean
 - e. Enter the standard deviation
 - f. Enter the number of negatives (0)
 - g. Enter the weighing balance uncertainty (calculated using the average weight of the sample size in the appropriate Measurement Uncertainty Worksheet)
 - h. Report the calculated weight of the appropriate number of units (90% of the population for Hypergeometric or the total population for Bayesian), ensuring the range is sufficiently above the necessary weight limit
 - ** The total population is not necessarily the same (N) value that was used in the sampling plan calculation. The total population (N) is the total population of that item (sub-item). For one calculation, (N_1) would represent the positive population, for the next calculation (N_2) would represent the not analyzed portion. [Where the called population (N_1) + the not analyzed portion (N_2) = the total population (N).]

For example:

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-H-1C Page 3 of 5 Version 2023.08.01

There are 1000 packets of suspected heroin. When utilizing the Bayesian sampling plan, the total population is 1000 for determination of weight. If the Hypergeometric sampling plan was utilized at 90% of the population, the determination of weight would then be performed twice: the first time with a total population (N) of 900, and the second time with the remaining population (N) of 100. This may also be applied by using the total population of 1000, then the called population of 900, and by difference determine, the calculated weight of the 100 packets of the remaining population.

REPORT WORDING

The following are examples of descriptors that clarify that the number of units or the weight was extrapolated/estimated. When statistics are used for weight determination, use the word "calculated." For unit number determinations use the word "estimated." These are only examples and not an exhaustive list. Remarks lines are necessary when a sampling plan is utilized.

Determined number of units with known weights using Bayesian Sampling. . .

Item 1 218.9 grams of an estimated 721 tablets	3,4-MDMA
--	----------

REMARKS: The Bayesian sampling plan was used to analyze Item 1.

Determined number of units with known weights using Hypergeometric Sampling. . .

Item 1-1	12.3 grams of an	estimated 1620 paper	LSD
	squares		
Item 1-2	1.3 grams of an	estimated 180 paper	Not Analyzed
	squares		

REMARKS: The Hypergeometric sampling plan was used to analyze Item 1.

Calculated weight with known units using Bayesian Sampling . . .

Item 1	412 vials of liquid weighing a calculated PCP
	604.1 grams

REMARKS: The Bayesian sampling plan was used to analyze Item 1.

Calculated weight with known units using Hypergeometric Sampling . . .

Item 1-1	900 packets of pow	der weighing a	Heroin
	calculated 109.2 grams		
Item 1-2	Item 1-2 100 packets of powder weighing a calculated 12.1 grams		Not Analyzed

REMARKS: The Hypergeometric sampling plan was used to analyze Item 1.

Calculated weight and units with Bayesian Sampling . . .

Item 1	A calculated 417.9 grams of powder from	Methamphetamine
	an estimated 2786 packets	

REMARKS: The Bayesian sampling plan was used to analyze Item 1.

Calculated weight and units with Hypergeometric Sampling . . .

Accepted Date: August 1, 2023 DC-H-1C Procedure: Drug Chemistry Procedures Manual Page 4 of 5 Number of Units

Version 2023,08.01

Item 1-1	A calculated 427.1 grams of chunky	Cocaine
	substance from an estimated 1836 packages	
Item 1-2	A calculated 47.4 grams of chunky	Not Analyzed
	substance from an estimated 204 packages	

REMARKS: The Hypergeometric sampling plan was used to analyze Item 1.

REFERENCES

- 1. European Network of Forensic Science Institutes, Drugs Working Group. Guidelines on Representative Drug Sampling; 2003.
- 2. European Network of Forensic Science Institutes, Drugs Working Group. Guidelines on Sampling of Illicit Drugs for Qualitative Analysis; Second Edition; 2016.
- 3. Hedayat, A.S. and Zhang, W.G. "Sampling Plans and Related Statistical Inferences of Forensic Drug Study" 1994 Technical Report No. 94-01.
- 4. Drug Chemistry Training Manual Section DC-IA-1.

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-H-1C Page 5 of 5 Version 2023.08.01

DRUG CHEMISTRY PROCEDURES MANUAL

METHOD: GAS CHROMATOGRAPHY - INFRARED SPECTROMETRY (GC-IR)

Reviewed by:		
Forensic Scientist Adrienne A. Hirsch, Chairperson Drug Chemistry Command Advisory Board		
Approved by:		
Bureau Chief Timothy A. Tripp		
Drug Chemistry Command Coordinator		
Forensic Sciences Command		

Accepted Date: February 1, 2023 Drug Chemistry Procedures Manual DC-I-1 Page 1 of 7 Version 2023.02.01

When a gas chromatograph is coupled with a Fourier Transform infrared spectrometer, it gives rise to a hyphenated technique known as gas chromatography-infrared spectroscopy, or GC-IR. The GC-IR combines a chromatography separation technique with confirmatory structural information from the infrared spectrometer, allowing for the positive identification of a compound. While the GC-IR would likely not be the first step in the analytical process for routine casework, it could be employed for difficult cases that involve identical-looking GC/MS spectra or co-eluting positional isomers. The instrument can be used with an automated sampler.

The qualitative analysis of unknown substances by GC-IR is accomplished by direct comparison with a standard spectrum for an identification. Comparison of retention time data generated by the GC can be used as a preliminary test. Identifications made using the FT-IR rely on comparisons of peak positions and relative peak intensities between samples and standard spectra. When retention time data is used in conjunction with infrared spectral data, a GC-IR run is still considered a single test for the purposes of meeting the minimum requirement of two tests.

Sample preparation may or may not require extraction. Due to the separating power of the GC, the same vial run on the GC-MS can also be run on the GC-IR. The computer is used to acquire data in a form that can be used by the chemist. It should not alter the fundamental data.

If the analysis cannot occur at the originating laboratory, a representative sample of the substance and/or vial with dried sample is necessary to perform GC-IR analysis. Sample preparation will be performed at the originating laboratory, and then transferred to the closest laboratory with an instrument in service for analysis to be completed. The sample workflow is provided below.

SAFETY CONSIDERATIONS

Standard Laboratory Practices

Use personal protective equipment to cover eyes and skin while working with liquid nitrogen.

PREPARATIONS

The samples should be dissolved in a suitable solvent, e.g., methanol, chloroform, etc.

INSTRUMENTAION

Dani Gas Chromatograph with autosampler

DiscovIR Fourier Transform Infrared Spectrophotometer

Accepted Date: February 1, 2023 Drug Chemistry Procedures Manual DC-I-1 Page 2 of 7 Version 2023.02.01

Reference: Operator's manual

MINIMUM STANDARDS AND CONTROLS

The following are requirements to meet the minimum standards and controls for gas chromatography – infrared spectroscopy:

I. Documentation

- 1. A copy of the GC-IR blank report shall be included before each sample run.
- 2. A copy of the GC-IR sample report, which includes both the chromatogram and the spectrum, will be included in the case file for each sample run. Using the Print Report workbook, at least two peaks will be labeled with the wavenumber of the apex. These peaks should be within the 2000 1300 cm⁻¹ region, whenever possible. The peaks selected for labeling shall correlate directly to the peaks used for comparison to a reference standard. The print out of the reference standard with peaks labeled will also be included.
- 3. The gas chromatography conditions, including column type (included in the method name or analytical notes packet not included by software) and parameters, injection temperature, injection volume, split ratio, oven temperatures, oven ramps, hold times, gas flow, transfer line temperature, restrictor temperature, and IR parameters including disk temperature, disk speed, data collection time, track pointer, and chamber pressure will be on the report.
- 4. The item number, analyst's initials, and date will be recorded on the report and all spectra. Item number is optional on the standards and blanks.
- 5. The worksheet will indicate the result of the IR and any additional spectra will be referenced to the worksheet (excluding standards). Chromatograms and spectra shall be traceable to the GC-IR from which they were generated. Data that is NOT suitable for comparison, but is included in the case file, must be distinguishable from data that is suitable for comparison. This can be accomplished by associating samples with their corresponding spectra and results in the "Notes" panel in LIMS or through annotations on the included spectra.

II. Screening parameters

1. Per the manufacturer, the IR screening parameters are as follows:

Scan: 1 (real time) as opposed to number of scans

Resolution: 4 cm⁻¹

Starting wavenumber: 4000 cm⁻¹ Ending wavenumber: 700 cm⁻¹

Accepted Date: February 1, 2023 Drug Chemistry Procedures Manual DC-I-1 Page 3 of 7 Version 2023.02.01 **Procedure:** Gas Chromatography - Infrared

Spectrometry (GC-IR)

Gain: 1

- 2. For a general screening run, the injection volume will be 1 microliter (2 microliters, if needed) and the split ratio will be between 5:1 and 20:1.
 - a. "Weak" methods that alter the split ratio or injection volume to allow more sample onto the column are acceptable for use after a general screening run has been attempted or determined based on previous GC-MS run.
 - b. Methods tailored for the identification of a particular drug (or class of drugs) are exempt from these requirements.

III. Comparisons

- 1. Any qualitative comparison(s) will be made to in-house standards after the data has been assessed for suitability (see DC-App II).
- 2. Spectral comparisons
 - a. For spectral comparisons (including positive identification, standard reference, and documentation criteria) refer to DC-F-1/III.
- 3. Retention time comparisons
 - a. For retention time comparisons (including positive indications, standard reference, and documentation criteria), refer to DC-D-1/III.

IV. Function Checks/Positive Controls

- 1. A logbook (or online equivalent) will be kept for the instrument to record maintenance, function (QC) checks, positive controls, standards for comparisons, and column installation date.
 - a. A polystyrene standard will be run at least once a month or before operation if not used on a routine basis. The results of this function check are preserved in a data table on the instrument. A passing function check will have at least two polystyrene wavenumbers between 2000 and 1300 cm⁻¹ fall within 1 cm⁻¹ of the associated NIST reference wavenumbers. A copy of this table (to include the NIST reference numbers and the current polystyrene run) will be maintained in the logbook (or online equivalent).
 - b. The GC-IR has two function checks (referred to as QC tests) that should be performed prior to the first sequence of the day:
 - 1. Align (throughput) test The purpose of this test is to ensure that the instrument is operating optimally. The results shall be between 4 and 8 volts, with ideal readings being between 5 and 7 volts.

Accepted Date: February 1, 2023 Drug Chemistry Procedures Manual DC-I-1 Page 4 of 7 Version 2023.02.01

- 2. Signal-to-Noise test- This test will help determine if the background is interfering with the sample signal. The instrument runs this test five times. The average result of these is normally between 0.5 and 1.0 with a maximum upper limit of 1.5. If the signal-to-noise ratio is above 1.5, then the test will be completed again. If the second test fails, then contact vendor for further assistance.
- c. Positive controls shall be run at least monthly, or before operation if not used on a routine basis
 - 1. A program to be used as a general drug screen or unknown run will be checked by running low and high boiling standards. A general screening run shall demonstrate the ability to detect both GHB (or GBL) and Buprenorphine (or Trazodone.) Any change to this method (GC or IR parameters) will require a new positive control to be run.
 - 2. The control spectra will be peak-picked and compared to previous peak-picked spectra and maintained in the instrument logbook (or online equivalent). Deviations greater than +/- 1 cm⁻¹ of prominent peaks in the 2000-1300 cm⁻¹ region from the prior function check will need to be considered. Trending deviations should be investigated and addressed.
 - 3. The chromatogram must be compared to a previously accepted control or reference material and examined for peak shape, height, and retention time reproducibility.

PROCEDURE OR ANALYSIS

- 1. A background spectrum (collected with every run) should be included in the GC-IR report.
- 2. A blank is required prior to every sample run on the GC-IR, and the report for each blank will be included in the case file.
- 3. Each sample will be run immediately following a blank and will be set to overlay on the same disc location as its associated blank.

SAMPLE SCREENING/UNKNOWN PROGRAM

The following method is an example of a general drug screen. It includes low boilers and high boilers.

Temperatures/Degrees (Celsius)

Injector 250 Disc -35 Transfer line 280

Accepted Date: February 1, 2023 Drug Chemistry Procedures Manual DC-I-1 Page 5 of 7 Version 2023.02.01

Restrictor 280

Oven 60 for 0.80 min, ramp to 300°C at 35°C/minute, hold at 300°C for 6.35

min

Column 15M, HP-35, 0.25mm ID, 0.25 μm film

Carrier Gas Helium

Other Supplies Liquid Nitrogen

<u>IR parameters</u> (most are hard wired into the instrument [cannot be changed])

Scan: 1 (real time) as opposed to number of scans

Resolution: 4 cm⁻¹

Starting wavenumber: 4000 cm⁻¹ Ending wavenumber: 700 cm⁻¹

Gain: 1

REPORT WORDING

See Appendix I – Report Wording


REFERENCES

Accepted Date: February 1, 2023

Drug Chemistry Procedures Manual

- 1. The Drug Chemistry Training Manual, Section TBD.
- 2. Abdel-Hay, Karim M., et al. "GC-MS and GC-IRD Studies on the Six-Ring Regioisomeric Dimethoxybenzylpiperazines (DMBPs)." *Drug Testing and Analysis*, vol. 5, no. 7, 2012, pp. 560–572.
- 3. Shipman, Robert, et al. "Forensic Drug Identification by Gas Chromatography Infrared Spectroscopy."
- 4. Bartick, Edward G. "Application of Vibrational Spectroscopy in Criminal Forensic Analysis." *Handbook of Vibrational Spectroscopy*, 2002, pp. 1-11.
- 5. Dawson, James Zachary. "The Validation of a GC-IR and GC-MS and GC-IR Analysis of Methcathinone Analogs."
- 6. Drug Identification Procedures Manual, Gas Chromatography-Fourier Transform Infrared Spectroscopy, Georgia Bureau of Investigation, Division of Forensic Sciences

DC-I-1 Page 6 of 7 Version 2023.02.01



DRUG CHEMISTRY PROCEDURES MANUAL

PROTOCOL:	ANALYSIS OF SUSPECTED CONTROLLED SUBSTANCES
METHOD:	ANALYSIS OF TABLETS AND CAPSULES
PROCEDURE:	ANALYSIS OF TABLETS AND CAPSULES
Reviewed by:	
	rienne A. Hirsch, Chairperson mand Advisory Board
Approved by:	
Bureau Chief Timothy Drug Chemistry Com Forensic Sciences Co	mand Coordinator
Forensic Sciences Co.	mmanu

Accepted Date: August 1, 2023 DC-IA-1 Procedure: Analysis of Tablets and Capsules

Page 1 of 4

Version 2023.08.01

Drug Chemistry Procedures Manual

Items containing controlled substances in tablets and/or capsules will sometimes be submitted for analysis. One procedure that can be used for the identification of these materials is the Physical Identification procedure. If more than one tablet and/or capsule is to be identified to meet statutory requirements, the required number of tablets and/or capsules must be tested individually. If necessary, the submission may be analyzed using the Bayesian or Hypergeometric sampling plans. The calculated number of units must each be individually tested to meet the Minimum Standards and Controls for analysis.

SAFETY CONSIDERATIONS

No additional safety considerations, just follow the requirements of the selected testing procedure.

PREPARATIONS

Follow the requirements of the selected procedure.

INSTRUMENTATION

Follow the requirements of the selected procedure.

MINIMUM STANDARDS AND CONTROLS

- 1. When applicable, the worksheet/work notes will reflect the sampling plan used.
- 2. The population will be determined to be visually homogenous.
- 3. When applicable, the results of the sampling plan calculations will be included in the case file.
- 4. Unless using a statistical sampling plan, only the items tested will be identified.

PROCEDURE OR ANALYSIS

- 1. Follow the "Physical Identification" procedures and should a result be obtained, the analyst will determine if additional testing is required for the charge. If more than one tablet or capsule is needed to meet the statutory limits, the appropriate number of tablets must be tested individually or, if the sample allows, the population may be analyzed using a statistical sampling plan. Hypergeometric Sampling and Bayesian Sampling are examples of acceptable sampling plans.
- 2. For obviously clandestine dosage units or units for which the "Physical Identification" procedure does not provide a result, analysis will continue using the powder sample method. If more than one tablet or capsule is needed to meet the statutory limits, the appropriate number of tablets must be tested individually or, if the sample allows, the

Accepted Date: August 1, 2023 DC-IA-1 Procedure: Analysis of Tablets and Capsules

Page 2 of 4 Version 2023.08.01 population may be analyzed using a statistical sampling plan. Hypergeometric Sampling and Bayesian Sampling are examples of acceptable sampling plans.

- 3. The number of units to be tested will be randomly selected from the total population.
- 4. If a negative result is obtained, the statistical sampling plan will be aborted and testing the appropriate number of units necessary for the charge will be done.

REPORT WORDING

The analyst will use a remarks line on the report to indicate the sampling model used.

REFERENCES

- 1. European Network of Forensic Science Institutes, Drugs Working Group. Guidelines on Representative Drug Sampling; 2003.
- 2. Coulson, S.A.; Coxon, A.; and Buckleton, J. "How Many Samples from a Drug Seizure Need to be Analyzed?" Jour. For. Sci. 2001; 46(6):1456-1461.
- 3. Aitken, C. G. G. "Sampling How Big a Sample?" Jour. For. Sci. 1999; 44(4):750-760.
- 4. Frank, R.S.; Hinkley, S.W.; and Hoffman, C.G. "Representative Sampling of Drug Seizures in Multiple Containers" Jour. For. Sci. 1991:36(2):350-357.
- 5. Hedayat, A.S. and Zhang, W.G. "Sampling Plans and Related Statistical Inferences of Forensic Drug Study" 1994 Technical Report No. 94-01.
- 6. SWGDRUG Methods and Reports Subcommittee. Minimum Recommended Standards for Sampling Seized Drugs for Qualitative Analysis 2004.
- 7. Colon, M.; Rodriguez, G.; and Orlando, D. "Representative Sampling of 'Street' Drug Exhibits" Jour. For. Sci. 1993; 38(3):641-648.
- 8. Clark, A. B. and Clark, C. C. "Sampling of Multi-Unit Drug Exhibits" Jour. For. Sci.. 1990; 35(3): 713-719.
- 9. Joyce, James, "Bayes' Theorem", The Stanford Encyclopedia of Philosophy (Fall 2008) Edition), Edward N. Zalta (ed.), URL http://plato.stanford.edu/archives/fall2008/entries/bayes-theorem/>.
- 10. ASTM E2548-16, Standard Guide for Sampling Seized Drugs for Qualitative and Ouantitative Analysis, ASTM International, West Conshohocken, PA 2016, www.astm.org

Accepted Date: August 1, 2023 Procedure: Analysis of Tablets and Capsules DC-IA-1

Page 3 of 4 Drug Chemistry Procedures Manual Version 2023.08.01 11. From Procedures or Appendices as needed.

Drug Chemistry Procedures Manual

Accepted Date: August 1, 2023

DC-IA-1 Page 4 of 4 Version 2023.08.01

The materials contained in this document are protected under federal law and may not be disseminated or reproduced without the express written permission of the Illinois State Police.

Procedure: Analysis of Tablets and Capsules

DRUG CHEMISTRY PROCEDURES MANUAL

PROTOCOL:	ANALYSIS OF SUSPECTED CONTROLLED SUBSTANCES
METHOD:	ANALYSIS OF POWDERED SAMPLES
PROCEDURE:	ANALYSIS OF POWDERED SAMPLES
Reviewed by:	
	rienne A. Hirsch, Chairperson mand Advisory Board
Approved by:	
Bureau Chief Timoth Drug Chemistry Com Forensic Sciences Co	mand Coordinator

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-IB-1 Page 1 of 3 Version 2023.08.01 Procedure: Analysis of Powdered Samples

Many samples submitted to the laboratory for analysis consist of powders in one form or another, e.g., fine/coarse mixtures, chunky, etc. A characteristic of all of these is the ability to reduce them to homogeneous mixtures. However, depending on the situation, it may not be necessary to reduce each sample to a uniform mesh size. The experience of the analyst will determine this as well as the purpose of the analysis (qualitative or quantitative). Minimum Standards and Controls are not to be used as a substitute for good scientific procedures. On an individual case, the minimum indicated may not suffice to complete the identification as defined. It is the primary responsibility of the chemist to identify the controlled substance rather than fulfill these standards.

After evidence handling procedures have been completed and the mass determined for the sample, a portion can be selected for analysis. The requirement to use less than 50% of the sample in the analysis can be exceeded if the analysis dictates it. However, for small amounts, it may be necessary to save the extracted material used in the analysis.

Once the sample is ready for analysis, the analyst must select the procedures necessary to detect and positively identify or eliminate the presence of any controlled substances. This choice is left up to the analyst as long as the result meets the requirements listed in the general introduction to the analysis of controlled substances. The results of the analysis will be reported as indicated in Appendix I – Report Wording.

SAFETY CONSIDERATIONS

Follow the requirements of selected procedure.

PREPARATIONS

Follow the requirements of each procedure. It may be necessary to extract samples prior to analysis.

INSTRUMENTATION

Follow the requirements of selected procedure.

MINIMUM STANDARDS AND CONTROLS

Follow the requirements of selected procedure.

PROCEDURE OR ANALYSIS

Follow the requirements of selected procedure.

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-IB-1 Page 2 of 3 Version 2023.08.01 Procedure: Analysis of Powdered Samples

REPORT WORDING

See Appendix I - Report Wording.

REFERENCES

- 1. Drug Chemistry Training Manual.
- 2. From Procedures or Appendices as needed.

Accepted Date: August 1, 2023 DC-IB-1 Procedure: Analysis of Powdered Samples
Drug Chemistry Procedures Manual Page 3 of 3

Version 2023.08.01

DRUG CHEMISTRY PROCEDURES MANUAL

PROTOCOL:	ANALYSIS OF SUSPECTED CONTROLLED SUBSTANCES
METHOD:	ANALYSIS OF LIQUIDS, PAPER, NON-CANNABIS PLANT MATERIAL, RESIDUES, AND FOOD PRODUCTS
PROCEDURE:	ANALYSIS OF LIQUIDS, PAPER, NON-CANNABIS PLANT MATERIAL, RESIDUES, AND FOOD PRODUCTS
Reviewed by:	
	rienne A. Hirsch, Chairperson mand Advisory Board
Approved by:	
Bureau Chief Timothy	y A. Tripp
Drug Chemistry Com	mand Coordinator
Forensic Sciences Co	mmand

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-IC-1 Page 1 of 3 Version 2023.08.01 **Procedure:** Analysis of Liquids, Paper, Non-Cannabis Plant Material, and Residues

Other laboratory submissions for drug analysis consist of these five general categories – Liquids, Non-Cannabis Plant Material, Samples on Paper, Residues, or Food Products.

Each of these has particular handling or extraction procedures but all are analyzed in the same manner after isolation of the controlled substance from the initial matrix. The following are some general extraction procedures for the analysis of these types of samples.

Liquids: Sometimes can be extracted using chloroform or similar organic solvent.

The addition of dilute acid or base solutions to the initial aqueous matrix can assist both the extraction and help in diluting the sample. Other procedures can be found in the Appendix III under Extractions and

Separations.

Paper: This usually consists of LSD, an NBOMe compound, or a synthetic

Cannabinoid spotted on various types of paper. The sample can be directly extracted with an organic solvent and sonication or extracted with ammonium hydroxide solution and chloroform. See Appendix III for other extractions. Generally, the paper being analyzed should be weighed in its entirety and reported appropriately. There may also be times when the paper can be considered a residue. When that occurs, the

analyst will analyze and report the paper as a residue.

Residues: These can be analyzed with various wash techniques e.g. methanol, and

the volume reduced prior to GC/MS analysis. In order for residues to be analyzed, a request from the State's Attorneys Office must be submitted

and approved by the Lab Director or designee.

Non-Cannabis These may require some blending, grinding, or sample reduction of the Plant Material: plant tissue prior to extraction. Once the matrix is broken down, organic

plant tissue prior to extraction. Once the matrix is broken down, organic solvents and extractions can sometimes help remove the controlled

substance.

Food Products: Food products vary from candies spotted with suspect LSD or NBOMe,

gummy candies containing benzodiazepines, to commercially prepared foods containing THC. Care should be taken to minimize the impact of the sample matrix on instrumentation through careful preparation and

extractions.

SAFETY CONSIDERATIONS

Follow the requirements of selected procedure.

PREPARATIONS

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-IC-1 Page 2 of 3 Version 2023.08.01 **Procedure:** Analysis of Liquids, Paper, Non-Cannabis Plant Material, and Residues This will depend on the matrix.

INSTRUMENTATION

This will depend on the matrix.

MINIMUM STANDARDS AND CONTROLS

Follow the requirements of selected procedure.

PROCEDURE OR ANALYSIS

Follow the requirements of selected procedure.

REPORT WORDING

See Appendix I - Report Wording.

REFERENCES

- 1. Drug Chemistry Training Manual.
- 2. From Procedures or Appendices as needed.

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-IC-1 Page 3 of 3 Version 2023.08.01

Procedure: Analysis of Liquids, Paper, Non-Cannabis Plant Material, and Residues

DRUG CHEMISTRY PROCEDURES MANUAL

PROTOCOL: ANALYSIS OF A CONTROLLED SUBSTANCE

METHOD:	QUANTITATION
PROCEDURE:	CENTRALIZED QUANTITATION
Reviewed by:	
Forensic Scientist Adri Drug Chemistry Comm	ienne A. Hirsch, Chairperson nand Advisory Board
Approved by:	
Bureau Chief Timothy Drug Chemistry Comn Forensic Sciences Con	nand Coordinator

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-IIA-1 Page 1 of 6 Version 2023.08.01 Procedure: Centralized Quantitation

INTRODUCTION

The quantitation of scheduled substances will only be performed at a centralized laboratory location. This section covers the protocol for sampling a case for quantitation. The procedure used for quantitation of a scheduled substance is at the discretion of the chemist as long as minimum standards and control criteria are met.

A representative sample of the entire submitted substance is necessary to perform quantitation. Sample preparation will be performed at the originating laboratory, and then transferred to the centralized laboratory for quantitation.

SAFETY CONSIDERATIONS

Standard Laboratory Practices for Use of Solvents. Refer to current DOT and Postal requirements when shipping caustic liquid samples.

PREPARATIONS

None Required.

INSTRUMENTATION

Balances only.

MINIMUM STANDARDS AND CONTROLS

The following are general minimum standards and controls for quantitation:

- 1. Quantitation will be performed using proven methods which are accepted by the scientific community.
- 2. Quantitation will be performed only upon approval by laboratory management of both the submitting laboratory and the centralized quantitation laboratory. For the Forensic Science Center at Chicago, this is the Section Chief or appropriate designee. Only one single item will be quantitated.
- 3. Calculations will be performed using only scientifically approved methods. All quantitation results will be reported to two significant figures (i.e. a sample of 56.75% will be reported as 56% and a sample of 5.67% will be reported as 5.6%)
- 4. Instrumental linearity will be established.
- 5. Each centralized quantitation Drug Chemistry Section will incorporate in-house quantitative procedures, including uncertainty measurement and proper use and tracking of quantitation reference materials, into the Facility Operations Manual. These procedures will be available for inspection by the quality review coordinator(s) and other inspection

Accepted Date: August 1, 2023 DC-IIA-1 Procedure: Centralized Quantitation
Drug Chemistry Procedures Manual Page 2 of 6

Version 2023.08.01

teams. Ultimate responsibility for accuracy in quantitation will rest with the analyst and the laboratory director/section chief.

- 6. Volumetric glassware used for the preparation of quantitation samples will be checked through the appropriate creation of a calibration curve and analysis of positive control samples. In addition, visual checks of the volumetric glassware will be done prior to each use and any damaged volumetrics will be discarded.
- 7. A control chart must be prepared and measurement uncertainty determined (as outlined in Appendix V) for a quantitation procedure and drug before such analysis can be performed in casework.
- 8. A control sample must be analyzed with each case (as outlined in Appendix V). The control should come from the same stock that was used to create the control chart. If that control sample is unavailable, a new sample must be prepared and a new control chart created.
- 9. The control sample must fall within 2 standard deviations (2 σ) on the control chart for the analysis to be valid.

PROCEDURE OR ANALYSIS

- 1. All quantitations will have laboratory management / supervisor approval. Qualitative analysis must be completed prior to consideration for quantitation. If a request for quantitation as a supplemental report is granted, the case will be resubmitted to the originating laboratory for sample preparation prior to transferring to the centralized quantitation laboratory.
- 2. Collect a representative sample. The method used for sample collection will be recorded on the worksheet; e.g. blender, crushing and sifting, crushing mortar and pestle, etc. An acceptable range of the subsample is no less than 1.0 gram to 5 grams.
 - A. For powder samples, the entire sample will be crushed and the subsample (target amount is 4 grams) will be made homogeneous.
 - B. Liquid samples should be placed into disposable containers. If there are two separate layers then each layer will be pipetted separately into its own disposable container.
- 3. Assign the subsample an identification subitem number in LIMS from the original case item number. Record the mass of the subitem number in LIMS. The mass of the subitem will not be listed on the laboratory report.
- 4. Complete the Quantitation Sample Collection Form using the form located in DC-IIA-1. The form will be sent to the centralized laboratory and placed in the case file.
- 5. Notify the receiving laboratory/person of the quantitation.

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-IIA-1 Page 3 of 6 Version 2023.08.01 Procedure: Centralized Quantitation

- 6. Relocate the subitems in LIMS.
- 7. Prepare and transfer the sample using necessary precautions to prevent contamination and to maintain integrity of evidence and to meet US Postal and DOT regulations.
- 8. Analysis of the subitem at the centralized location will be performed using an approved quantitation procedure.
- 9. The subitem will be tracked through LIMS. If the centralized quantitation site is the laboratory from which the case originated, return of the quantitation sample with the original submission is an option.
- 10. The centralized laboratory will issue a report using report wording guidelines found in DC-Appendix I. If the report is supplemental, the report will reflect the original report date and name of the original analyst. An optional evidence disposition statement may be added stating how evidence will be returned.

SHIPPING PRECAUTIONS

The following precautions will be observed when shipping samples:

- 1. All cases will be transferred using current DOT and postal requirements.
- 2. All powder samples must be placed in a heat sealed plastic bag. All liquid samples must be placed in airtight containers (i.e. paint cans with friction lids, glass jars with tight fitting screw lids) before placing in outer packaging.
- 3. Always pack liquid products in sufficient cushioning and absorbent material to absorb any breakage and, as necessary, to conform to DOT regulations for shipping of hazardous materials.
- 4. No pressurized canisters will be shipped.
- 5. Consult your supervisor if you have any packaging concerns.

REPORT WORDING

See Appendix I - Report Wording.

REFERENCES

1. Drug Chemistry Training Manual – Section DC-IA-7.

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-IIA-1 Page 4 of 6 Version 2023.08.01 Procedure: Centralized Quantitation



QUANTITATION SAMPLE COLLECTION FORM

Name:	Date	/ /
Laboratory:		
Case Number:		
Item Number:		
Description of subsample:		
Form:		
Was a representative sample collected following the guidelines in YES	the drug chemistry p	procedures manual?
Weight of representative sample:		
Assigned subsample identification number:		
Total number of subsamples		
Has qualitative analysis been performed? YES	NO _	
Total weight/volume reported:		
Substance(s) confirmed:		
Laboratory report date://		
Observations or comments:		
Quantitation person/laboratory notified:		
Purpose of quantitation:		
Analyst Signature:		
Supervisor Signature:		

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual

Use one form for each subsample

DC-IIA-1 Page 6 of 6 Version 2023.08.01 Procedure: Centralized Quantitation

DRUG CHEMISTRY PROCEDURES MANUAL

PROTOCOL: ANALYSIS OF A CONTROLLED SUBSTANCE

METHOD:	QUANTITATION
PROCEDURE:	QUANTITATION BY GAS CHROMATOGRAPHY
Reviewed by:	
Forensic Scientist Tiffa Drug Chemistry Comm	ny A. Neal, Chairperson and Advisory Board
Approved by:	
Bureau Chief Timothy Drug Chemistry Comm Forensic Sciences Com	and Coordinator

Accepted Date: January 11, 2018 Drug Chemistry Procedures Manual DC-IIA-3 Page 1 of 6 Version 2018.01.11

INTRODUCTION

For most samples, gas chromatography (GC) is the method of choice, since it provides both separation and quantitation of mixtures at one time. There are two methods for quantitation by GC, the external and internal standard methods.

The columns, conditions for the gas chromatograph, solvents and internal standards should be chosen based on the sample being tested. These factors are left to the discretion of the chemist

Solvents should be chosen that will insure total dissolution of the substance being quantitated. In many cases chloroform is preferred over methanol because sugars are generally insoluble in the chloroform. A mixture of chloroform and methanol can also be used.

To insure that the entire sample injected into the GC is being measured, care must be taken to insure that sodium and sulfate salts are dissociated fully. This problem can be eliminated by adding either a drop of acetic acid or sodium hydroxide to the solution before injection onto the gas chromatograph.

Multiple injections of the standard should be made to insure reproducibility of the system and method. A concentration curve of standards ranging from 0.5 mg/mL to 1.5 mg/mL can be done to test the linearity.

SAFETY CONSIDERATIONS

Standard Laboratory Practices including the use of solvents.

PREPARATIONS

<u>Preparations for Internal Standard Procedure</u>

1. Prepare the internal standard solution.

The internal standard solution should be at a concentration of approximately 1 mg/mL. A large enough quantity should be made in order to dilute all samples (the standard and the unknown solutions). The internal standard should elute at an appropriate time, have no interferences, and provide a reproducible peak for quantitation. Examples of hydrocarbons which can be used as internal standards are tetracosane, docosane, nonadecane. Other substances could be used - for example propiophenone (P-1-P) can be used for quantitating methamphetamine or dipentyl phthalate for cocaine.

Accepted Date: January 11, 2018 Drug Chemistry Procedures Manual DC-IIA-3 Page 2 of 6 Version 2018.01.11

2. Prepare the standard solution.

A primary standard should be used. An exact amount is weighed (on an analytical balance), recorded, and diluted with internal standard by using a repipetter or volumetric flask. The concentration of the standard should be approximately 1 mg/mL.

3. Prepare the unknown solution.

The salt form of the unknown should be determined by the analyst. If it is a different salt than the standard being used, adjustments for the differences in molecular weights must be performed.

The sample must be made homogenous before any analysis is performed. The unknown solution is prepared in the same manner as the standard solution. The concentration of the substance being quantitated should be approximately 1 mg/mL.

To determine the amount of unknown sample to use, its purity is approximated. To obtain a 1 mg/mL sample, the following table can be used:

Estimated Purity	Amount sample (for 1 mL internal standard solution
10%	10.0 mg
25%	4.0 mg
50%	2.0 mg
75%	1.3 mg
100%	1.0 mg

Preparations for External Standard Procedure

The unknown and standard solutions are made as in the internal standard method except an internal standard solution is not used. The unknown and standard are each diluted with solvent only. Both resulting solutions are injected on the gas chromatograph and the areas of the resulting peaks are obtained.

INSTRUMENTATION

The GC Program used for quantitation will depend upon the substances being quantitated and vary with the column diameter and the conditions. It is impractical to list all of the possible combinations.

Accepted Date: January 11, 2018 Drug Chemistry Procedures Manual DC-IIA-3 Page 3 of 6 Version 2018.01.11

An example of a program for the quantitation of cocaine on an Agilent 6890 is given below:

Instrument: Agilent 6890 Detector: FID - 280°

Injector: 250°

Column: HP-1, 15 meter, 0.53 mm diameter, 2.65 micron coating Other Conditions: 210° isothermal; split 10:1; flow 11.7 mLs/min Helium

Length of Run: Approximately 3 minutes

MINIMUM STANDARDS AND CONTROLS

Refer to Gas Chromatography Procedure for instrument minimum standards and controls.

The following are general minimum standards and controls for quantitation:

- 1. Quantitation will be performed using proven methods.
- 2. Quantitation will be performed only upon approval by laboratory management of both the submitting laboratory and the centralized quantitation laboratory. For the Forensic Science Center at Chicago, this is the Section Chief or appropriate designee. Only one single item will be quantitated.
- 3. Calculations will be performed using only scientifically approved methods. All quantitation results will be reported to two significant figures (i.e. a sample of 56.75% will be reported as 56% and a sample of 5.67% will be reported as 5.6%)
- 4. Instrumental linearity will be established.
- 5. Each centralized quantitation Drug Chemistry Section will incorporate in-house quantitative procedures, including uncertainty measurement and proper use and tracking of quantitation reference materials, into the Facility Operations Manual. These procedures will be available for inspection by the quality review coordinator(s) and other inspection teams. Ultimate responsibility for accuracy in quantitation will rest with the analyst and the laboratory director/section chief.
- 6. Volumetric glassware used for the preparation of quantitation samples will be checked through the appropriate creation of a calibration curve and analysis of positive control samples. In addition, visual checks of the volumetric glassware will be done prior to each use and any damaged volumetrics will be discarded.
- 7. A control chart must be prepared and measurement uncertainty determined (as outlined in Appendix V) for a quantitation procedure and drug before such analysis can be performed in casework.

Accepted Date: January 11, 2018 Drug Chemistry Procedures Manual DC-IIA-3 Page 4 of 6 Version 2018.01.11

- 8. A control sample must be analyzed with each case (as outlined in Appendix V). The control should come from the same stock that was used to create the control chart. If that control sample is unavailable, a new sample must be prepared and a new control chart created.
- 9. The control sample must fall within 2 standard deviations (2 σ) on the control chart for the analysis to be valid.

PROCEDURE OR ANALYSIS

Procedure for Internal Standard Method

An internal standard is added to the unknown, control, and the standard solutions. Each solution is injected on the gas chromatograph and the areas of the resulting peaks are obtained. These peak areas and the weights of the unknown sample and standard are used to calculate the purity of the sample. Calculations are performed as described below.

Multiple injections of the standard, control and unknown are made. Each solution should be run at least twice. The integration of the areas of the eluted peaks is recorded.

Calculation

The responses of the standard and the unknown are normalized to the internal standard using the peak areas from the GC chromatogram.

Rstd = Area standard/Area of its internal standard

Runk = Area unknown/Area of its internal standard

Multiple runs are calculated separately and then averaged together. These average R values are inserted in the following formula to determine the concentration of the unknown:

The symbol X provides the units for the quantitation. If X is 100%, the calculation is percent as the standard salt. If X is the average weight of a tablet, the calculation is mg of the standard salt per tablet. If X is 1, the calculation is mg/mL.

If the salt form of the unknown and the standard are different, adjustments for the differences in molecular weights must be performed. The final result is multiplied by the molecular weight of the salt form of the unknown and divided by the molecular weight of the standard salt form.

Accepted Date: January 11, 2018 Drug Chemistry Procedures Manual DC-IIA-3 Page 5 of 6 Version 2018.01.11

Most gas chromatographs come with computers that do all of the above calculations. Rather than weighing a single standard at 1 mg/mL, a range of standards can be prepared and injected to create a standard curve. The concentrations of the standard samples and the areas of the eluted peaks are used to create a calibration table. This table is stored on the computer. The unknown is then prepared and injected. The areas of the eluted peaks are compared back to the table to determine the amount of unknown in the sample. No manual calculations are necessary.

Procedure for External Standard

This procedure is similar to the internal standard method except that no internal standard is added to the solutions. This method is reliable if automatic injection techniques are used to insure reproducibility. The calculations assume that the injection size for both the unknown and the standard are the same. If not, the calculations must correct the responses for this difference.

Calculation

Multiple runs are performed and the resulting peak areas averaged. The following formula is used to determine the concentration of the unknown:

The symbol X is defined in the internal standard method. If the injection sizes of the standard and unknown are not equal, the area of each must be normalized by dividing by its injection size.

REPORT WORDING

See Appendix I - Report Wording.

REFERENCES

- 1. Drug Chemistry Training Manual Section DC-IA-7.
- 2. Grob, R. L. Modern Practice of Gas Chromatography, 2nd ed., John Wiley and Sons, New York, NY, 1985, pp. 390-397, 409-412.

Accepted Date: January 11, 2018 Drug Chemistry Procedures Manual DC-IIA-3 Page 6 of 6 Version 2018.01.11

DRUG CHEMISTRY PROCEDURES MANUAL

PROTOCOL: ANALYSIS OF A CONTROLLED SUBSTANCE

METHOD:	QUANTITATION
PROCEDURE:	QUANTITATION BY GC/MS SELECTED ION MONITORING (SIM)
Reviewed by:	
	rienne A. Hirsch, Chairperson mand Advisory Board
Approved by:	
Bureau Chief Timothy	
Drug Chemistry Come Forensic Sciences Come	
rorensic Sciences Coi	mmanu

Accepted Date February 1, 2023 Drug Chemistry Procedures Manual DC-IIA-6 Page 1 of 5 Version 2023.02.01

INTRODUCTION

The most common method of scanning with GC/MS is to scan a fairly wide range of mass to charge in order to obtain a complete mass spectrum for identification purposes (see Mass Spectrometry method). With selected ion monitoring (SIM) the mass spectrometer is directed to scan only a preselected range or number of masses. Because of this, the mass spectrometer spends its signal collection time only on masses of interest. One can take advantage of this increased signal to noise ratio to enhance the sensitivity of the instrument. In addition to increased sensitivity, the SIM Method also is used to quantitate samples. This is the purpose of this method. An example of this type of analysis for methamphetamine quantitation is presented below. SIM quantitation can be used for other drugs, e.g., cocaine, heroin, etc., with the appropriate internal standard.

SAFETY CONSIDERATIONS

Standard Laboratory Practices including the use of solvents.

PREPARATIONS

Reagents

Propiophenone (P-1-P) Chloroform Methamphetamine HCl (Crystalline) Sodium Hydroxide

0.5 N NaOH solution -20 grams of Sodium Hydroxide pellets or flakes are dissolved with 1 liter of distilled water. This will generate some heat and should be done with stirring.

Preparations for Internal Standard Procedure

1. Prepare the internal standard solution.

An internal standard solution of propiophenone (P-1-P) is prepared by adding 1.3 mL of P-1-P and diluting to 1 liter with chloroform. This is the base for all solutions.

2. Prepare the standard solution.

A standard solution of methamphetamine HCl is prepared by adding 25 mg of primary standard to 25 mL of previously prepared internal standard solution. Any amount can be prepared as long as the 1 mg/mL ratio is kept.

Accepted Date February 1, 2023 Drug Chemistry Procedures Manual DC-IIA-6 Page 2 of 5 Version 2023.02.01

3. Prepare the unknown solution.

The salt form of the unknown should be determined by the analyst. If it is a different salt than the standard being used, adjustments for the differences in molecular weights must be performed.

The sample must be made homogenous before any analysis is performed. The unknown solution is prepared in the same manner as the standard solution. The concentration of the substance being quantitated should be approximately 1 mg/mL.

To determine the amount of unknown sample to use, its purity is approximated. To obtain a 1 mg/mL sample, the following table can be used:

Estimated Purity	Amount sample (for 1 mL internal standard solution
10%	10.0 mg
25%	4.0 mg
50%	2.0 mg
75%	1.3 mg
100%	1.0 mg

INSTRUMENTATION

GC/MS in SIM mode.

Reference: Operator's Manual

MINIMUM STANDARDS AND CONTROLS

Refer to Mass Spectrometry Procedure for instrument minimum standards and controls.

The minimum general standards and controls for quantitation are the following:

- 1. Quantitation will be performed using proven methods.
- 2. Quantitation will be performed only upon approval by laboratory management of both the submitting laboratory and the centralized quantitation laboratory. For the Forensic Science Center at Chicago, this is the Section Chief or appropriate designee. Only one single item will be quantitated.

Accepted Date February 1, 2023 Drug Chemistry Procedures Manual DC-IIA-6 Page 3 of 5 Version 2023.02.

- 3. Calculations will be performed using only scientifically approved methods. All quantitation results will be reported to two significant figures (i.e. a sample of 56.75% will be reported as 56% and a sample of 5.67% will be reported as 5.6%)
- 4. Instrumental linearity will be established.
- 5. Each centralized quantitation Drug Chemistry Section will incorporate in-house quantitative procedures, including uncertainty measurement and proper use and tracking of quantitation reference materials, into the Facility Operations Manual. These procedures will be available for inspection by the quality review coordinator(s) and other inspection teams. Ultimate responsibility for accuracy in quantitation will rest with the analyst and the laboratory director/section chief.
- 6. Volumetric glassware used for the preparation of quantitation samples will be checked through the appropriate creation of a calibration curve and analysis of positive control samples. In addition, visual checks of the volumetric glassware will be done prior to each use and any damaged volumetrics will be discarded.
- 7. A control chart must be prepared and measurement uncertainty determined (as outlined in Appendix V) for a quantitation procedure and specific drug before such analysis can be performed in casework.
- 8. A control sample must be analyzed with each case (as outlined in Appendix V). The control should come from the same stock that was used to create the control chart. If that control sample is unavailable, a new sample must be prepared and a new control chart created.
- 9. The control sample must fall within 2 standard deviations (2 σ) on the control chart for the analysis to be valid.

PROCEDURE OR ANALYSIS

Once the solutions (standard, sample, and control) have been prepared they are extracted in the following manner:

- Approximately 1 mL of solution is placed in a culture tube (about 1/3 of a 10 x 75 mm size) and an equal amount of 0.5 N NaOH is added and mixed together.
- 2. The tube is centrifuged and the chloroform layer removed. This chloroform is centrifuged twice more to remove water.
- 3. The chloroform solution is transferred to an autosampler vial.

The vial is placed on mass spectrometer for analysis. The following is an example of the conditions for an Agilent GC/MSD.

Accepted Date February 1, 2023 Drug Chemistry Procedures Manual DC-IIA-6 Page 4 of 5 Version 2023.02.01

GC

Column: HP-1 capillary, 12m, 0.2 mm I.D., 0.33 micrometer

Carrier Gas: Helium Inlet: 230°C Detector: 280°C Isothermal temperature: 100°C

MSD

Ions scanned: 58, 77, 91, 105, 134, 148

Dwell time: 100Integration: T = 16

Inject the standard methamphetamine solution and integrate the areas of the peaks. Choose the one ion in P-1-P and the one ion in methamphetamine that are closest in area (response). This is usually the 105 ion for P-1-P and the 58 ion for methamphetamine. Make multiple injections of all solutions (the standard methamphetamine, the control methamphetamine, and the sample being tested) and average the integrated areas of the selected ions for each.

Calculation

The integrated areas of mass 105 for P-1-P and mass 58 for methamphetamine are ratioed:

The concentration of methamphetamine in the sample is obtained using this equation:

REPORT WORDING

See Appendix I - Report Wording.

REFERENCES

1. Drug Chemistry Training Manual – Section DC-IA-9.

Accepted Date February 1, 2023 Drug Chemistry Procedures Manual DC-IIA-6 Page 5 of 5 Version 2023.02.01

DRUG CHEMISTRY PROCEDURES MANUAL

PROTOCOL:	ANALYSIS OF A CONTROLLED SUBSTANCE
METHOD:	DETERMINATION OF OPTICAL ISOMERS
PROCEDURE:	POLARIMETRY
Reviewed by:	
Forensic Scientist Adri Drug Chemistry Comn	enne A. Hirsch, Chairperson nand Advisory Board
Approved by:	
Bureau Chief Timothy	A. Tripp
Drug Chemistry Comn Forensic Sciences Com	nand Coordinator

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-IIB-1 Page 1 of 3 Version 2023.08.01 Procedure: Polarimetry

INTRODUCTION

For some substances which exist as enantiomers, only one of the pair is controlled e.g., dextropropoxyphene. The polarimeter is used to determine the direction of rotation of plane polarized light, which defines the enantiomer present. It is the analyst's responsibility to ensure the rotation is due to the substance being tested. Many substances, including sugars, are optically active compounds.

SAFETY CONSIDERATIONS

Standard Laboratory Practices for handling solvents.

PREPARATIONS

The sample is dissolved in chloroform, methanol, or other suitable solvents.

Note: Problems with optical activity have been encountered while using methanol as a solvent. Sugars, methamphetamine, and related compounds can be affected.

INSTRUMENTATION

Polarimeter

Reference: Operator's Manual

MINIMUM STANDARDS AND CONTROLS

The following are the minimum standards and controls for the use of the polarimeter:

- 1. The worksheet will reflect the direction of rotation.
- 2. The light source (sodium or mercury) and wavelength will be recorded on the worksheet/work notes.
- 3. The solvent will be recorded if it is other than methanol.
- 4. A logbook (or online equivalent) will be kept for the instrument to record maintenance and function checks. Either the sodium or mercury lamp as well as the optical rotation should be checked when the instrument is used.

PROCEDURE OR ANALYSIS

Note: The instrument should be tested to ensure proper results. An optical rotation test must be performed prior to running an unknown. To ensure stabilization, the power and lamps should be turned on for one hour prior to taking a reading.

1. Zero the instrument with a solvent blank.

Accepted Date: August 1, 2023 DC-IIB-1 Procedure: Polarimetry
Drug Chemistry Procedures Manual Page 2 of 3

Version 2023.08.01

- 2. The unknown is dissolved in a suitable solvent and filtered if necessary. Place the solution in a polarimeter cell. The cell is placed in the polarimeter and allowed to stabilize.
- 3. The direction of rotation is noted. Several different wavelengths can be used if the degree of rotation is small.

REPORT WORDING

See Appendix I - Report Wording.

REFERENCES

- 1. Drug Chemistry Training Manual Section DC-IA-15.
- 2. Willard, L. Instrumental Method of Analysis, 6th ed., 1981, Wadsworth Publishing: Belmont, CA, pp. 412-427.

Accepted Date: August 1, 2023 DC-IIB-1 Procedure: Polarimetry Drug Chemistry Procedures Manual Page 3 of 3

Version 2023.08.01

DRUG CHEMISTRY PROCEDURES MANUAL

PROTOCOL:	ANALYSIS OI	F SUSPECTED CA	NNA	ABIS SAM	IPLES
METHOD:	THE IDENTIF	ICATION OF CAN	INAE	BIS	
PROCEDURE:	BOTANICAL MATERIAL	OBSERVATION	OF	LEAFY	PLANT
Reviewed by:					
Forensic Scientist Tiffa Drug Chemistry Comm		son			
Approved by:					
Bureau Chief Timothy Drug Chemistry Comm Forensic Sciences Com	and Coordinator				

Accepted Date: December 23, 2019 Drug Chemistry Procedures Manual DC-IIIA-1 Page 1 of 4 Version 2019.12.23 **Procedure:** Botanical Observation of Leafy Plant Material

INTRODUCTION

Cannabis is controlled in the state of Illinois under the Cannabis Control Act (CCA), Chapter 720, Act 550 and the Cannabis Regulation and Tax Act (CRTA), Chapter 410, Act 705 of the Illinois Compiled Statutes. This is presented as a reference to be referred to for weight limits, penalties, and other specific requirements of the law.

The term Cannabis, when it appears on a report, has the same definition as that stated in the Cannabis Control Act.

Cannabis can be positively identified if the leaf material has cystolithic and covering hairs on opposing surfaces, along with other testing. For identification criteria and other guidelines for Cannabis analysis see Appendix IV-B, the Cannabis Minimum Standards and Controls.

Other Related Procedures: Duquenois-Levine Test, Thin-Layer Chromatography, Gas Chromatography/Mass Spectrometry.

SAFETY CONSIDERATIONS

Warning:

A fungi, Aspergillas fumigates, may be found on decaying plant material. Spores are released when the plant material is removed from its packaging. Breathing these spores may result in aspergillosis, which affects the pulmonary system in different ways. Wearing a dust mask and/or working in a ventilation hood is advisable.

PREPARATIONS

Not Required.

INSTRUMENTATION

Stereoscope

Reference: Operator's Manual

MINIMUM STANDARDS AND CONTROLS

- 1. See Chemistry Minimums Standards and Controls: Administrative Policies for Cannabis Analysis (Appendix IV-B) for general minimum standards for Cannabis identification.
- 2. For both macroscopic and microscopic observations, positive or negative results will be recorded on the worksheet and must include a description of the observed botanical details.

Accepted Date: December 23, 2019
Drug Chemistry Procedures Manual

DC-IIIA-1 Page 2 of 4 Version 2019.12.23 **Procedure:** Botanical Observation of Leafy Plant Material

PROCEDURE OR ANALYSIS

- 1. Plant material is placed in a suitable container and the mass determined for the report.
- 2. If possible, the entire contents should be viewed with and without magnification to determine uniformity.

Macroscopic Examination

- 1. Macroscopic identification can prove useful for the identification of Cannabis, especially in conjunction with a microscopic examination.
- 2. Gross morphological characteristics that may be observed include the palmate arrangement of the leaflets, the pinnate leaf venation, the serrated edges of the leaflet, the buds (with or without seeds) and, if present, fluted stems and stalks. Stems, a support structure for another part of the plant such as a leaf or flower may also have hairs on the surface.
- 3. Due to the compressed or processed nature of many samples, some of these characteristics may not be discernible.
- 4. Plant material shall be considered to have positive macroscopic examination results consistent with Cannabis when at least one of the above characteristics is observed.
 - a. Positive or negative results will be recorded on the worksheet and must include a description of the observed macroscopic details.

Microscopic Examination

- 1. The plant material is observed under a stereoscope with a magnification strong enough to determine the necessary characteristics.
- 2. The microscopic test is positive for the presence of Cannabis when cystolithic hairs and covering hairs are present on opposing surfaces of the same leaf.
 - a. Positive or negative results will be recorded on the worksheet and must include a description of the observed microscopic details.

REPORT WORDING

See Appendix I - Report Wording.

Accepted Date: December 23, 2019 Drug Chemistry Procedures Manual

DC-IIIA-1 Page 3 of 4 Version 2019.12.23 **Procedure:** Botanical Observation of Leafy Plant Material

REFERENCES

- 1. Arizona Department of Safety Information Bulletin, 85-01, 1985.
- 2. U. S. Internal Revenue Service, Description of the Plant, IRS 973004-51-3, Washington, D.C., 1951: pp. 1-10.
- 3. Thornton, J. and Nakamura G. "Journal of the Forensic Science Society", Vol. 12, No. 3, 1972, pp. 461-519.
- 4. Mitosinka, Gerald T., Thornton, John I., and Hayes, Thomas L. "Journal of Forensic Sciences Soc.", Vol. 12, 1972, pp. 461-519.
- 5. Stern, William, author, Joyce, G. R.B., and Curry, S. H. eds., The Botany and Chemistry of Cannabis, 1970, pp. 1-10.
- 6. Quimby, Maynard W., et al, "Mississippi Grown Marijuana Cannabis Sativa Cultivation and Observed Morphological Variations", Econ. Bot., Vol. 27, 1973, pp. 117-127.
- 7. Clarke, R., The Botany and Ecology of Cannabis, Podds Press, Ben Lomond, CA, 1977, pp. 1-10, 150-153, and 163-168.
- 8. Drug Chemistry Training Manual Section DC-IA-2.
- 9. Illinois Criminal Law and Procedures. Current Edition: Section 720, Act 550, West Publishing Corporation, St. Paul, MN

Accepted Date: December 23, 2019 Drug Chemistry Procedures Manual DC-IIIA-1 Page 4 of 4 Version 2019.12.23 **Procedure:** Botanical Observation of Leafy Plant Material

DRUG CHEMISTRY PROCEDURES MANUAL

PROTOCOL:	ANALYSIS OF SUSPECTED CANNABIS SAMPLES
METHOD:	THE IDENTIFICATION OF CANNABIS
PROCEDURE:	THE USE OF THE DUQUENOIS-LEVINE TEST FOR THE IDENTIFICATION OF CANNABIS
Reviewed by:	
Forensic Scientist Adri Drug Chemistry Comn	denne A. Hirsch, Chairperson mand Advisory Board
Approved by:	
Bureau Chief Timothy Drug Chemistry Comn Forensic Sciences Com	nand Coordinator

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-IIIA-2 Page 1 of 4 Version 2023.08.01

INTRODUCTION

The Duquenois-Levine test can be used for the identification of Cannabinoids. To identify samples as Cannabis, two positive tests are acceptable if one of the tests provides structural confirmation (e.g. GC-MS). A positive Duquenois-Levine test is one testing option for the identification of Cannabis and Cannabinoids.

SAFETY CONSIDERATIONS

Standard Laboratory Practices.

PREPARATIONS

Vanillin. Crystalline product (99%) 95% Ethanol Acetaldehyde Concentrated Hydrochloric Acid Chloroform

Note: Selected Chloroform must not contain Amylene as a preservative. Use only Ethanol

Stabilized Chloroform.

Duquenois Reagent: One gram of vanillin is added to 50 mL of absolute or 95% ethanol. To

this solution, 0.6 mL of cold acetaldehyde is added and the solution mixed together. The 0.6 mL of acetaldehyde is not critical and may be

approximated by 12 drops.

INSTRUMENTATION

No Instrumentation Required.

MINIMUM STANDARDS AND CONTROLS

- 1. See Chemistry Minimums Standards and Controls: Administrative Policies for Cannabis Analysis (Appendix IV-B) for general minimum standards for Cannabis identification.
- 2. The prepared Duquenois Reagent will be labeled with the preparer's identity, and date made and expiration date.
- 3. The Duquenois Reagent will be tested when prepared and as indicated in QM-14, using primary or secondary standards. A logbook (or online equivalent) will be kept of the testing to include the identity of the preparer, the date the reagent was

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-IIIA-2 Page 2 of 4 Version 2023.08.01

authenticated (or re-authenticated), and the expiration date of the reagent. Any manufactured reagents will be tested when opened and as indicated in QM-14; if no manufacturer's expiration date is given, it will be assigned a one year date and treated in the same manner as in-house reagents.

4. The observed color change and transfer will be documented on the worksheet to indicate results (e.g. purple / purple).

PROCEDURE OR ANALYSIS

The Duquenois-Levine test is conducted in three steps:

- Step 1: Extract the sample using petroleum ether. Other solvents, such as methanol, hexane, chloroform, or methylene chloride may be used to extract the sample without affecting the results of the test.
- Step 2: Dry the extract, add Duquenois Reagent followed by concentrated Hydrochloric Acid in approximately equal amounts. Wait up to 2 minutes and note the color, if any, that develops.
- Step 3: Add chloroform. Note the color, if any, that transfers to the chloroform layer.

 *See note on Chloroform in Preparations section.

Though the colors for this test are somewhat subjective, a positive result ranges from a blue to purple for the top layer coupled with a transfer of a purple to blue color to the bottom chloroform layer. The colors formed are due to the concentrations of the various Cannabinoids present and can vary with the age and condition of the sample.

REPORT WORDING

See Appendix I - Report Wording.

REFERENCES

- 1. Duquenois, P., Moustapha, H. N., "Journal of the Egyptian Medical Association', Vol. 21, pp. 224-227, 1938 (French).
- 2. Official Methods of the AOAC, 14th ed., AOAC, Washington D. C., 1984, p. 774.
- 3. Butler, W., "Journal of the AOAC", Vol. 45, No. 3, 1962, pp. 597-600.
- 4. Thornton, J. and Nakamura G. "Journal of the Forensic Science Society", 1972, Vol. 12, No. 3, pp. 461-519.

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-IIIA-2 Page 3 of 4 Version 2023.08.01

- 5. Drug Chemistry Training Manual Section DC-IA-2.
- 6. Chemical Companies:

Sigma-Aldrich Chemical Company P O Box 14508 St. Louis, MO 63178-4508 1-800-325-3010 Fisher Scientific 300 Industry Drive Pittsburgh, PA 15275 1-800-766-7000

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-IIIA-2 Page 4 of 4 Version 2023.08.01

DRUG CHEMISTRY PROCEDURES MANUAL

APPENDIX I: REPORT WORDING

Reviewed by:	
Forensic Scientist Adrienne A. Hirsch, Chairperson Drug Chemistry Command Advisory Board	_
Approved by:	
Bureau Chief Timothy A. Tripp Drug Chemistry Command Coordinator Forensic Sciences Command	-

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-App I Page 1 of 3 Version 2023.08.01 Appendix I: Report Wording

APPENDIX I

REPORT WORDING

The report represents a summary of analytical findings. It does not include all information contained in the notes. The report includes the following:

- 1. The weight of the substance is reported to one tenth of a gram, unless more crucial figures are needed for charge determination (with the exception of some bulk balances). If the mass is less than 0.1 gram, it shall be reported as either less than 0.1 gram or a residue. When a Sampling Plan is utilized and the weight is determined, a calculated weight may be reported.
- 2. The controlled substance identified is reported as it is found in the Controlled Substances Act. Salt forms are listed only when necessary. The most common example of the appropriate use of a salt form is when quantitation is reported or when reporting cocaine base. For substances that are controlled via their chemical classification, the findings must include the name of the substance and its classification in the law.
- 3. Additional information may be included if necessary. The following is a summary of the criteria and recommended report wording for various drug chemistry results.
- 4. There are additional report wordings examples in the Sampling Section of the Procedures Manual (H-1, H-1A, H-1B and H-1C).

CRITERIA

RECOMMENDED REPORT FORMAT

1. Positive Identification

a. Drugs Substance name (Abbreviation)

Chemical name (common name), a [classification

from the law] compound

b. Cannabis (specific cannabinoid)

c. Quantitation

XX (compound) XX (% calculated as *)

*appropriate salt form or free base

2. No Identification

a. Drugs No Scheduled Substance Found

No scheduled substance indicated

b. Suspected Cannabis No Cannabis Found

Accepted Date: August 1, 2023 DC-App I Appendix I: Report Wording

Drug Chemistry Procedures Manual Page 2 of 3
Version 2023.08.01

The materials contained in this document are protected under federal law and may not be disseminated or reproduced without the express written permission of the Illinois State Police.

c. Cannabis Testing did not indicate any other scheduled substance d. Cannabis No other scheduled substance found e. Drugs and Cannabis No other controlled substances found 3. No Analysis Performed Not Analyzed No Other Items Analyzed 4. Qualifiers/Inconclusive Findings Physically resemble pharmaceutical preparations which do not contain a scheduled substance Physically resembles a pharmaceutical preparation containing XXX; no further analysis Testing indicated the possible presence of , however, this was not confirmed. Testing indicates the presence of _____ however, this was not confirmed due to insufficient sample. Testing indicates the presence of however, there is insufficient reference material available for identification at this time. Testing did not indicate a controlled substance Testing did not indicate a scheduled substance Testing did not indicate any other scheduled substance Testing performed; no conclusion drawn.

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-App I Page 3 of 3 Version 2023.08.01 Appendix I: Report Wording

DRUG CHEMISTRY PROCEDURES MANUAL

APPENDIX II: DATA SUITABILITY

Reviewed by:		
Forensic Scientist Adrienne A. Hirsch, Chairperson Drug Chemistry Command Advisory Board		
Approved by:		
Bureau Chief Timothy A. Tripp Drug Chemistry Command Coordinator Forensic Sciences Command		

Accepted Date: December 6, 2023 Drug Chemistry Procedures Manual DC-App II Page 1 of 5 Version 2023.12.06

APPENDIX II

Data, including instrumental data, observations, and calculations, obtained from analysis of an unknown sample must first be evaluated for suitability prior to drawing any conclusions utilizing the following suitability assessments. If a deficiency is indicated, mitigation steps will be necessary to allow for an appropriate and meaningful comparison to be made.

I. Definitions and Documentation

- A. Data that is suitable for comparison meets the minimum standards and controls in addition to the requirements outlined in this Appendix.
 - 1. Data will be included in the case file and documented in LIMS per the policies of each technique.
 - 2. Data that provides information with limitations (e.g. indications on a GC-MS, lack of isomer differentiation, weak color tests, etc.) is still suitable. Results will be documented per the policies of each technique to reflect any limitations.
- B. Data that does not meet the minimum standards and controls and/or the requirements outlined in this Appendix will be considered rejected data.
 - 1. The decision to reject data will be made by the forensic scientist authoring the report.
 - i. If the suggestion to reject data is made by a technical reviewer, this will be succinctly documented in the routing history through the rejection of the case.
 - 2. For techniques which produce instrumental data, the data itself will be clearly identified as rejected and included in the casefile as delineated in the Quality Manual (QM-12).
 - 3. For techniques which do not generate instrumental data, succinct documentation of the observations in the LIMS matrix will suffice.
 - 4. The reasoning for the rejection, along with the date the data was evaluated and deemed rejected, will be succinctly documented in the LIMS matrix.

II. For Instrumental Techniques (GC-FID, GC-IR, GC-MS, AND FTIR)

- A. Instrument Performance and Policy
 - 1. Instrument acquisition failures, including missed injections and instrument stoppages, will be evaluated for their effect on data acquisition. In order to utilize acquired data for comparison, all associated data will meet the minimum standards

Accepted Date: December 6, 2023

Drug Chemistry Procedures Manual

Drug Chemistry Procedures Manual

Drug Chemistry Procedures Manual

Page 2 of 5

Version 2023.12.06

and controls applicable to the technique(s) employed If the data does not meet established minimum standards and controls, or there is no data acquired, then the associated data will be rejected for comparison to a reference standard.

- 2. In order to utilize acquired data for comparison, all associated blanks and controls will meet the minimum standards and controls applicable to the technique(s) employed.
 - i. If the blanks and controls do not meet the established minimum standards and controls, then the associated data will be rejected for comparison to a reference standard.

B. Detector Response

- 1. When using a technique that produces a detector response, the response will be at least three times the noise level to be considered a peak suitable for comparison to a reference standard. The short-term noise levels (those directly adjacent to the signal response) are used for determining response suitability. If a visual assessment does not clearly demonstrate a signal-to-noise ratio greater than 3:1, then a mathematical technique will be employed. (Use of chromatographic data processing software to determine signal-to-noise ratios is acceptable.)
 - i. If the response is not at least three times the noise level to be considered a peak, the data will be rejected for comparison to a reference standard.

C. Chromatographic Peak Shape

- 1. Acceptable peaks are typically Gaussian, but slight asymmetry and tailing is normal with temperature-gradient methods. In the event that a chromatographic peak is not Gaussian, the analyst will evaluate the level of fronting or tailing to determine the significance of the irregularity.
- 2. The peak of a single analyte usually produces a single apex to be used for comparison. In the event of a split peak, a single distinct apex which is at least two times the height of any secondary apex not baseline resolved, may be used for comparison to a reference standard.
 - i. If the peak shape is considered unacceptable, the data will be rejected for comparison to a reference standard and mitigation steps will be taken upon reanalysis of the sample.

D. Resolution

1. If multiple peaks are present, chromatographic resolution shall be sufficient to evaluate a substance with minimal interference from other substances or impurities. Resolution will also be sufficient to differentiate between IR bands and mass assignments. Analysts will assess the extent to which any potential overlap

Accepted Date: December 6, 2023 Drug Chemistry Procedures Manual DC-App II Page 3 of 5 Version 2023.12.06

affects identification of a specific analyte to the exclusion of interferences as follows.

- i. Baseline resolution between multiple peaks is recommended. At minimum, adjacent chromatographic peaks must have discernable apexes.
- ii. Data processing procedures can be used (e.g., spectral subtractions, extracted ion chromatogram, etc.).
- iii. If the resolution is not sufficient to show separation, then the associated data will be rejected for comparison to a reference standard.

III. For Non-Instrumental Techniques (TLC, Color Tests)

A. Blanks and Controls

- 1. Required blanks and controls will meet the minimum standards and controls applicable to the technique(s) employed to utilize the associated data for comparison.
 - i. If the blanks and controls do not meet the established minimum standards and controls, then the associated data will be rejected for comparison to a reference standard.

B. Color Tests

- 1. Visually assess the results for the presence or absence of positive test indications (color changes) as defined by minimum standards and controls or in comparison to a primary reference standard.
 - i. The absence of response will not be used as a preliminary test for the positive identification of a controlled substance.
 - ii. Reasons for color test data to be rejected may include:
 - a. a reagent batch is expired
 - b. the reagent fails quality checks
 - c. a substance known to inhibit color is present in the sample (e.g. tableting dyes, DMSO, etc.)

C. Thin Layer Chromatography

- 1. Visually assess the plate for the presence or absence of positive test indications (spot appearances) as defined by minimum standards and controls.
 - i. If the reference materials fail to produce data, the plate will be rejected.
- 2. The spots of the target analyte and the reference standard(s) are suitable for comparison when they are approximately circular or a rectangular band (not a streak), adequately resolved from other sample components as well as other standards included on the plate, and visible when exposed to UV light or a chemical visualizing reagent.
 - i. If the spots fail to meet the above criteria, the data will be rejected.

Accepted Date: December 6, 2023 Drug Chemistry Procedures Manual DC-App II Page 4 of 5 Version 2023.12.06

Note: Concentration disparities and their impact on data suitability

Characteristics that may be affected by concentration disparities may include chromatographic peak shape, retention time, mass spectral ion ratios, TLC spot size and shape, and intensity of any color reactions. While concentration disparities alone are not a reason to reject data, their impact may be cause for a rejection. Mitigation steps for many issues often begin with an assessment of the concentration of a sample. When experimental conditions, including concentrations, between the sample and the reference standard are similar, meaningful comparisons are more likely.

MINIMUM STANDARDS AND CONTROLS FOR TESTING TECHNIQUES

Minimum standards and controls for each individual procedure or testing technique can be found in the relevant section of the Procedures Manual.

Accepted Date: December 6, 2023 Drug Chemistry Procedures Manual DC-App II Page 5 of 5 Version 2023.12.06

DRUG CHEMISTRY PROCEDURES MANUAL

APPENDIX III: EXTRACTION, SEPARATION, AND DERIVATIZATION METHODS

Reviewed by:
Forensic Scientist Adrienne A. Hirsch, Chairperson Drug Chemistry Command Advisory Board
Approved by:
Bureau Chief Timothy A. Tripp Drug Chamistry Command Coordinator
Drug Chemistry Command Coordinator Forensic Sciences Command

Accepted Date: February 1, 2023 Drug Chemistry Procedures Manual DC-App-III Page 1 of 9 Version 2023.02.01 **Appendix III:** Extraction, Separation, and Derivatization Methods

APPENDIX III EXTRACTION AND SEPARATIONS

INTRODUCTION

The purpose of an extraction is to separate drugs from a matrix or other drugs. The matrix can be a variety of materials including, but not limited to, a liquid, solid, time release, or food. Since the process of manufacturing both legitimate pharmaceuticals as well as clandestine street drugs can vary significantly, it would be impossible to create an exhaustive list of all possible extractions. Therefore, this policy presents general guidelines and examples of the types of potential extractions available.

SAFETY CONSIDERATIONS

Standard laboratory practices involving the use of solvents, acids, and bases.

PREPARATIONS

Use the following table to assist in the preparation of the various reagents:

Definitions

Formality (F)	gram formula weight liter	The number of formula weights of solute in one liter of solution.
Molarity (M)	<u>moles</u> liter	The number of moles of solute in one liter of solution.
Molality (m)	<u>moles</u> kilogram	The number of moles of solute of per kilogram solvent.
Normality (N)	<u>equivalents</u> liter	The number of equivalents of solute in one liter of solution.
Weight %	weight of solute x 100 weight of solution	Concentrations of commercial aqueous reagents are weight %.
Volume %	volume of solute x 100 volume of solution	
Weight Volume %	weight of solute mg x100 volume of solution, mL	Weight volume percent is used to indicate dilute aqueous solutions of solid reagents.

Stock Chemicals:

The composition of some inorganic acids and bases as supplied by vendors (either as concentrated aqueous solutions or as solids) are given below:

Accepted Date: December 20, 2021 DC-App-III Appendix III: Extraction, Separation, and Drug Chemistry Procedures Manual Page 2 of 9
Version 2021.12.20

	Formula			
Acid/Base	<u>Weight</u>		Molarity	% by Weight
Acetic Acid (CH ₃ COOH)	60.05		17.5	99-100
Ammonium Hydroxide (NH ₄ OH)	35.05		7.4	28-30
Hydrochloric Acid (HCl)	36.46		12.0	36.5-38
Nitric Acid (HNO ₃)	63.02		16.4	69
Phosphoric Acid (H ₃ PO ₄)	98.00		14.7	85
Potassium Carbonate (K ₂ CO ₃)	138.21			
Sulfuric Acid (H ₂ SO ₄)	98.08		18.0	95-98
Sodium Bicarbonate (NaHCO ₃)	84.02			
Sodium Carbonate (Na ₂ CO ₃)	105.99	(anhy)		
Sodium Hydroxide (NaOH)	40.01			

Preparation of Reagents

The following charts can be used as a reference for the preparation of various concentrations (dilutions) of acids and bases:

	Desired	Quantity of Concentrated Acid/
Liquid Acid/Base Reagents	Concentration	Base Diluted to 1 Liter
Acetic Acid	3N	172 mL
Ammonium Hydroxide	3M, 3N	405 mL
Hydrochloric Acid	3N	250 mL
Hydrochloric Acid	0.1N	8 mL
Hydrochloric Acid	15% (4.4M)	367 mL
Nitric Acid	3N	183 mL
Phosphoric Acid	3M, 9N	205 mL
Sulfuric Acid	3M, 6N	168 mL
Sulfuric Acid	6M, 12N	336 mL
Sulfuric Acid	0.1N	2.8 mL
	Desired	Quantity for Dilution

	Desired	Quantity for Dilution
Solid Basic Reagents	<u>Concentration</u>	to 1 Liter
Potassium Carbonate	5%	50 g
Sodium Bicarbonate	1 M	84 g
Sodium Carbonate	1.5M, 3N	156 g
Sodium Carbonate	2%	20 g
Sodium Hydroxide	0.5N	20 g
Sodium Hydroxide	2N	80 g

INSTRUMENTATION

None Required.

MINIMUM STANDARDS AND CONTROLS

Accepted Date: December 20, 2021 DC-App-III Appendix III: Extraction, Separation, and Drug Chemistry Procedures Manual Page 3 of 9
Version 2021.12.20

- 1. All extractions will be recorded on the worksheet.
- 2. Stock bottles of dilutions/reagents are to be tested when prepared and as indicated in QM-14, using pH paper or another appropriate test. A logbook (or online equivalent) will be kept of the testing to include at least the name (or initials) of the preparer of the reagent, the date the reagent was authenticated (or re-authenticated), and the expiration date of the reagent. Any manufactured reagents/dilutions will be tested when opened and as indicated in QM-14; if no manufacturer's expiration date is given, it will be assigned a one year date and treated in the same manner as in-house reagents/dilutions.
- 3. All stock solutions will be properly labeled (including a hazard label), initialed by the preparers, and dated. This includes an expiration date.

PROCEDURE OR ANALYSIS

Solvent Extractions

Solvent extractions (dry extractions) are based on the differences in solubilities between substances.

Dry extractions involve washing a sample with a solvent in order to isolate a compound of interest from a mixture. If the desired component is soluble in the solvent and the other components are not, the solvent can be separated from the insoluble, either by filtering or using a centrifuge. This solvent is then dried down to yield the desired component. Conversely, a solvent may be selected to wash away unwanted soluble components from a mixture, leaving behind the insoluble compound of interest.

	<u>Chloroform</u>	<u>Methanol</u>	Ether	<u>Acetone</u>
Acetaminophen	v sl sol	sol	insol	sol
Aspirin	sol	sol	sol	sol
Amphetamine HCl	sol	sol	insol	sl sol
Amphetamine SO4	insol	sl sol	insol	
Benzocaine	sol	sol	sol	
Caffeine	sol	sl sol	sl sol	sol
Cocaine HCl	sol	sol	insol	insol
Cocaine free base	sol	sol	sol	sol
Codeine	sol	sol	sl sol	insol
Codeine Phosphate	insol	sl sol	insol	
Diazepam	sol	sol	sl sol	
Diphenhydramine HCl	sol	sol	insol	
Ephedrine	sol	sol	sol	sol
Ephedrine HCl	v sl sol	sol	insol	
Heroin HCl	sol	sol	insol	
Heroin	sol	sol	insol	
Lidocaine	sol	sol	sol	
Lidocaine HCl	sl sol	sol	insol	
Methamphetamine HCl	sol	sol	insol	insol
Nicotinamide	sl sol	sol	sl sol	
ted Date: December 20, 2021	DC-App-III	Appendix III:	Extraction, Separ	ation, and

Accepted Date: December 20, 2021 DC-App-III Appendix III: Extraction, Separation, and Drug Chemistry Procedures Manual Page 4 of 9 Derivatization Methods

Version 2021.12.20

Procaine	sol	sol	sol	
Procaine HCl	sl sol	sol	insol	
Tetracaine	sol	sol	sol	
Tetracaine HCl	sl sol	sl sol	insol	insol

A variation of the solvent wash procedure is to use acid or base washed solvents. One part acid or base is added to ten parts solvent.

Acid/Base Extractions (Liquid/Liquid)

Amphetamine

Codeine

The liquid/liquid extraction uses two immiscible solvents. Water or aqueous acid/base and immiscible organic solvents are normally used. The desired component is partitioned into one solvent while the other components are partitioned into another solvent. Separating the two phases will yield the desired substance.

Note: Chloroform is best for general screens. Fewer drugs extract into hexane, however it usually yields a cleaner sample.

Note: If the substance being extracted is volatile (such as methamphetamine) concentrated HCl gas should be bubbled through the solvent layer before evaporation to yield the insoluble hydrochloride salt.

EXAMPLES OF ACID/BASE EXTRACTIONS

1. NaOH, hexane. Bubble HCl through hexane.

1		,	8
Chlordizaepoxide	1.	NaOH, chloroform.	Petroleum ether recrystallization.
Cocaine	1. 2.	NaOH, hexane. Wash with chlorofor	rm and pet ether mixture.

1

2. Acetone wash, dry insolubles, add water, then K₂CO₃ and hexane (separates out acetaminophen or aspirin).

Diazepam

1. HCl, chloroform.

2. Chloroform, pet ether, or acetone wash.

3. Na OH allows forms.

3. NaOH, chloroform.

1. NH₄OH, chloroform.

Dihydrocodeine 1. K₂CO₃, hexane. Petroleum ether recrystallization.

Ephedrine 1. NaOH, hexane. Bubble HCl through hexane.

Heroin 1. 3N HCl, chloroform.

Hydromorphone 1. NH₄OH, chloroform.

Accepted Date: December 20, 2021 DC-App-III Appendix III: Extraction, Separation, and Drug Chemistry Procedures Manual Page 5 of 9 Derivatization Methods

Version 2021.12.20

LSD

1. Water, NH₄OH, chloroform.

Methamphetamine

- 1. NaOH, hexane. Bubble HCl through hexane.
- 2. Wash with acetone. To insolubles, add chloroform: pet ether or NaOH, hexane (with HCl bubbled through). This separates ephedrine which is soluble in acetone.

Morphine

1. Concentrated NH₄OH, warm chloroform: isopropanol (3:1).

PCP

- 1. HCl, chloroform.
- 2. NaOH, hexane.
- 3. Chloroform wash.

Propoxyphene

- 1. H₂CO₃, hexane. Petroleum ether recrystallization.
- 2. K₂CO₃, hexane. Bubble HCl through hexane. Discard hexane. Wash insoluble white powder with hexane, discarding solvent. To the white powder add K₂CO₃, hexane. Dry hexane, petroleum either recrystallization.

REFERENCES

- 1. Drug Chemistry Training Manual Section DC-IA-6.
- 2. Clarke, E. G. C., *The Isolation and Identification of Drugs*, 2nd ed, The Pharmaceutical Press: London, England, 1986, pp. 1-14.

Accepted Date: December 20, 2021 Drug Chemistry Procedures Manual

DC-App-III Page 6 of 9 Version 2021.12.20 **Appendix III:** Extraction, Separation, and Derivatization Methods

DERIVATIZATION

INTRODUCTION

Derivatization is used to reduce or eliminate the problems of activity related to any hydroxyl (free, or existing as part of a carboxylic acid, e.g. GHB), or amine group (e.g. d,l-amphetamine, d,l-methamphetamine). These functional groups usually cause peak tailing or loss of response due to the interactions of the functional groups with liners, or active sites on the columns. This activity can be reduced or eliminated by chemically converting active groups to inactive species. Derivatizing the sample prior to using a gas chromatograph or mass spectrometer would overcome problems in identification and characterization.

SAFETY CONSIDERATIONS

Standard laboratory safety procedures for handling corrosive materials and solvents. Special handling requirements are included with the material safety data sheets and should be read prior to the use of these derivatizing agents.

INSTRUMENTATION

Gas Chromatography with Flame Ionization Detection or Gas Chromatography-Mass Spectrometry

MINIMUM STANDARDS AND CONTROLS

- 1. The derivatizing methods will be noted on the worksheet.
- 2. A standard will be run using the same derivatizing method used on the sample to establish reference data and to authenticate the reagents. Any manufactured reagents will be tested when opened and as indicated in QM-14; if no manufacturer's expiration date is given, it will be assigned a one year date and treated in the same manner as in-house reagents.
- 3. Refer to the standards and controls associated with the instrumental procedures of choice (GC-FID or GC-MS).

PROCEDURE OR ANALYSIS

The following procedures or analyses are examples of derivatization methods available. For all methods the following procedures should be noted:

- A. Store unused derivatizing agent in the refrigerator capped and sealed to protect from moisture.
- B. The derivatizing agent must be at room temperature before use.

1. Intended Use: d,l-amphetamine, d,l-methamphetamine

Reagents: (S)-(-)-N-(Trifluoroacetyl) prolyl Chloride (purchased as 0.1 M solution in

dichloromethane)

Conc. Hydrochloric Acid

Methanol

1% HCl in Methanol: Add one milliliter of concentrated HCl to 99 mL of

Methanol.

Accepted Date: December 20, 2021 DC-App-III Appendix III: Extraction, Separation, and Drug Chemistry Procedures Manual Page 7 of 9 Derivatization Methods

Version 2021.12.20

Procedure:

- 1. For a powdered sample, add several milligrams to screw top test tube.
- 2. Add ½ mL of derivatizing agent to the tube.
- 3. Place the tube in a heating block (setting of 5 or 6 about 65°C) for 10 to 15 minutes.
- 4. Remove from heat and, if necessary, dilute with dichloromethane.

Notes:

- 1. If the original sample is a liquid, e.g. after extraction ½ mL of 1% Methanolic HCl can be added to reduce evaporation of amines. Take this to dryness before derivatizing.
- 2. If the sample is a free base liquid the derivatizing agent can be added directly.
- 3. Do not use methanol or ethanol as solvents since they can be derivatized (Step 4).
- 4. Store unused derivatizing agent in the refrigerator capped and sealed to protect from moisture.
- 5. The derivatizing agent must be at room temperature before use.

For comparison purposes, a standard should also be derivatized. Once the sample is derivatized, it can be used with the GC-FID or GC-MS. The d and l derivatives of Amphetamine and Methamphetamine can be distinguished by retention time.

2. Intended Use: GHB

Note: Due to the absence of the hydroxyl substituent on GBL, it is not

derivatized during the reaction.

Reagents: Dichloromethane (CH₂Cl₂)

Bis(trimethysilyl) trifluoroacetamide (BSTFA)

Bis(trimethysilyl) trifluoroacetamide (BSTFA) with 1%

trimethylchlorosilane (TCMS)

Procedure:

- 1. Use 5 mL of sample.
- 2. Add 5 mL CH₂Cl₂ vortex, remove organic layers and place into a clean test tube.
- 3. Dry down organic layer (no heat).
- 4. Add 100 microliters of BSTFA and cap tightly (sample is volatile).
- 5. Place in a 70°C oven for 30 minutes.
- 6. Place into a microvial and inject on GC-FID or GC-MS.

REPORT WORDING

See Appendix I - Report Wording.

Accepted Date: December 20, 2021 Drug Chemistry Procedures Manual

DC-App-III Page 8 of 9 Version 2021.12.20 **Appendix III:** Extraction, Separation, and

Derivatization Methods

REFERENCES

- 1. McKibben, T., "Separation and identification of Drug Eniantiomers Via (N-TFA-(S)-Prolylchlroide Derivatization", J. CLICA, January 1992, Vol. 1, No. 2.
- 2. Blumenfeld, M., Suntay, R. and Harvard, M., "Sodium Gamma-Hydroxybutyric Acid: a new anaesthetic adjuvant", Anesth. Analg. Curr. Response: Vol. 41, No. 6, 1962, pp. 721-726.
- 3. Koresh, S., "Gamma-Hydroxybutyrate (GHB)," Wisconsin State Crime Milwaukee, Nov. 1997.
- 4. Andrews, K., "The Headaches of Analyzing a GHB Sample," DEA Western Laboratory, 1998.
- 5. Loiken, J. and Paloucek, F., <u>Poisoning and Toxicology Handbook</u>, 2nd ed., Lexi-Comp Inc., Hudson, OH, 1995, pp. 376-377.
- 6. McCann, M., Sorrentino, A., "Detection of GHB in Alcoholic and Non-Alcoholic Beverages," Chemistry memo 99-Chem-13, Illinois State Police, 1999.
- 7. McCann, M., "Notes for the GHB Derivatization Procedure Using BSTFA," Chemistry Memo 01-Chem-08, Illinois State Police, 2001.
- 8. McCusker, Rachel R., Paget-Wilkes, Helen, Chronister, Chris W., Goldberger, Bruce A., "Analysis of Gamma-Hydroxybutyrate (GHB) in Urine by Gas Chromatography-Mass Spectrometry", Journal of Analytical Toxicology, Vol 23, September 1999.
- 9. Ciolino, Laura A., Mesemer, Mantal Z., Satzger, R. Duane, Machal, A. Caroline, McCauley, Heather A., Mohrhaus, Angie S., "The Chemical Interconversion of GHB and GBL: Forensic Issues Implications", Journal of Forensic Science 2001; 46(6):1315-1323.

Accepted Date: December 20, 2021 DC-App-III Appendix III: Extraction, Separation, and Drug Chemistry Procedures Manual Page 9 of 9 Derivatization Methods

Version 2021.12.20

ILLINOIS STATE POLICE

DRUG CHEMISTRY PROCEDURES MANUAL

APPENDIX IV:	CHEMISTRY MINIMUM STANDARDS AND CONTROLS
SECTION A:	ADMINISTRATIVE POLICIES APPLICABLE TO ANY ANALYSES
Reviewed by:	
Forensic Scientist Adrienne A Drug Chemistry Command A	
Approved by:	
Bureau Chief Timothy A. Tri	ipp
Drug Chemistry Command C	
Forensic Sciences Command	

Accepted Date: March 1, 2024 Drug Chemistry Procedures Manual DC-App IV-A Page 1 of 11 Version 2024.03.01

APPENDIX IV

Minimum Standards and Controls are not to be used as a substitute for good scientific procedures. On an individual case, the minimum indicated may not suffice to complete an identification as defined. It is the primary responsibility of the chemist to identify the controlled substance rather than simply fulfill these standards.

ADMINISTRATIVE POLICIES APPLICABLE TO ANY ANALYSES

A. Tests and Controls

- 1. Routine Formulations, Standard Tests There is no need to include how tests are performed in the case file, as long as they are standard tests performed routinely. The same reasoning applies to formulations of reagents, solutions, and standard in-house methods. Many of these will be found in the chemistry section procedures manual or a laboratory's chemistry section manual.
- 2. All reference spectra /chromatograms used for identification shall be included in the case file.

3. GC-FID and GC-MS Blank Policy

The blank serves two primary functions: first, as a quality check on the chemicals used during the sample preparation process and second, as a quality assurance measure for monitoring laboratory technique and instrumentation. For the purposes of this policy, lab case item or item refers to the parent item received from an agency that may include one or more unknown units for analysis. Unit(s) refers to the unknown object(s) requiring analysis received within the item. Sample(s) refers to the analyzed portion(s) of the unit.

a. When blanks need to be run:

Prior to the sample run, at least one blank will be injected per lab case item under the same conditions and method as the sample run(s). This includes all instrument parameters from the injection to detection. A blank will be run between different items in a case if different instrument methods are used. In cases where a trace or residue amount of a substance is suspected, a blank will be run immediately before the suspected trace or residue sample. For multiple unit cases, no more than ten samples will be run after a single blank.

b. Preparation of blanks:

The blank will be prepared in the same manner as the sample. This includes all solvents and reagents, including those for extraction and derivatization. Any solvent other than methanol must be noted on the worksheet. If the sample is diluted in an internal standard solution, the blank will be prepared from the

Accepted Date: March 1, 2024 Drug Chemistry Procedures Manual DC-App IV-A Page 2 of 11 Version 2024.03.01

internal standard solution. If the sample is extracted, the blank will be extracted. If the sample is concentrated prior to injection, the blank is to be concentrated as well. In such cases that a neat sample must be injected directly, the solvent chosen for the blank should be documented on the worksheet.

c. Blank acceptance:

If the blank has a peak at the same retention time as the target compound, the blank will be further evaluated for acceptability. For GC-MS, noise that is attributed to column/septa bleed and/or peaks that are attributed to solvent components do not invalidate the blank. It is also acceptable if the blank has peaks at retention times other than the target compound. For GC-MS chromatograms, any peak(s) present will be checked and documented in the case file. If the blank is determined to be unacceptable, the blank and unit(s) will be run again. Raised gas chromatograph baselines also do not invalidate the blank.

d. Documentation:

Blanks will be included in the working file and will be noted on the worksheet. In multiple unit cases, all consecutive blanks run between samples will be included. Each blank for a case must be labeled in a way that specifies when (e.g., timestamp) it was run in relation to the sample(s). Labeling blanks with the item number is optional.

B. Evidence Handling Procedures

These are general procedures for the handling of Chemistry evidence.

1. Seals

- a. Whenever possible, all evidence is to be sealed when received, when placed in the vault and when not actually being analyzed. If possible, handle evidence in a manner which preserves the integrity of the material inside and does not destroy or alter existing seals.
- b. After analysis, seals on internal packaging are only necessary to preserve the condition of the evidence (to prevent leakage or cross-contamination). All external packages shall be sealed. The minimum marks needed on these exterior seals are initials and date.

2. Markings

a. All external packages of evidence will contain the case number, item number, initials and date. After analysis, internal packaging will be marked with a minimum of the item/subitem number in a manner that allows for individual

Accepted Date: March 1, 2024 Drug Chemistry Procedures Manual DC-App IV-A Page 3 of 11 Version 2024.03.01

identification as reflected on the worksheet. Any additional markings can be at the discretion of the analyst. The internal packaging will then be sealed into an outer package that is marked with the case number, item number, date and initials.

C. Analysis of Evidence

- 1. When conducting casework, all observations, examinations and conclusions must be recorded and conducted in accordance with Command Directives guidelines.
- 2. In general, it is not necessary to conduct an analysis on each item submitted. Evidentiary value and agency needs should determine the extent of analysis.
- 3. If possible, no more than half the evidence shall be consumed in analysis.
- 4. Every attempt shall be made to preserve evidence. When the entire sample is used, extracts must be returned to the case.
- 5. Per Command Directives ESH Appendix 16, field test kits are not to be submitted as evidence. If a field test kit is found within submitted evidence, it will be packaged to prevent contamination of other evidence and returned to the agency. DO NOT DISCARD!

D. Mass Determination

1. Balances will be checked weekly using masses across the range of the balance, including those listed in QM-11, according the table below.

Balance Capacity	<u>Weights</u>
200 g, 400 g	0.1 g, 1 g, 10 g, 200 g
500 g, 610 g	0.1 g, 1 g, 10 g, 500 g
4,000 g	0.1 g, 1 g, 10 g, 2,000 g
6,000 g, 8,000 g	500 g, 1,000 g 5,000 g
10,000 g, 32,000 g, 150,000 g	500 g, 5,000 g, 10,000 g

The examiner's identity, date, and exact masses obtained will be recorded in a logbook (or online equivalent). Balances not used routinely will be checked monthly. A balance check will be effective for seven days. Each laboratory will have a policy to follow should a balance fail to pass a standardized weight check.

a. Balances and weight sets will be calibrated by an ISO certified vendor on a routine basis as required by QM-11.

Accepted Date: March 1, 2024 Drug Chemistry Procedures Manual DC-App IV-A Page 4 of 11 Version 2024.03.01

- 2. The net mass of all substances will be determined prior to analysis with the following exceptions:
 - a. Samples involving trace or residual amounts of material.
 - b. Instances in which gross/estimated mass determination of numerous samples indicates a mass less than legal limits as set by statute(s).
 - c. Instances in which the net or gross/estimated mass far exceeds the maximum legal limits mass as set by statute(s). In this instance, a sample with net mass exceeding the legal limit would suffice.
 - d. Samples involving pharmaceutical preparations where preliminary identification indicates a non-scheduled substance.
 - e. Samples involving pharmaceutical preparations where preliminary identification indicates a lower scheduled substance than a previously identified higher schedule substance.
 - f. Cases involving the submission of individual suspected Cannabis plants or the submission of representative samples of individual suspected Cannabis plants where the agency plans to pursue charges based on the number of plants present, not the weight.
 - g. For cases involving large amounts of evidence (e.g. powders, chunky substances, etc.), a gross weight will be obtained and the evidence will be screened. Instances where indications of a highly potent substance that may pose a risk to the analyst's safety are present (e.g. carfentanil), no further weighing will take place.
- 3. The balance reading should be recorded using the following conventions:
 - a. The mass will be reported to the 0.1 gram decimal place when the balance used permits. Never round off the balance readings. Record all numbers read from the balance on the worksheet. For the report, the additional digits are dropped e.g, a balance reading of 553.1 grams will be reported as 553.1 grams, a balance reading of 10,352 grams will be reported as 10,352 grams and a balance reading of 1.341 grams will be reported as 1.3 grams. The mass will be reported out to the crucial figure when needed for charge determination. At a weight class, truncation occurs after the final digit significant to the charge determination e.g., a balance reading of 1.008 grams will be reported as 1.008 grams for a 1 gram weight class and a balance reading of 1.032 grams is reported as 1.03 grams for a 1 gram weight class.
 - b. Less than one gram is singular and shall be preceded by a zero to indicate the placement of the decimal. Example: 0.1 gram. Note: One gram is included as singular.

Accepted Date: March 1, 2024 Drug Chemistry Procedures Manual DC-App IV-A Page 5 of 11 Version 2024.03.01

- c. If the mass is less than 0.1 gram, it shall be reported as less than 0.1 gram. For smaller amounts, an option is to report it as a residue.
- d. If the charge is affected in a multiple item/exhibit case, truncating must occur after the addition of the masses of the items/exhibits.
- e. Hand-rolled cigarettes are weighed in their entirety. The plant material is not separated from the paper.
- f. Legitimate pharmaceutical capsules are weighed in their entirety. For clandestine capsules, the capsule material is to be treated as packaging. An exception can be made for substances that are subject to a dosage unit count in Illinois statutes.
- 4. Measurement uncertainty will be calculated for every case as needed per Appendix V.

E. Sampling

- 1. When possible, the analyst shall take a representative sample on which to perform tests.
- 2. It is not necessary to test every item in a case in order to make a determination about the presence of Cannabis or a Controlled Substance. Sample requirements for multiple item cases are listed in the Sampling Plan under Section H (DC-H-1).

F. Worksheet

- 1. The worksheet shall be a summary of all tests done and their results.
 - a. Identification of the instrument and balance used in the analysis will be noted in the case records
- 2. On each worksheet, the following information must be found:
 - a. The case number assigned to a particular item of evidence.
 - b. The item number.
 - c. The initials or signature of the analyst.
 - d. The date the worksheet was completed.
 - e. A header which includes "Illinois State Police, Division of Forensic Services, Forensic Sciences Command."
- 3. Included on the worksheet should be the following:

- a. A description of that item to include packaging, repackaging (if different than original), and a physical description of the contents.
- b. All tests and measurements performed on the item, including their results, and any of the information required elsewhere under minimum standards and controls.
- c. The conclusions reached by the analyst.

G. Reference Materials and Collections

1. Reference Materials

A. In-house Drug Standards

- 1. The name of the drug, date received, the source, and lot number, will be recorded for all controlled drug standards and the record will be revised as drugs are received or consumed. If a quantitative drug standard is to be stored, the expiration date and/or re-authentication date will also be recorded.
- 2. When first used, IR, MS, or other approved techniques will be run, and the spectrum will be used to authenticate and verify the identity of the drug with literature and/or in-house standards.
 - a. For qualitative standards, no expiration dates will be assigned. Some standards might have dates assigned by the manufacturer. The continued use of the standards in obtaining IR and MS data serves to verify that the standards are fit for use. As long as the data obtained from drug standard can serve to verify the identity of the standard, it can be used past any manufacturer supplied expiration date.
 - b. Drug standards that are used in quantitative work will be assigned an expiration date if not supplied with one by the manufacturer. The date will not be more than five years from the date of receipt. All quantitative drug standards can be re-authenticated; the newly assigned expiration date will not be more than 5 years from the date of reauthentication.
 - c. Any standard that is deemed to be unfit for use will be discarded.
- 3. Primary standards are defined as those obtained from legitimate sources; secondary standards as those obtained from other sources and verified inhouse. Secondary standards which are used in analysis will be inventoried and authenticated in the same manner as primary standards.

Accepted Date: March 1, 2024 Drug Chemistry Procedures Manual DC-App IV-A Page 7 of 11 Version 2024.03.01

4. All controlled standards will be inventoried yearly. Those over 1 gram will be weighed. Documentation of the annual inventory will include a document with a physical (or digital equivalent) signature certifying the audit, the number of standards listed in inventory and the number of standards found during the physical inventory.

B. Literature Sources and External Standard References

- 1. If no in-house drug standard is available for comparison, literature and external sources may be referenced. In determining the legitimacy of external sources, analysts should consider the credibility and qualifications of the author, publication and format of the reference (e.g. scholarly journals or internet sites), date of publication or acquisition, and accompanying documentation (method parameters, lot numbers, etc.).
- 2. In general, library searches should not be considered legitimate references for data comparisons. Exceptions include peer-reviewed and published libraries or libraries created within the Command using traceable reference materials. Any library reference meeting these exceptions must be evaluated for legitimacy and relevance similar to any literature or other external reference.

C. Other Reference Materials

- 1. PFTBA This reference material is used to tune a mass spectrometer. PFTBA will be obtained from ISO accredited vendors. Appropriate documentation, such as a certificate of analysis, should be retained when available. The process of tuning the mass spectrometer will serve to authenticate the PFTBA reference material. Since the tune is verified every time it is performed, the PFTBA can be used past a manufacturer provided expiration date.
- 2. Polystyrene This reference material is used during the function check for infrared spectrophotometers. It must be a traceable standard, from an ISO accredited vendor, with appropriate documentation. If the standard is provided with a manufacturer's expiration date, the standard may be re-authenticated to extend the date in five year intervals. The new date and analyst's identity should be included on the standard or in the logbook (or online equivalent).

2. Reference Collections

A. In-house spectral libraries

1. All spectra included in such collection will be uniquely identified as to the substance, its source (lot number or other identifier), and to the instrument on which it was acquired.

Accepted Date: March 1, 2024 Drug Chemistry Procedures Manual DC-App IV-A Page 8 of 11 Version 2024.03.01

- 2. The collection will be kept within the Drug Chemistry section.
- 3. The collection can be archived as needed according to local procedures.

B. Sample collection for reagent testing

- 1. A collection of known materials may be kept for the purposes of testing reagents (color tests, TLC visualization sprays, etc.)
- 2. These materials may be purchased or samples taken from casework.
- 3. Each item in the collection will be uniquely identified.
- 4. Access to the collection will be limited, and use will be limited to the testing of reagents.

H. Abbreviations

The following are the abbreviations allowed for use in LIMS. They can be used as written or with any variation in case type (upper or lower).

1. General

Accepted Date: March 1, 2024

a.	ASA	Assistant State's Attorney
b .	bl	blank
c.	BSB	background subtraction
d.	c/ or cont	contains/ing
e.	CIA	consistent in appearance
f.	Cland	clandestine
g.	Conc	concentrated
h.	Dist	distance
i.	EIC	extracted ion chromatogram
j.	est	estimated
k.	ET	evidence tape/d
1.	Evap	evaporated
m.	Exp	expected
n.	Ext	extraction
0.	Func	function
p.	GW	gross weight
q.	HS	heat sealed
r.	Inc	included
s.	Ind	indicates/d
t.	Inv	inventory
u.	LAM	Laboratory Asset Manager (module in the LIMS)
v.	LIMS	Laboratory Information Management System

Drug Chemistry Procedures Manual

Page 9 of 11

Version 2024.03.01

Standards and Controls: Administrative Policies
Applicable to Any Analyses

Appendix IV-A Chemistry Minimum

DC-App IV-A

w. mL milliliter

x. MU Measurement Uncertainty

y. NA Not Analyzed z. NR No Reaction

aa. NSbb. NSSFcc. NSSInot scheduled/non scheduledbb. NSSFNo scheduled substance foundNo scheduled substance indicated

dd. PD Police Department

ee. pg page

ff. pharm pharmaceutical

gg. prep prepared hh. quant quantitation ii. RT retention time

jj. SA/SAO State's Attorney/State's Attorney's Office

kk. SDT Subpoena Duces Tecum

ll. SN Serial number mm. STD standard

nn. TIC total ion chromatogram

oo. Unk unknown

pp. USC United States Currency

qq. Wt weight

2. Scientific

a. CHCl3 chloroform

b. D/L Duquenois-Levine

c. g gram

d. HCl hydrochloric acid

e. M molar f. MeOH methanol g. N normal

Notes may also contain instrument names, drug names, chemical formulas, generally accepted nomenclature, and routinely used scientific abbreviations. The list above includes examples but is not a fully comprehensive list.

3. Symbols

number a. & or + and b. c. < less than > greater than d. indicates e. f. micro μ times X

Accepted Date: March 1, 2024 Drug Chemistry Procedures Manual DC-App IV-A Page 10 of 11 Version 2024.03.01

h. ? indicates

i. ✓ checked/ok; looked at

j. - subtracted

MINIMUM STANDARDS AND CONTROLS FOR TESTING TECHNIQUES

Minimum standards and controls for each individual procedure or testing technique can be found in the relevant section of the procedures manual.

Accepted Date: March 1, 2024 Drug Chemistry Procedures Manual DC-App IV-A Page 11 of 11 Version 2024.03.01

ILLINOIS STATE POLICE

DRUG CHEMISTRY PROCEDURES MANUAL

APPENDIX IV:	CHEMISTRY MINIMUM STANDARDS AND CONTROLS
SECTION B:	ADMINISTRATIVE POLICIES FOR CANNABIS ANALYSIS
Reviewed by:	
Forensic Scientist Tiffany A. Drug Chemistry Command A	
Approved by:	
Bureau Chief Timothy A. Tr Drug Chemistry Command C Forensic Sciences Command	Coordinator

Accepted Date: December 23, 2019 Drug Chemistry Procedures Manual DC-App IV-B Page 1 of 3 Version 2019.12.23 **Appendix IV-B:** Chemistry Minimum Standards and Controls: Administrative Policies for Cannabis Analysis

APPENDIX IV-B

Minimum Standards and Controls are not to be used as a substitute for good scientific procedures. On an individual case, the minimum indicated may not suffice to complete an identification as defined. It is the primary responsibility of the chemist to identify the controlled substance rather than simply fulfill these standards.

ADMINISTRATIVE POLICIES FOR CANNABIS ANALYSIS

The Illinois Cannabis Control Act (CCA), Chapter 720, Act 550 and the Cannabis Regulation and Tax Act (CRTA), Chapter 410, Act 705 of the Illinois Compiled Statutes contain the regulations associated with the control of Cannabis.

While the protocols, methods and procedure give directions for the analysis of Cannabis, there are some specific administrative procedures directly applicable to Cannabis analysis. These various procedures are listed in this appendix.

The following are procedures associated with the identification of Cannabis:

A. Positive Identification

- 1. To identify plant material as Cannabis, two positive tests are acceptable if one of the tests provides structural confirmation (e.g. GC-MS). Additional tests may be done at the discretion of the analyst. The tests used for Cannabis analysis are listed below:
 - a. Macroscopic Examination See DC-IIIA-1.
 - b. Microscopic Examination See DC-IIIA-1.
 - c. Duquenois-Levine (D-L) test See DC-IIIA-2.
 - d. TLC See DC-C-1.
 - e. GC-FID See DC-D-1.
 - f. GC-MS See DC-G-1.

The macroscopic and microscopic examinations, when performed together, count as one test. It is permissible to perform a microscopic examination in conjunction with another test that provides structural confirmation, however, it is not sufficient to perform the macroscopic examination with any other technique, even if the second technique provides structural confirmation.

Accepted Date: December 23, 2019 Drug Chemistry Procedures Manual DC-App IV-B Page 2 of 3 Version 2019.12.23 **Appendix IV-B:** Chemistry Minimum Standards and Controls: Administrative Policies for Cannabis Analysis

- 2. It is not necessary to test every item in a case in order to make a determination about the presence of Cannabis. Sample requirements for multiple item cases are listed in the Sampling Plan under Section H.
- 3. Cases found to contain Cannabis will also specify the cannabinoid identified on the report.
- 4. Other tests may be submitted at the discretion of the chemist as long as they meet the minimum standards and controls guidelines.

B. E-cigarette cartridges

Because of the level of difficulty associated with opening e-cigarette cartridges, as well as the sheer volume necessary to meet weight class limits, when one cartridge has been analyzed and found to contain a cannabinoid, no others will be tested. If the one analyzed cartridge does not contain a cannabinoid, the analyst will use his or her discretion to determine if more items need to be analyzed. Further analysis on any remaining cartridges submitted will be at the discretion of laboratory management and only completed if requested by the State's Attorney's Office. The unanalyzed cartridges will NOT need a gross or estimated weight. They will be reported as cartridges (additional description optional) and a conclusion of "Not Analyzed".

C. Not Cannabis Determination

At least two negative tests are required to eliminate the possibility of the presence of Cannabis. When "Not Cannabis" is the only determination made for a piece of evidence, one of these must be an instrumental test that also eliminates the possibility of other controlled substances, including high molecular weight synthetic cannabinoids. It is not necessary to call "Not Cannabis" when another substance is identified.

D. No Analysis Determination

When identifying Cannabis, the entire amount submitted does not need to be analyzed. Analysis need only be conducted to the weight limits for Illinois penalties.

MINIMUM STANDARDS AND CONTROLS FOR TESTING TECHNIQUES

Minimum standards and controls for each individual procedure or testing technique can be found in the relevant section of the procedures manual.

ILLINOIS STATE POLICE

DRUG CHEMISTRY PROCEDURES MANUAL

APPENDIX IV:	AND CONTROLS
SECTION C:	ADMINISTRATIVE POLICIES FOR CONTROLLED SUBSTANCE ANALYSIS
Reviewed by:	
Forensic Scientist Adrienne A. Drug Chemistry Command Ad	
Approved by:	
Bureau Chief Timothy A. Tripp Drug Chemistry Command Coo Forensic Sciences Command	

Accepted Date: March 1, 2024 Drug Chemistry Procedures Manual DC-App IV-C Page 1 of 5 Version 2024.03.01 **Appendix IV-C:** Chemistry Minimum Standards and Controls: Administrative Policies for Controlled Substance Analysis

APPENDIX IV

Minimum Standards and Controls are not to be used as a substitute for good scientific procedures. On an individual case, the minimum indicated may not suffice to complete an identification as defined. It is the primary responsibility of the chemist to identify the controlled substance rather than simply fulfill these standards.

ADMINISTRATIVE POLICIES FOR CONTROLLED SUBSTANCE ANALYSIS

The Illinois Controlled Substances Act governs most substances controlled in the state of Illinois. The act is found in Chapter 720, Section 570 of the Illinois Compiled Statutes. Substances controlled via administrative rule are listed separately in the Illinois Administrative Code, Title 77, Chapter X, Subchapter e, Part 2070. Additionally, the Kratom Control Act, The Methamphetamine Control and Community Protection Act, and the Methamphetamine Precursor Control Act are of interest to the Drug Chemistry Section. These can be found in Chapter 720, Sections 642, 646, and 648 respectively of the Illinois Compiled Statutes.

While the protocols, methods and procedures give directions for the analysis of suspected controlled substances, there are many administrative procedures which must be addressed and which do not lend themselves to a specific analysis. These various procedures are collected into this appendix.

The following are procedures associated with the identification of any substances, regardless of their control status:

A. Positive Identification

1. There are minimum tests necessary for the identification of a drug. Two tests must be used to confirm the presence of a drug. One test will include IR, MS or another approved technique providing structural confirmation. The other test will be an approved preliminary testing technique or acceptable instrumental screening test in which the drug is indicated.

It is acceptable to use two mass spectra to meet the minimum test requirements only if the following conditions are met:

- a. The second mass spectrometer is different from the first AND there is a column phase change.
- b. When a purchased reference standard is available and the sample warrants use of two mass spectra (e.g. residues, complex mixtures, synthetic drugs), the mass spectral data will be used **and**, **if they are the only tests used to make a determination**, a documented comparison of retention time data for at least one of the runs will also be utilized.

Accepted Date: March 1, 2024
Drug Chemistry Procedures Manual

DC-App IV-C Page 2 of 5 Version 2024.03.01 **Appendix IV-C:** Chemistry Minimum Standards and Controls: Administrative Policies for Controlled Substance Analysis c. When purchased reference standards are unobtainable, the results of two GC-MS runs will be compared to two literature sources and documented in the case file. Therefore, these cases are exempt from the retention time comparison requirement.

Additional tests will be done at the discretion of the analyst.

- 2. It is not necessary to test every item in a case in order to make a determination about the presence of a controlled substance. Sample requirements for multiple item cases are listed in the Sampling Plan under Section H.
- 3. Any specialized analytical procedures used will be documented in the laboratory's chemistry section manual or on the worksheet.

B. No Scheduled Substance Found Determinations

- 1. At least two different tests, excluding color tests, will be used that together eliminate the possibility of the sample containing a controlled substance.
 - a. Two GC-MSs must only be used when the sample warrants it (e.g. residues, complex mixtures).
 - i. The second mass spectrometer is different from the first AND there is a column phase change.
 - ii. Retention time data must be taken into consideration and documented in the case file. When it is not appropriate to make a retention time comparison to a standard, e. g. no peaks are present, peaks do not meet acceptance criteria or peaks present do not correspond to a controlled substance, the reason the comparison was not performed will be documented. This can be documented as "No relevant peaks for retention time comparison" or "No peaks of interest for retention time comparison" or other wording that acknowledges why the retention time data could not be taken into consideration.
- 2. A determination of no scheduled substance found requires one test to be a general screening run on a GC-MS instrument.
- 3. When testing shows possible indications of a substance of interest, for example through weak color tests or a mass spectrum with the presence of major ions associated with a possible controlled substance, it is necessary for the analyst to document an attempt to increase the sensitivity of the analytical process. This can be achieved in the following ways, often resulting in additional testing beyond the minimum two tests required:
 - a. An increase in sensitivity through sample preparation (e.g. use of more sample, extraction and concentration to a microvial) or

Accepted Date: March 1, 2024 Drug Chemistry Procedures Manual DC-App IV-C Page 3 of 5 Version 2024.03.01 **Appendix IV-C:** Chemistry Minimum Standards and Controls: Administrative Policies for Controlled Substance Analysis

- b. An increase in sensitivity through instrumental techniques (e.g. lower split ratio, increased injection volume, manual injections)
- 4. A determination of no scheduled substance found can be made without excluding all possible controlled substances. Unless additional information is provided, only those drugs normally encountered in a laboratory need to be eliminated.
- 5. If the form of the item is not consistent with the normal dosage form of a particular controlled substance, then the presence of that controlled substance need not be eliminated unless analysis is requested by the submitting agency (i.e., the presence of LSD in white powders).
- 6. "No scheduled substance found" is not an acceptable finding when non-scheduled synthetic drugs are present in a sample and can be identified, either conclusively or preliminarily. The use of "no scheduled substance found" should be primarily focused on cases including, but not limited to, non-scheduled pharmaceutical type compounds (e.g. caffeine, acetaminophen, diphenhydramine, etc.), cutting agents and tableting materials (e.g. inositol, stearic acid), and samples with no compounds of interest present.

C. No Analysis Determination

- 1. Not all items need to be analyzed. Unless additional information is provided, the chemist need only identify the amount of controlled substance that would bring the highest penalty for the defendant according to the appropriate statutes. Once the highest penalty class has been obtained, no further analysis will be done.
- 2. Factory sealed and labelled containers of cutting agents need not be analyzed (i.e., inositol, mannitol, baking soda, etc.).
- 3. Non-controlled pharmaceuticals with identifiable markings need not be confirmed through analysis unless there is evidence of tampering or reasons to suspect a counterfeit.
- 4. Factory sealed and labelled pharmaceutical preparations and blister packs do not need to be opened or confirmed through analysis unless they are scheduled substances and either the only item in a case or the item with the highest penalty.
- 5. In cases that are multi-item, if the chemist observes the samples to be similar, randomly removes one that tests negative, the one tested would be reported as NSSF and the rest may be reported as No Analysis or Not Analyzed. For items not in commonly seen drug form (i.e., lima beans, marbles, rice), the one tested would be reported as NSSF and the rest may be reported as No Analysis or Not Analyzed.

MINIMUM STANDARDS AND CONTROLS FOR TESTING TECHNIQUES

Accepted Date: March 1, 2024 Drug Chemistry Procedures Manual DC-App IV-C Page 4 of 5 Version 2024.03.01 Appendix IV-C: Chemistry Minimum Standards and Controls: Administrative Policies for Controlled Substance Analysis

Accepted Date: March 1, 2024 Drug Chemistry Procedures Manual	DC-App IV-C Page 5 of 5 Version 2024.03.01	Appendix IV-C: Chemistry Minimum Standards and Controls: Administrative Policie for Controlled Substance Analysis	es
Minimum standards and controls found in the relevant section of the	for each individual procede e Procedures Manual.	ure or testing technique can be	

for Controlled Substance Analysis

ILLINOIS STATE POLICE

DRUG CHEMISTRY PROCEDURES MANUAL

APPENDIX IV:	AND CONTROLS:		
SECTION D:	ADMINISTRATIVE POLICIES FOR SPECIFIC CONTROLLED SUBSTANCES		
Reviewed by:			
Forensic Scientist Adrienne A Drug Chemistry Command A			
Approved by:			
Bureau Chief Timothy A. Trip Drug Chemistry Command Co Forensic Sciences Command			

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-App IV-D Page 1 of 6 Version 2023.08.01 **Appendix IV-D:** Chemistry Minimum Standards and Controls for Specific Controlled Substances

APPENDIX IV

Minimum Standards and Controls are not to be used as a substitute for good scientific procedures. On an individual case, the minimum indicated may not suffice to complete an identification as defined. It is the primary responsibility of the chemist to identify the controlled substance rather than simply fulfill these standards.

ADMINISTRATIVE POLICIES FOR SPECIFIC CONTROLLED SUBSTANCES

The Illinois Controlled Substances Act governs most substances controlled in the state of Illinois. The act is found in Chapter 720, Section 570 of the Illinois Compiled Statutes. Substances controlled via administrative rule are listed separately in the Illinois Administrative Code, Title 77, Chapter X, Subchapter e, Part 2070. Additionally, the Kratom Control Act, The Methamphetamine Control and Community Protection Act, and the Methamphetamine Precursor Control Act are of interest to the Drug Chemistry Section. These can be found in Chapter 720, Sections 642, 646, and 648 respectively of the Illinois Compiled Statutes.

While the protocols, methods and procedures give directions for the analysis of suspected controlled substances, there are some substances that require specific testing in order to make a positive identification, sometimes going beyond the two test minimum for a typical identification. These various procedures are collected into this appendix.

1. Psilocyn and Psilocybin

- a. In order to distinguish and independently identify psilocyn and/or psilocybin in a sample, one of the following methods will be employed:
 - i. A Weber color test (see DC-B-1) is sufficient to indicate the presence of psilocyn, provided the following criteria are met:
 - 1. A primary psilocyn standard produces a positive Weber test, AND
 - 2. A primary psilocybin standard produces a negative Weber test, AND
 - 3. Both standards for (1) and (2) are tested on the same day as the sample(s), AND
 - 4. Both standards for (1) and (2) are logged in the casefile or a logbook (or the online equivalent). Documentation must include lot numbers or laboratory inventory number and color test results for each standard tested. Analysts may only use a verification performed by another analyst if all of the above criteria are met and the verification was logged in the logbook (or online equivalent).

Note: If utilizing Weber reagent with a liquid extract, it must be a solvent only extract.

- ii. A prep TLC will be run indicating the presence of both psilocyn and psilocybin in a separated state, then at least one spot will be scraped and confirmed by either IR or GC/MS.
- iii. A solvent only extract will be run on TLC and if psilocyn and/or psilocybin are present in separated states, the sample will also be analyzed using GC-MS, GC-IR or IR.

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-App IV-D Page 2 of 6 Version 2023.08.01 Appendix IV-D: Chemistry Minimum Standards and Controls for Specific Controlled Substances

- b. When a negative Weber color test is produced for a sample suspected to contain hallucinogenic mushrooms, one of the other techniques listed above shall be employed to attempt to distinguish and independently identify psilocyn and/or psilocybin.
- c. If the analyst cannot distinguish between psilocyn and psilocybin after attempting at least one of the techniques listed above, then the results will be reported as:

Psilocyn and/or Psilocybin. The specific compound(s) could not be differentiated.

2. Salvinorin A

- a. For the analysis and storage of Salvinorin A, the following guidelines are recommended:
 - i. Extract using methanol or chloroform. For leafy material, grind in mortar and pestle, shake or stir for one minute before removing the supernatant.
 - ii. For small sample amounts, use boiling chloroform. Place the sample containing chloroform in a water bath; choose a setting to boil the chloroform, but not the water; evaporate the solvent to microvial volume.
 - iii. Due to stability concerns, extracts should be analyzed within 24 hours.
 - iv. Salvinorin A standards must be stored in the refrigerator in light-resistant or applicable containers.

3. Isomer determinations

a. Optical Isomers

- i. When Methorphan is identified in a substance that cannot be physically identified as a pharmaceutical preparation, *and* it cannot be isolated in a state sufficiently pure for effective optical isomer determination via polarimetry, then it is appropriate to identify Methorphan with a qualification that informs the agencies that the optical isomer of Methorphan could not be determined, however all of its isomers are listed in the Illinois Compiled Statutes.
- ii. When Propoxyphene is identified in a substance that cannot be physically identified as a pharmaceutical preparation, *and* it cannot be isolated in a state sufficiently pure for effective optical isomer determination via polarimetry, then it is appropriate to identify Propoxyphene with a qualification that informs the agencies that the optical isomer could not be determined.

b. Positional Isomers

- i. Synthetic cathinones, cannabinoids, opioids, and phenethylamines often have positional isomers that produce similar mass spectral data. In order to identify a specific positional isomer, analysts must have the necessary data to support the identification.
- ii. The following are options for identification of a positional isomer. (Note: not every option will work for every drug. This is dependent on the substance and instrument parameters. More than one technique may be necessary.)

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-App IV-D Page 3 of 6 Version 2023.08.01 Appendix IV-D: Chemistry Minimum Standards and Controls for Specific Controlled Substances

- 1. Mass spectral comparison of the sample to the standard of the different isomers (or comparison of the mass spectra of the isomers to each other).
- 2. Comparison of retention time data between the sample and the standards of the different isomers.
- 3. Comparison of IR data obtained via FTIR or GC-IR between the sample and the standard.
 - i. If a positional isomer still cannot be determined, it is acceptable to use the following remarks lines in conjunction with a general identification that does not identify the positional isomer. (The choice depends on whether or not the isomers are controlled as well.)
 - 1. Remarks: The positional isomer of XXX could not be determined.
 - 2. Remarks: The positional isomer of XXX could not be determined, however, all of its positional isomers are controlled in the Illinois Compiled Statutes.
 - a. Example: Methylethcathinone, a synthetic cathinone.

Remarks: The positional isomer of Methylethcathinone could not be determined, however, all of its positional isomers are controlled in the Illinois Compiled Statutes.

4. Khat

- a. Suspected Khat cases containing fresh plant material should be refrigerated upon arrival at the laboratory and analyzed as soon as possible to minimize the conversion of cathinone to cathine.
- b. The following technique is one possible extraction for suspected Khat:

Grind plant material with a 1:1 mixture of cold CHCl3: Saturated Na2CO3. Sit for 10 minutes while remaining cold. Filter through glass wool, remove the chloroform layer, evaporate with air, and reconstitute in a microvial of methanol.

5. Clandestine Laboratories

- a. Analytical Considerations
 - i. Evidence submitted from a clandestine laboratory will be limited to the identification of controlled substances and possible precursors. No capacity calculations, theoretical yields, or determination of routes of synthesis will be performed.
 - ii. Clandestine lab samples can be solid, liquid, or a combination of the two. Liquids may be multilayered and may require sampling from each layer.
 - iii. Testing liquids with Watesmo paper and/or pH paper can provide a good starting point for analysis. A basic aqueous sample may only require extracting with a suitable solvent. A non-aqueous sample can be injected neat but may require clean-up steps to remove interfering peaks (i.e. using hydrochloric acid fumes to

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-App IV-D Page 4 of 6 Version 2023.08.01 Appendix IV-D: Chemistry Minimum Standards and Controls for Specific Controlled Substances

- precipitate out the suspected methamphetamine and then separating the precipitate from the original solvent).
- iv. For solids, it is best to avoid sampling any Lithium metal that may be present. Be aware that performing a Sodium Nitroprusside color test on a strongly basic item containing methamphetamine may result in a false negative red color.

b. Safety Considerations

- i. Evidence may contain strong acids or bases which can cause injuries if they come into contact with skin. Because they can also penetrate clothes or lab coats, extra care should be taken when handling clandestine lab evidence.
- ii. Clandestine labs often contain solvents which emit noxious or harmful vapors. For this reason, these samples should be handled in the hood, opened slowly, with the mouth of the container of evidence directed towards the rear of the hood.

c. Storage Considerations

- i. Bottles containing clandestine lab evidence should be stored upright in order to prevent leakage.
- ii. When possible, clandestine lab evidence should be stored in a cabinet designed for this purpose.

6. Opium

- a. In order to identify Opium, the following five compounds need to be identified:
 - i. Morphine
 - ii. Codeine
 - iii. Thebaine
 - iv. Papaverine
 - v. Noscapine
- b. Analytical Considerations
 - i. Preliminary
 - 1. Color tests: Use Mecke, Marquis or Froehde's as a preliminary test.
 - 2. GC/FID: Extract the sample and analyze. All five compounds' retention times must be recorded.
 - ii. Confirmatory
 - 1. GC/MS: Extract the sample and identify the above listed compounds.
 - 2. A primary Opium standard may also be used for comparison after the confirmation of the above compounds.
- c. It is acceptable to use the following remarks line when identifying Opium.
 - i. Remarks: The five individual compounds of Morphine, Codeine, Thebaine, Papaverine and Noscapine have been identified when confirming Opium.

REFERENCES

- 1. Panicker, S.; Wojno, H.; and Ziska L.; Quantitation of the Major Alkaloids in Opium from *Papaver Setigerum* DC; Microgram Journal, Volume 5 (January December 2007): 13-19
- 2. Choate, B.; Opium; Botanical Workshop, MAFS Conference; October 7, 1998

Accepted Date: August 1, 2023 Drug Chemistry Procedures Manual DC-App IV-D Page 6 of 6 Version 2023.08.01 **Appendix IV-D:** Chemistry Minimum Standards and Controls for Specific Controlled Substances

ILLINOIS STATE POLICE

DRUG CHEMISTRY PROCEDURES MANUAL

CHEMICTOV MINIMI IM CTANDADDC

AFFENDIA IV:	AND CONTROLS		
SECTION E:	ADMINISTRATIVE POLICIES FOR FOOD PRODUCT SAMPLING		
Reviewed by:			
Forensic Scientist Tiffany A. Drug Chemistry Command A	-		
Approved by:			
Bureau Chief Timothy A. Trip	 pp		
Drug Chemistry Command Co	oordinator		
Forensic Sciences Command			

Accepted Date: December 23, 2019 Drug Chemistry Procedures Manual

ADDENIDIV IV.

DC-App IV-E Page 1 of 2 Version 2019.12.23 **Appendix IV-E** Chemistry Minimum Standards and Controls: Administrative Policies For Food Product Sampling

APPENDIX IV

This section will provide instruction on how best to sample various food products for analysis. This will by no means be an all-inclusive list, as analysts will need to use their own discretion on a case-by-case basis.

Minimum Standards and Controls are not to be used as a substitute for good scientific procedures. On an individual case, the minimum indicated may not suffice to complete an identification as defined. It is the primary responsibility of the chemist to identify the controlled substance rather than simply fulfill these standards.

ADMINISTRATIVE POLICIES FOR FOOD PRODUCT SAMPLING

A. Guidelines

- 1. Food products that are consistent in appearance in a single container will be seen as one comingled unit and tested as one sample. This includes, but is not limited to, gummies (not individually wrapped), cereal, chips, cookies, and other candies.
- 2. Factory sealed containers that are labeled with their contents, in accordance with state guidelines, will not be analyzed unless there is evidence of tampering.
- 3. A large food product that has been cut, but not separated (i.e., a pan of brownies or bars), will be considered one unit and tested as one item.
- 4. Individually wrapped items will be treated as separate items and tested separately.
- 5. Because of the difficulties associated with analyzing food products due to complex matrices, only one sample from one item will initially be analyzed. The analyst will then note whether the remaining samples are consistent in appearance. Analysis on the remaining samples/items will be at the discretion of laboratory management and only completed if requested by the State's Attorney's Office.
- 6. If further analysis is approved to meet statutory requirements, the required number of samples must be tested individually or, if the sample allows, the submission may be analyzed using an approved sampling method. The calculated number of samples determined by the sampling method must each be individually tested to meet the Minimum Standards and Controls for analysis.

MINIMUM STANDARDS AND CONTROLS FOR TESTING TECHNIQUES

Minimum standards and controls for each individual procedure or testing technique can be found in the relevant section of the procedures manual.

Accepted Date: December 23, 2019
Drug Chemistry Procedures Manual

DC-App IV-E Page 2 of 2 Version 2019.12.23 Appendix IV-E Chemistry Minimum Standards and Controls: Administrative Policies For Food Product Sampling

ILLINOIS STATE POLICE

DRUG CHEMISTRY PROCEDURES MANUAL

APPENDIX V: MEASUREMENT UNCERTAINTY

Reviewed by:
Forensic Scientist Adrienne A. Hirsch, Chairperson Drug Chemistry Command Advisory Board
Approved by:
Bureau Chief Timothy A. Tripp Drug Chemistry Command Coordinator Forensic Sciences Command

Accepted Date: March 1, 2024 Drug Chemistry Procedures Manual DC-App-V Page 1 of 9 Version 2024.03.01

INTRODUCTION

All measurements are associated with a level of uncertainty. When the most significant contributing sources are taken into account, a reasonable approximation of the true uncertainty can be given. The uncertainty of measurement is a calculated range of values at a given confidence interval that allows us to express how certain we are that the "true" value is within the stated interval.

The measurement uncertainty associated with mass determination is affected by factors such as the resolution of the balance, repeatability, and linearity. Even though balances are calibrated routinely, there is still an amount of uncertainty associated with the calibration. Process uncertainty considers the reproducibility of measurement over a variety of environmental conditions, different locations, different personnel, and replicate measurements of similar objects. The standard weights utilized for function checks are calibrated at a specified interval and carry an amount of calibration uncertainty. These components are able to be quantified and used to calculate the measurement uncertainty. Once the standard uncertainties are calculated for the above contributions, the combined standard uncertainty is calculated and then used to calculate the expanded uncertainty at a confidence level of *at least 95.45%*. The expanded uncertainty is calculated for each balance readability and then utilized in the equation to calculate the total uncertainty for the mass determination.

Each individual measurement has an uncertainty associated with it. When multiple measurements are combined to obtain a total mass, their uncertainties must also combine. In order to calculate the measurement uncertainty, the root sum square (RSS) method is used.

Accepted Date: March 1, 2024 DC-App-V Appendix V: Measurement Uncertainty
Drug Chemistry Procedures Manual Page 2 of 9
Version 2024.03.01

MEASUREMENT UNCERTAINTY FOR MASS DETERMINATION

SAFETY CONSIDERATIONS

Follow the requirements of the selected procedure.

PREPARATIONS

Follow the requirements of the selected procedure.

INSTRUMENTATION

Follow the requirements of the selected procedure.

DEFINITIONS

Linearity:	The ability of the balance to have consistent sensitivity throughout		
	the weighing range.		
Process uncertainty:	This is equal to the standard deviation calculated from the function		
	check data obtained from all personnel, laboratories, and		
	instrumentation.		
Readability:	The smallest increment of a balance's readout. For example, the		
	Mettler Toledo XPR603 balances have a readability of 0.001 g.		
	Also known as resolution.		
Repeatability:	Taking the same measurement(s) under the same conditions.		
Root Sum Square:	A statistical method of dealing with a series of values where each		
	value is squared, the sum of these squares is calculated and the		
	square root of that sum is then taken.		
Type A uncertainty:	This type of uncertainty is estimated by statistical analysis of a		
	series of repeated measurements.		
Type B uncertainty:	This type of uncertainty is estimated by means other than from		
	observed measurement.		

MINIMUM STANDARDS AND CONTROLS

- 1. Calculations for the measurement uncertainty associated with mass determination must be included on the worksheet or in the case file for all reported masses greater than or equal to 0.1 gram. Measurement uncertainty does not need to be calculated for items that are not analyzed or deferred.
- 2. The total uncertainty must be calculated using the root sum square method. This can be completed using a LIMS worksheet included in the case file or the calculations will be shown in their entirety with the weight measurement(s) in the case notes through the matrix.
 - a. The weight and uncertainty must be recorded to the same number of decimal places as the balance readability, and the uncertainty must always be rounded up (never down or truncated).

Accepted Date: March 1, 2024 Drug Chemistry Procedures Manual DC-App-V Page 3 of 9 Version 2024.03.01

- i. If more than one balance is used and one of the balances has less readability, the recorded weight and uncertainty will be recorded to the readability of the least precise balance.
- 3. The calculated measurement uncertainty will only be included on the report in situations where it is crucial to the determination of the weight class or penalty and could potentially result in a lower weight class.
 - a. The weight and uncertainty must be reported to the same number of decimal places as the balance readability, and the uncertainty must always be rounded up (never down or truncated).
 - b. Refer to the "Application of Measurement Uncertainty for Mass Determination" section below for additional reporting guidelines and truncating rules.
- 4. In the case that the uncertainty is deemed crucial to the determination of a weight class, analysis must continue until either enough units have been tested to negate the importance of the measurement uncertainty, or no additional units remain to be tested.
- 5. In cases with more than two units where an analyst will be adding together individual mass measurements to obtain a total mass, a gross weight will be recorded in the case file. In cases where it is not possible to obtain a gross weight (e.g. tablets, paper squares), a net weight of the total number of units will be obtained. Exceptions to this policy will be noted on the worksheet.
- 6. The measurement uncertainty evaluation budget table for each balance readability will be saved in LAM.
- 7. The following events will be assessed against the current budget table: addition of new personnel, acquisition of new balances, or updated calibration certificates.
 - a. If there is no impact to the expanded uncertainty calculated with the MU budget table, this evaluation will be recorded in LAM.
 - b. If there is a change to the expanded uncertainty, the evaluation will be recorded in LAM and the updated budget table and MU calculations will be uploaded to LAM.

PROCEDURE OR ANALYSIS

Evaluation of Measurement Uncertainty

The full evaluation of measurement uncertainty (MU) will be completed by the Command Advisory Board (CAB) chair or designee as required by QM-18. As part of the MU evaluation, the rounded expanded uncertainty will be calculated for each balance readability for Command.

If using the LIMS worksheet, the rounded expanded uncertainty will be populated for use in the calculation of the total MU.

Accepted Date: March 1, 2024 Drug Chemistry Procedures Manual DC-App-V Page 4 of 9 Version 2024.03.01

The following items are stored in LAM: Budget tables, MU contributions, current MU value, and MU calculations.

Uncertainty Component	Distribution	Туре	Divisor	Standard Uncertainty Calculation (u _s)	Component Contribution %
Linearity (L)	Rectangular	В	$\sqrt{3}$	$u_{s_L} = \frac{L}{\left(2 \times \sqrt{3}\right)}$	u_s^2
Resolution (R)	Rectangular	В	$\sqrt{3}$	$u_{s_R} = \frac{R}{\left(2 \times \sqrt{3}\right)}$	$\frac{u_s^2}{\sum u_s^2} \times 100$
Repeatability (r)	Normal (k=1)	В	1	$u_{s_r} = \frac{r}{1}$	
Calibration Uncertainty (<i>U_c</i>)	Normal (k=2)	В	2	$u_{s_{U_c}} = \frac{U_c}{2}$	
Process Uncertainty (U _p)	Normal (k=1)	A	1	$u_{s_{U_p}} = \frac{U_p}{1}$	
Standard Weight Uncertainty (<i>U_w</i>)	Normal (k=2)	В	2	$u_{s_{U_w}} = \frac{U_w}{2}$	
Combined S Uncertain		$u_c = \sqrt{\left(\sum u_s^2\right)}$			
Expanded Uncertainty, k=2 (U)		$U = k \times u_c = 2 \times u_c$			

For each balance readability:

- 1. Look up the balance linearity, readability (resolution), and repeatability from manufacturer documentation for each balance type. Identify the highest value for each.
- 2. Evaluate process uncertainty utilizing the function check data stored since the last MU calculation.

Determine the standard deviation for statewide data for each required weight. The process uncertainty is equal to the calculated standard deviation from the collected function check data for that date range. At least 60 total data points are needed in order to evaluate the measurement uncertainty utilizing a coverage factor of k=2.

3. Find the highest calibration uncertainty from the most recent balance calibrations at the largest weight used in the process uncertainty determination.

Accepted Date: March 1, 2024 Drug Chemistry Procedures Manual DC-App-V Page 5 of 9 Version 2024.03.01

All balances used in casework are routinely calibrated by an ISO accredited vendor. As part of the calibration, the estimated calibration uncertainty associated with that balance is to be determined by the vendor. The uncertainty may be given as a value or a linear equation that allows the uncertainty to be calculated at any mass across the range of the balance.

- 4. Find the highest calibration uncertainty from the weights utilized to check the balances statewide. The standard weights utilized for function checks are calibrated as required by QM-11.
- 5. Enter the appropriate values into the budget table and calculations. Standard uncertainty is calculated in grams. Combined uncertainty is calculated using the root sum squares method.
- 6. A minimum coverage factor of k=2, corresponding to a 95.45% confidence level, will be used in determining the expanded uncertainty.
- 7. Update the documentation in LAM.

Events Impacting Measurement Uncertainty

In addition to the required full evaluation per QM-18, the impact of the following events on measurement uncertainty will be assessed by the Training Coordinator, CAB chair, or designee.

- I. New personnel are beginning casework
- II. New balances are acquired
- III. Balances are recalibrated.
- 1. Obtain necessary data to compare to the current budget table.
 - a. New personnel and balance acquisitions: A minimum of 20 data points per person or balance will need to be collected through the use of function check data. The data will be added to the current MU evaluation data and the standard deviation will be recalculated.
 - b. Balance acquisition and calibrations: The calibration uncertainty component will be calculated with the updated calibration uncertainty equations provided by the vendor.
- 2. Evaluate the values from above against those in the current budget table.
 - a. If the values are lower than those in the current budget table, the new information has been evaluated against the current measurement uncertainty and has been found consistent. This will be documented in LAM.

Accepted Date: March 1, 2024 Drug Chemistry Procedures Manual Page 6 of 9
Version 2024.03.01

DC-App-V Appendix V: Measurement Uncertainty
Page 6 of 9
Version 2024.03.01

- b. If the calculations show a higher standard deviation for process uncertainty or a new highest calculated calibration uncertainty, the rounded expanded uncertainty will be re-calculated.
 - i. If the rounded expanded uncertainty does not change, the new information has been evaluated against the current measurement uncertainty and has been found consistent. This will be documented in LAM.
 - ii. If the rounded expanded uncertainty increases, the new information is not consistent with the current measurement uncertainty and requires the budget table and calculations to be updated. This will be documented in LAM and the section will be notified of the change.

Uncertainty Calculations for Casework

Weights obtained from a single balance for a single population

The root sum square method is used to calculate the total uncertainty. In order to account for the tare of the weighing vessel with each recorded weight, the number of recorded weights will be multiplied by two. In some cases, this will be an overestimation, which is acceptable because it maintains the minimum required confidence interval.

$$U_t = \sqrt{(2N) \times (u_b)^2} = \sqrt{(2N)} \times u_b$$

 U_t = total measurement uncertainty for the weighing process

N = number of recorded weights used to determine the final weight

u_b = rounded expanded uncertainty of the balance from the MU budget table

Weights obtained across multiple populations or utilizing balances with different readabilities

In the event that weights across multiple populations (case items) must be combined to reach weight class or that balances with different readabilities are utilized to obtain a weight of a single population, the total uncertainty will need to be calculated for each population and/or balance. The root sum square method is utilized for this calculation. The total uncertainty for each weighing will be rounded up to the readability of the balance prior to combining the uncertainties.

$$U_t = \ U_{t_{B1}} + U_{t_{B2}} + \cdots x$$

 U_t = total measurement uncertainty for the sum value

 $U_{t_{B1}}$ = rounded total measurement uncertainty for balance/population 1 $U_{t_{B2}}$ = rounded total measurement uncertainty for balance/population 2

Continue adding uncertainties for the number of separate balances/populations, x.

Accepted Date: March 1, 2024 DC-App-V Appendix V: Measurement Uncertainty
Drug Chemistry Procedures Manual Page 7 of 9
Version 2024.03.01

Application of Measurement Uncertainty for Mass Determination

- 1. If the total mass combined with the uncertainty could result in a change to a lower weight class, the uncertainty must be included on the report.
 - a. Example 1: 1.005 g of cocaine with an uncertainty of \pm 0.008 g at a 95.45% confidence level
 - i. This would give a range of values between 1.013 g and 0.997 g
 - ii. The value could result in a lower weight class, so the uncertainty must be included on the report.
 - b. Example 2: 1.011 g (typically truncated to 1.01 g on report) of heroin with an uncertainty of \pm 0.009 g at a 95.45% confidence level
 - i. This would give a range of values between 1.020 g and 1.002 g
 - ii. The value would remain above the weight class, so the uncertainty would not be included on the report.
 - c. Example 3: 0.998 g (truncated to 0.9 g on a report) with an uncertainty of \pm 0.004 g at a 95.45% confidence level
 - i. This would give a range of values from 1.002 g to 0.994 g
 - ii. The uncertainty would not be included on the report because the value is truncated to 0.9 g which accounts for the uncertainty of the balance in a manner which gives the benefit of the doubt to the defendant.

REPORT WORDING

When the measurement uncertainty must be included on the report, a remarks line using the following format should be used:

REMARKS: The uncertainty associated with the mass measurement in Item [Z] is [xxx] at a 95.45% confidence level.

Accepted Date: March 1, 2024 Drug Chemistry Procedures Manual DC-App-V Page 8 of 9 Version 2024.03.01

REFERENCES

- 1. Bell, S. (March 2001). A Beginner's Guide to Uncertainty of Measurement. Number 11 (Issue 2). National Physical Laboratory (NPL), Teddington, Middlesex, United Kingdom.
- 2. European Federation of National Associations of Measurement, Testing and Analytical Laboratories EuroLab. (June 2002). Measurement Uncertainty in Testing: A Short Introduction on How to Characterise Accuracy and Reliability of Results Including a List of Useful References. Berlin, Germany.
- 3. European Federation of National Associations of Measurement, Testing and Analytical Laboratories EuroLab. (August 2006). Guide to the Evaluation of Measurement Uncertainty for Quantitative Test Results. Paris, France.
- 4. European Federation of National Associations of Measurement, Testing and Analytical Laboratories EuroLab. (March 2007). Measurement Uncertainty Revisited: Alternative Approaches to Uncertainty Evaluation. Paris, France.
- 5. Illinois State Police Quality Manual Section QM-11 and QM-18.
- 6. Taylor, Barry N., and Chris E. Kuyatt. (September 1994). "Guidelines for Evaluating and Expressing the Uncertainty of NIST Measurement Results." NIST Technical Note 1297.
- 7. Harris, Georgia L. (May 2019). "Selected Laboratory and Measurement Practices and Procedures to Support Basic Mass Calibrations (2019 Ed). NIST. "SOP 29 Standard Operating Procedure for the Assignment of Uncertainty". Page 1-11. https://doi.org/10.6028/NIST.IR.6969-2019

Accepted Date: March 1, 2024 DC-App-V Appendix V: Measurement Uncertainty
Drug Chemistry Procedures Manual Page 9 of 9
Version 2024.03.01